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ABSTRACT 
MUC4 based immunotherapy for pancreatic cancer 
Kasturi Banerjee, Ph.D. 
University of Nebraska Medical Center, 2018 
Supervisor: Maneesh Jain, PhD. 
 Pancreatic Cancer (PC) is a lethal disease claiming approximately 45000 lives in 
the US in 2018, and it establishes an elaborate immunosuppressive tumor 
microenvironment that aids in disease pathogenesis. Immunotherapy has emerged as a 
strategy to target tumor cells by reprogramming patient’s immune system. Challenges 
present in PC immunotherapy are: i) identifying a tumor-associated antigen that could be 
targeted, ii) identifying adjuvants that could efficiently deliver antigens, iii) eliciting robust 
anti-tumor responses and iv) overcoming peripheral tolerance and immunosuppression 
elicited by the tumor.  
Firstly, we detected circulating autoantibodies to MUC4 present in PC patients and 
observed that IgM autoantibodies to MUC4 peptides significantly correlate with overall PC 
patient survival, thus suggesting that MUC4 could potentially be targeted for PC 
immunotherapy. Our group is the first to successfully purify recombinant MUC4β protein 
and characterize its immunogenic activity. We addressed the challenge of protein delivery 
by encapsulating MUC4β in novel polyanhydride nanoparticles (MUC4 nanovaccine). In 
the second part of the dissertation, we characterized MUC4 nanovaccine in both in vitro 
and in vivo system. Our studies showed that MUC4 nanovaccine could robustly activate 
dendritic cells (DCs) and induce secretion of Th1 cytokines in vitro. High levels of Th1 
IgG2b anti-MUC4β antibodies were detected in MUC4 nanovaccine-immunized mice.  
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As described in the third part of the dissertation, we observed that ex vivo T-cells 
activated by MUC4 nanovaccine-pulsed DCs showed enhanced cytotoxic killing of 
miniMUC4 tumor cells, when compared to soluble MUC4β mixed with empty nanoparticles 
(MUC4+NP). We validated our data in an in vivo subcutaneous PC tumor mouse model, 
and observed enhanced immune cells infiltration and corresponding levels of necrosis in 
miniMUC4 tumors corroborated with low tumor volume of miniMUC4 tumor (in comparison 
to contralateral vector control tumor) in MUC4-immunized mice. Furthermore, the 
presence of PD-L1 surface expression on miniMUC4 tumor cells indicated active 
immunosuppression lodged by tumor cells in response to IFNγ-secreting infiltrating 
cytotoxic T-cells. 
Taken together, studies in this dissertation demonstrate that MUC4 nanovaccine 
could serve as a potential strategy for PC immunotherapy. 
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CHAPTER 1A: INTRODUCTION 
 
The material covered in this chapter is the subject of one review article 
 
1. Banerjee K., Kumar S., Ross K. A., Gautam S., Poelaert B., Nasser M. W., Aithal A., 
Bhatia R., Wannemuehler M.J., Narasimhan B., Solheim J. C., Batra S. K. and Jain 
M., Emerging trends in the immunotherapy of pancreatic cancer; Cancer Letters, 417 
(2018) 35-46 
  
2 
 
1. Synopsis 
 Pancreatic cancer (PC) is the fourth leading cause of cancer-related deaths in the 
U.S., claiming approximately 45,000 lives every year. Much like other solid tumors, PC 
evades the host immune system and establishes itself by manipulating the immune 
system to establish an immunosuppressive tumor microenvironment (TME). Therefore, 
targeting and reinstating patient’s immune system could serve as a powerful therapeutic 
tool. Indeed, immunotherapy has emerged in recent years as a potential adjunct treatment 
for solid tumors including PC. Immunotherapy modulates the host’s immune response to 
tumor-associated antigens (TAAs), eradicates cancer cells by reducing host tolerance 
against TAAs and provides both short- and long-term protection against the disease. 
Passive immunotherapy like monoclonal antibodies or adoptive T-cell based therapy 
focuses on direct targeting of tumor cells, whereas, active immunotherapy like cancer 
vaccines specifically activates the patient’s immune cells against cancer cells. Such 
strategies have been tested for antitumor responses alone and in combination with 
standard care in multiple preclinical and clinical studies. In this review, we discuss various 
immunotherapy strategies used currently and their efficacy in abrogating self-antigen 
tolerance and immunosuppression, as well as their ability to eradicate PC.  
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2. Introduction to Immunotherapy 
It's forecasted that by 2030, pancreatic cancer (PC) will become the second 
leading cause of cancer-related deaths in the United States [1]. The current overall 
survival of PC patients by stage of disease progression is no more than 14% at Stage I, 
and the overall 5-year survival is approximately 8% [2]. The success rate of various 
treatment modalities for PC including surgery, chemotherapy, and radiation is limited and 
reoccurrence is typically inevitable [3]. In addition, late diagnosis of the disease further 
compounds the problem leading to high mortality rate. Recently immunotherapy has 
revolutionized cancer treatment especially in melanoma [4, 5]. It is increasingly being felt 
that immunotherapy if applied properly in combination with the standard of care can lead 
to better outcomes in solid tumors including PC. Studies support immunotherapy as a 
viable and metamorphic approach, which can boost and restore the immune system’s 
ability to fight against cancer.  
In this review, we describe the current understanding of different immunotherapeutic 
approaches including anti-cancer monoclonal antibodies (mAbs), T-cell-mediated 
immunotherapies and cancer vaccines, as powerful strategies for PC treatment. We will 
also discuss the clinical efficacy of immunotherapeutic strategies, challenges and assess 
their feasibility as next-generation treatment options, either alone or in combination with 
chemotherapy for PC treatment.  
3. Immunoediting and Immunosuppressive Microenvironment 
The interaction of the immune system with cancer cells is comprised of the three 
phases: Elimination, Equilibrium and Escape [6-8]. During the Elimination phase, the 
immune system can recognize and eliminate transformed cells. PC cells shed MICA that 
impairs cell surface expression of NKG2D receptor on T-cell and Natural Killer (NK) cells, 
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thus, helping tumor cells to escape immune surveillance by inhibiting the cytolytic activity 
of T-cell and NK cells [9, 10]. Transformed cells that escape the Elimination phase enter 
the Equilibrium phase, in which cancer cells undergo genomic editing and establish the 
tumor microenvironment (TME) that supports the growth of the early lesions. Finally, in 
the Escape phase, PC recruit immunosuppressive cells like myeloid-derived-suppressor 
cells (MDSCs), regulatory T-cells (Treg cells) and tumor-associated macrophages (TAMs) 
[11, 12]. These immature MDSCs induce apoptosis in activated T-cells. Depletion of 
MDSCs in an autochthonous PC mouse model results in the unmasking of adaptive 
immune responses, tumor cell death and remodeling of tumor stroma [13, 14]. PC 
conditioned media-treated CD4+ T-cells favored expansion of CD69+ activated Treg subset, 
which is known to suppress CD4+ T-cell proliferation, thus promoting immunosuppression 
[15].  
 PC tumor and stromal cells secrete angiogenic chemokines like vascular 
endothelial growth factor (VEGF), signaling molecules like galectin-1 (GAL-1) [16], anti-
inflammatory cytokines like Interleukin (IL)-10, IL-13 [17], and immune-inhibitory ligands 
like programmed death ligand 1 (PD-L1), cytotoxic T-lymphocyte-associated protein 4 
(CTLA-4), which further facilitate escape from cytotoxic cell-mediated death by cluster of 
differentiation (CD)8+ T-cells and NK cells  [13, 14, 18-22] (Figure 1). Additionally, 
exhausted CD8+ T-cells have chromatin-accessible-regions (ChARs) that serve as an 
enhancer to maintain high levels of programmed cell death protein 1 (PD-1), which further 
keeps CD8+ T-cells in an immunosuppressive state [23]. After escaping the 
immunosurveillance, immunologically and genetically modified tumor cells proliferate, 
which further prevent immunological [6, 8, 24]. Overall, cancer cells modify itself 
genetically and exploit the immunosuppressive behavior of the immune system to facilitate 
its escape from cell death mediated by CD8+ T lymphocytes and NK cells. 
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4. PC Microenvironment and Immune Suppression 
PC cells harbor limited genetic alterations and simultaneously modulate the TME to 
escape antitumor immune response. Several studies suggest that immunotherapeutic 
approaches are more effective in cancers with high mutation profile, displaying varied 
neoantigens, and having permeable tumor matrix architecture allowing better effector 
CD8+ T-cell infiltration [25, 26]. Furthermore, PC is an immunologically ‘cold’ tumor due to 
its low mutational load, dense desmoplasia and rigid extracellular matrix architecture, 
which restricts the access of effector immune cells to tumor islands, a phenomenon known 
as excluded infiltrate TME [27-31]. 
Activated PC stromal compartment excludes CD8+ T-cells, CD20+ B-cells, and 
CD56+ NK cells from the juxtatumoral region of the tumor. Administration of all-trans 
retinoic acid in a spontaneous K-rasLSL.G12D/+; p53R172H/+; Pdx-1Cre mice (KPC) mouse 
model induced quiescence in stromal cells, reduced fibronectin expression and 
correspondingly increased high influx of CD8+ T-cells into juxtatumoral compartment [32]. 
In PC tumor-bearing transgenic mice, ~55% of fibroblast activation protein-positive (FAP+) 
stromal cells were depleted by selective expression of the diphtheria toxin receptor, 
showed slow tumor growth only in the presence of CD4+ and CD8+ T-cells in the TME. 
Administration of anti PD1 and anti CTLA-4 antibodies along with FAP+ stromal cell 
deletion further reduced tumor growth in these mice [33]. Jiang et al. targeted focal 
adhesion kinase (FAK) using a selective FAK inhibitor VS-4718 and observed reduced 
tumor fibrosis and significantly increased survival of KPC mice, compared to untreated 
control mice. The authors demonstrated that FAK was hyperactive in neoplastic PC tumor 
and contributed to immunosuppressive TME by restricting cytotoxic CD8+ T-cells 
infiltration. Inhibition of FAK made TME penetrable, which increased adoptive cytotoxic 
anti-ovalbumin (OVA) CD8+ T-cells infiltration in the tumor and the efficacy of PD-1 
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antagonists in KPC mice when combined with low dose gemcitabine (25mg/kg) compared 
to combined treatment with vehicle, gemcitabine and anti PD-1 antibody [34]. These 
studies suggest that the presence of stroma in PC adds an obstacle to current 
immunotherapy strategies. 
Modulation of stromal cells and their effects are influenced by galectins, which are 
soluble immune-modulating glycoproteins involved in T-cell homeostasis. For example, 
GAL-1 is expressed primarily by pancreatic stellate cells (PSCs), and GAL-1 
overexpressing PSCs have been shown to induce apoptosis in co-cultured CD4+ and 
CD8+ T-cells compared to normal or quiescent PSCs [35, 36]. Another member of the 
galectin family, Galectin3 (Gal3), has also been demonstrated to play an important role in 
CD8+ T-cell biology by inducing the apoptosis in activated T-cells [37, 38]. Jaffee et al. 
found that neu-specific CD8+ T-cells have a high surface expression of lymphocyte 
activation gene 3 (LAG3), and Gal3 interaction with LAG3 induces immunosuppressive 
signaling in T-cells through the Gal3-LAG3 axis. This interaction reduces Interferon γ 
(IFNγ) production by CD8+ T-cells and abrogates their infiltration into the TME [39]. 
Immunization with GM-CSF/neu (granulocyte-macrophage colony-stimulating 
factor/neu) vaccine has higher efficacy in Gal3 knockout tumor-bearing mice when 
compared to wild-type tumor-bearing mice. After 60 days of treatment, approximately 80% 
of Gal-3-knockout mice were disease free, compared to 20% of wild-type mice. Neu-
specific CD8+ T-cells produced high amounts of interferon-gamma (IFNγ) and granzyme 
B. In addition, Gal3 knockout mice had increased infiltration of plasmacytoid dendritic cells 
(DCs), which have a higher potential to activate CD8+ T-cells than conventional DCs. 
Thus, galectins play an important role not only in modulating T-cell function but also in the 
recruitment of immunosuppressive myeloid-derived suppressor cells (MDSCs) [39]. 
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Apart from the establishment of stroma, tumor cells also modulate the cellular 
composition of their microenvironment. Tumor-associated macrophages (TAMs), which 
are M2 (pro-tumor) differentiated macrophages, express tolerance-inducing ligands such 
as PD-L1/L2, promote angiogenesis, and suppress adaptive immune responses through 
matrix remodeling carried out by matrix-metallopeptidases (MMPs) [40]. In addition, 
immunosuppressive CD4+FOXP3+ Treg cells heavily infiltrate human PC tumors. In the 
KPC mouse model Treg infiltration increases during the progression from pancreatic 
intraepithelial neoplasm (PanIN) to the advanced PC stage [13]. Similarly, increased 
numbers of CD68+ TAMs and MDSCs in circulation and TME are associated with disease 
invasiveness in PC patients [41, 42]. MDSCs also produce reactive oxygen species that 
further inhibit the antigen-specific response of CD8+ T-cells in TME [43].   
PC tumor cells secrete anti-inflammatory cytokines and angiogenic chemokines 
that promote an immunosuppressive TME while facilitating metastasis [3, 32, 41, 44]. 
These cytokines activate Treg and Th2 cells that prohibit anti-tumor responses elicited by 
other immune cells [24, 45-47]. Likewise, Indoleamine 2, 3-dioxygenase (IDO) enzyme is 
secreted by PC tumor cells that upregulate the growth of tumor cells by catabolizing 
tryptophan into kynurenine, and in turn inhibits T-cell and NK cells activation as well as 
induces Treg differentiation leading to immunosuppressive TME [3].  
Cytotoxic T-cells (CTLs), helper T-cells and DCs are functionally impaired in the 
immunosuppressive TME of PC, thus skewing to Th2 (tumor-tolerating) responses. 
Therefore, a proper understanding of these intricate cancer-immune system interactions 
is very essential to develop and monitor efficacious immunotherapies. The primary goal 
of PC immunotherapies is to target these interactions and the reprogramming of the 
immune system against PC tumor microenvironment  
8 
 
5. Immunotherapy Based Approaches 
The goal of immunotherapy is to induce antitumor responses by reprogramming and 
augmenting immune surveillance and removing immune suppression. These anti-cancer 
immunotherapeutic approaches are divided into ‘passive’ and ‘active’ immunotherapies. 
Passive immunotherapeutic strategies involve mAbs, adoptive T-cell transfers and 
genetically engineered T-cells. Whereas the active immunotherapeutic approaches 
include vaccine-mediated immunity induced by the administration of tumor-associated 
antigens (TAAs) [48]. The TAAs could be delivered in the form of DNA or peptide vaccines, 
as well as modified tumor cells or antigen-pulsed DCs. Due to genetic alterations or post-
translational modifications of proteins (such as glycosylation, phosphorylation, etc.), tumor 
cells can express proteins that differ from their counterpart in the normal cells or are 
aberrantly overexpressed in tumor tissues [49].  
5.1 Passive Immunotherapeutic Strategies 
Passive immunotherapy attacks cancer by directly targeting TAAs by the 
administration of diverse immune components that are engineered ex vivo. Following are 
the major passive immunotherapeutic strategies ongoing in preclinical studies or clinical 
trials and have been summarized in Table II. 
5.1.1 Antibody-Mediated Passive Immunotherapy 
 
Antibody-mediated immunotherapy involves targeting tumors using monoclonal 
antibodies (mAbs), antibody fragments, antibody-drug conjugates, or radio-
immunotherapy conjugates to inhibit tumor signaling, immune suppression, or immune 
checkpoint blockade.  
Anti CD40 mAbs 
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CD40 is a member of the tumor necrosis factor (TNF) receptor superfamily and is 
expressed primarily on APCs such as DCs, macrophages, monocytes, B-cells and some 
non-immune cells like cancer cells [50]. Anti-CD40 antibodies mimic the co-stimulatory 
signal of the CD40 ligand (CD40L). Tumor-bearing KPC mice with constitutive K-ras 
activation and gain-of-function p53 mutation when treated with anti-CD40 (clone FGK45, 
endotoxin-free), either alone or in combination with gemcitabine, showed detectable tumor 
regression. Treatment with anti-CD40 mAb bypassed the requirement for Toll-Like 
Receptors (TLRs), inflammasome, Type I interferons (IFNs), and stimulator of interferon 
genes (STING) to effectively prime adaptive T-cell responses against PC in these animals 
[51]. The mechanistic role of agonistic anti-CD40 mAb is to activate host antigen 
presenting cells (APCs) especially DCs, and also to induce clinically relevant antitumor T-
cell responses, reverse tumor-induced immune suppression and induce T-cell-
independent but macrophage-dependent tumor regression in PC patients [52]. In a clinical 
trial, 22 naïve patients with advanced PC were administered weekly doses of anti-CD40 
mAb in combination with gemcitabine, which led to the increased B-cell surface expression 
of co-stimulatory molecules CD86, HLA-DR, and CD54 at 24-48 h post-treatment [52-55]. 
In another study on 21 chemotherapy-naϊve and surgically incurable PC patients, 
treatment with gemcitabine and a human agonist anti-CD40 mAb (CP-870,893) for three 
weekly cycles showed the enhanced overall survival of 7.4 months compared to those 
who received gemcitabine alone with the median overall survival of 5.7 months. Upon 
biopsy, the tumors of anti-CD40 mAb-treated patients showed higher infiltration of 
macrophages, however, with accompanying absence of lymphocytes [55, 56]. 
Anti PD-L1mAbs 
 PD-1 (CD279) is a T-cell co-inhibitory receptor expressed on the surface of 
activated T-cells, Tregs and monocytes had extensively been exploited for immunotherapy. 
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PD-1 on T-cells interacts with two B7 family ligands, PD-L1 (CD274) and PD-L2 (CD273) 
expressed on tumor cells that leads to T-cell anergy or death and thus leading to tumor 
survival [57]. Presence of infiltrating PD-1+ T-cells in densely or loosely desmoplastic 
pancreatic tumors suggests tumor antigen-specific T-cell activation that correlates with 
increased overall survival, progression-free survival and distant-metastasis-free survival 
of PC patients [58]. Activated T lymphocytes infiltrating the TME express inflammatory 
cytokines like IFNγ that further stimulates PD-L1/L2 expression in the tumor cells [59, 60]. 
Blockade of PD-1 by an mAb abrogates the PD-1/PD-L1 axis and restore T-cell cytotoxic 
function [61]. In a preclinical study, combined treatment of Panc02 tumor-bearing mice 
with anti-PD-L1 mAb and gemcitabine significantly reduced average tumor volumes 
compared to gemcitabine and anti-PD-L1 mAb alone [62]. Due to the relative success of 
anti-PD-1 antibodies in both preclinical and clinical studies on selective solid tumors, the 
FDA recently approved two anti-PD-1 antibodies, pembrolizumab and nivolumab, for head 
and neck cancer, renal, melanoma, and non-small cell lung cancer treatment [63, 64]. 
Anti CTLA-4 mAbs 
 CTLA-4 is another co-inhibitory molecule expressed on the surface of activated T-
cells and Treg cells. CTLA-4 present on T-cells interacts with B7-1/B7-2 ligands on APCs, 
resulting in depletion and suppression of CD68-mediated T-cell-activation [65]. 
Ipilimumab, an antagonist mAb against CTLA-4, inhibits immunosuppression by Treg cells 
and enhances the antitumor activity of effector T lymphocytes and innate immune cells. In 
a preclinical study, in-vitro treatment with ipilimumab significantly enhanced T-cell 
proliferation (preferentially promoting CD8+ T-cell expansion), Th1 cytokines release 
(IFNγ, IL-2, and IL-12), and increased cytotoxicity of CD8+ T-cells against Colo356/FG PC 
cells [66, 67]. In a Phase Ib clinical trial, patients with previously treated or histologically 
proven PC were given ipilimumab alone or in combination with GVAX. Post-treatment, 
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both the single and combination treatments enhanced mesothelin (MSLN) specificCD8+ 
T-cell populations that correlated with increased survival of >4.3 months, as well as a 
decline in CA-19.9 levels in 7 out of 15 patients compared to patients treated with 
ipilimumab alone (0 out of 15 patients) [68]. Combination therapy of anti-CD40, anti-CTLA-
4 and anti-PD-1 antibodies with chemotherapy/nab-paclitaxel in KPC mice resulted in 
tumor regression in 39% of the animals (17 out of 44 mice), along with increased CD8+ T-
cell infiltration and reduction in Treg cells (7-fold CD8: Treg ratio) in the PC TME. 
Furthermore, PC tumor cells implanted on the opposite flank were rejected with no 
additional treatment in 67-86% of mice, suggesting the development of immunological 
memory [69].  
Other targeted therapy antibodies 
Additionally, antibodies like cetuximab, pertuzumab, and trastuzumab that bind to 
the extracellular domain of the human epidermal growth factor receptor 1 (HER1)/ 
epidermal growth factor receptor (EGFR) and inhibit their dimerization and internalization 
are under clinical investigation [70, 71]. In Phase II and III clinical studies, patients with 
metastatic PC were administered cetuximab in combination with gemcitabine leading to a 
stable disease in 63.4% of PC patients and a partial response in 12.2% of patients 
however there was no increase in the median overall survival of metastatic PC patients. 
[72]. Contrarily in IMPaCT clinical trial using next-generation sequencing technologies, 
personalized treatment of 5 PC patient’s tumors with human epidermal growth factor 
receptor 2 (HER2) amplification with trastuzumab showed no successful outcome [73]. 
Similarly, another Phase II clinical trial showed no responses in 33 advanced PC patients 
treated with trastuzumab (3.0 or 4.0 mg/kg then 1.5 or 2mg/kg, weekly) and cetuximab 
(400mg/m2 and then 250mg/m2) [74]. 
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Scales et al., developed an anti-mesothelin (anti-MSLN) antibody to the unfolded, 
non-glycosylated MSLN extracellular domain and conjugated it to the microtubule-
disrupting drug monomethyl auristatin E (MMAE). Humanized versions of anti-mesothelin 
(MSLN)-MMAE induced regression of MSLN-expressing HPAC xenografts in nude mice 
with a doubling delay to ≥74 days. Due to its robust and durable efficacy in mouse models, 
humanized anti-MSLN-MMAE is in Phase I clinical trials for PC [75]. Similarly, a Phase II 
clinical trial with the VEGF antibody bevacizumab in 19 out of 30 patients showed stable 
disease and partial response in 1 patient, although the antibody treatment alone did not 
improve the overall survival of patients [76].  
MDSCs are known to secrete tumor-promoting factors, such as prokineticin 2 
(PK2/Bv8). Anti-Bv8 antibody targeting the extracellular domain of Bv8 given in 
combination with gemcitabine reduced growth of orthotopic metastatic PC tumors, 
significantly reduced MDSCs infiltration, hypoxia and angiogenesis compared to mice 
treated with gemcitabine alone, indicating the significant potential of the anti-Bv8 antibody 
as a combinatorial or post-chemotherapy treatment in PC patients [77]. PC cells express 
antigens that are either unique to cancer or are being shared with other cancers with 
similar epithelial origin. The widely studied TAAs of PC that are currently utilized in 
vaccines in clinical trials are listed in Table I. 
5.1.2 Passive T-cell-Mediated Immunotherapy 
 Monoclonal antibody (mAbs) based targeted therapy can elicit direct killing of 
tumor cells but has not provided long-term benefit to PC patients. Multiple studies are 
evaluating the strategies to develop passive T-cell-mediated immunotherapies including 
increasing the number of antigen-specific CD8+ T-cells, the responsiveness of the antigen-
specific T-cells, or the affinity of the antigen-specific T-cell receptor (TCR) (e.g., with 
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transfected TCRs). Additional summary regarding the current clinical trials utilizing these 
strategies is provided in Table III. 
a) Adoptive T-cell transfer (ACT) 
 The primary objective of ACT therapy is to isolate and expand T-cells ex vivo and 
transfer these autologous lymphocytes with antitumor activity in cancer patients. This 
method leads to the expansion of antitumor T-cell populations in the patient resulting in 
increased cytokine release and tumor cell targeting.  
Kawaoka et al., developed CTLs by isolating T-cells from the blood of healthy 
volunteers expressing human leukocyte antigen (HLA)-A phenotype 24/26 and stimulating 
them with the MUC1-expressing human PC cell line YPK-1 (HLA-A phenotype 24/02) in 
combination with IL-2. The MUC1-specific CTLs killed five MUC1-expressing PC cell lines, 
irrespective of their HLA phenotype. 20 patients with either non-resectable or resectable 
PC were treated with MUC1-specific CTLs. Patients with non-resectable tumor did not 
show any improvement (median survival time (MST) of 5 months), however, 18 out of 20 
patients with resectable PC responded with an MST of 17.8 months [78]. 
 Murine PC cell lines have significant overexpression of telomerase activity. 
C57BL/6 mice were immunized with H2b-restricted telomerase peptide emulsified with 
incomplete Freund’s adjuvant, in complex with macrophage-activating lipopeptide-2 
(MALP-2, a Toll-like receptor 2/6 agonist) to drive the generation of telomerase-specific 
CTLs. Orthotopically implanted syngeneic tumor-bearing mice were treated with IL-2-
expanded anti-telomerase CTLs, which significantly reduced tumor volume compared to 
untreated mice. In addition, anti-telomerase CTL-treated mice developed higher numbers 
of both CD8+ central memory and effector antigen-specific T-cells [79]. Furthermore, in a 
clinical study, 46 PC patients with non-resectable and recurrent tumors received anti-CD3-
stimulated lymphokine-activated killer (CD3-LAK) therapy (25 patients) or RetroNectinVR 
14 
 
(CH296)-induced T-cell (RIT) therapy (21 patients) at 2-week intervals. The ACT treated 
patients showed an increased circulating levels of IFNγ, IL-12, and IL-2, suggesting that 
the combined circulatory levels of these cytokines may serve as a predictive marker of the 
clinical response to ACT in patients [80]. 
b) Chimeric antigen receptors (CAR) T-cells 
 Highly antigen-specific autologous T-cells that are genetically engineered to 
express tumor antigen-specific TCRs or immunoglobulin-based fusion proteins are known 
as chimeric antigen receptors (CAR) T-cells.  These engineered CAR T-cells are then 
cultured and expanded ex vivo for therapeutic purposes (Figure 2). 
The differential glycosylation pattern of mucins provides a unique repertoire of 
antigenic epitopes that can be exploited for developing tumor-specific CAR T-cells. Posey 
et al. designed a scFv of a high-affinity antibody (5E5) to detect truncated O-glycopeptide 
MUC1 epitopes (GSTAP with one or two Tn O-glycans on the Ser/Thr residues) that are 
not expressed in normal tissues. MUC1 CAR T-cells (composed of 5E5 mAb scFV on a 
CAR backbone of CD8α, transmembrane domain and costimulatory domains of 4-1BB 
and CD3ζ) were generated that target the Tn/STn glycopeptide epitope on MUC1, and 
upon recognition of MUC1-9Tn, secreted high quantities of IL-2 and IFNγ, but not in 
response to the non-glycosylated MUC1-60-mer. Hs766T pancreatic tumor-bearing mice 
when treated with 5E5 CAR T-cells showed potent responses and improved survival to 
113 days with 100% animals surviving compared to 40% and 33% of mice treated with 
non-transduced and CD19 CAR T-cells, respectively. In addition, many 5E5 CAR T-cells 
specifically accumulated in Hs766T tumors, in contrast to a small percentage of CD19 
CAR T-cells [81, 82].  
Carcinoembryonic antigen (CEA) is highly overexpressed on the surface of PC 
cells. Murine CEA binding domain (SCA431scFv)-containing CAR T-cells with intracellular 
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CD28-CD3 signaling domain were adoptively transferred into Panc02 CEA+ tumor-bearing 
CEA transgenic mice. Anti-CEA CAR T-cells significantly reduced the size of pancreatic 
tumors and produced long-term tumor elimination in 67% of the mice without inducing an 
autoimmune reaction. Upon re-challenge with CEA+ C15A3 cells, the animals rejected the 
cells and demonstrated increased serum levels of IL-1β and IL-5 [83]. A similar study 
reported the eradication of CEA+ tumors in CEA-transgenic mice as a primary response 
to anti-CEA CAR T-cells with CD3ζ endo-domain and rejection of CEA+ PC cells upon re-
challenge. Based on the CAR T-cell model, there is evidence that antigen-specific CD8+ 
T-cells can be induced to overcome self-tolerance and eliminate cancer cells while sparing 
normal cells [84].   
 Prostate stem cell antigen (PSCA) is another highly expressed TAAs in PC 
patients as well as in tumor-derived cell lines. In a recent study, PSCA-specific CAR T-
cells showed specific targeting and lysing of PSCA-expressing PC cells (ASPC1, Capan-
1) while PSCA-negative 293T-cells showed no cytotoxicity [85]. In another study, anti-
PSCA CAR T-cells were engineered using antigen-recognition domains derived from 
mouse or human antibodies with either one (CD28) or two (CD28 + 4-1BB) T-cell co-
stimulatory molecules linked to the CD3ζ endo-domain. These anti-PSCA CAR T-cells 
elicited antitumor responses in established human PC-derived xenograft tumors and 2 out 
of 5 mice showed complete tumor eradication [86].  
 MSLN is highly overexpressed on PC cells compared to its negligible expression 
in normal pancreas. Hingorani et al. developed MSLN peptide-specific high-affinity 
TCR1045 expressing CD8+ CAR T-cells that lysed KPC tumor cells in vitro and secreted 
IFNγ upon antigen recognition. A study in KPC mice showed that TCR1045 CAR T-cells 
infiltrated the pancreatic tumors four days post-injection and induced apoptosis of cancer 
cells after eight days of infusion. Upon the second infusion, TCR1045 CAR T-cells showed 
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10-fold increased retention in pancreatic tumor compared to non-specific (TCRgag) T-cells. 
However, mice in both treatment groups developed progressive disease. TCR1045 cell 
recipient mice showed less metastasis (46%) and overall survival of 96 days compared to 
64% metastatic lesions and survival of 54 days in TCRgag treated mice. Overall, these data 
suggest that tumor antigen-specific engineered T-cell therapies are viable options for the 
treatment of invasive PC [87].  
5.2 Active Immunotherapeutic Strategies 
Active immunotherapy relies on stimulation of the immune system through 
immunological recognition of TAAs by T and B lymphocytes. TAAs have been widely 
explored as cancer vaccines for the treatment of PC in both in vivo mouse models and 
clinical trials. Cancer vaccines can be whole cancer cell-based vaccines, antigenic-peptide 
pulsed vaccines or DC-based vaccines. These vaccines are developed to exploit and 
activate both innate and active immune arms to eradicate tumor cells and evade future 
recurrence of the disease. Cancer vaccines currently being investigated in clinical trials in 
PC are summarized in Table IV. 
5.2.1 Cancer Vaccines 
Mucin (MUC) Vaccines 
Mucins (MUCs) are glycoproteins that are differentially overexpressed in 
pancreatic tumor but is absent in normal pancreas. Some mucins (e.g., MUC1 and MUC4) 
have also been demonstrated to contribute to chemoresistance, and to enhance 
proliferation and survival of PC cells [88]. Therefore, mucins are being studied as potential 
candidates for vaccine development for PC. Studies conducted in human MUC1-
transgenic (MUC1.Tg) mice treated with MUC1 cancer vaccines failed to show any 
detectable responses against MUC1+ tumor cells despite, MUC1-specific T-cells 
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generating IFNγ, IL-4 and IL-10 cytokines. The immune responses in these mice were not 
skewed to either type 1 or type 2 immune response thus rendering the vaccine ineffective 
against the B16.MUC1 tumor.[89]. The CD8+ T-cell killing of MUC1-expressing tumor cells 
was found to be mediated by perforin and FasL cytolytic pathways. Also, lymphotoxin-α, 
but not TNF receptor-1 (TNFR-1), played a critical and non-redundant role in the cell-
mediated rejection of MUC1 expressing tumor cells [90]. In a Phase I clinical trial, MUC1-
peptide (GVTSAPDTRPAPGSTAPPAH)-pulsed DC vaccines were administered to 7 
patients with advanced PC. 2 out of 7 patients showed significantly increased mature DCs 
and peripheral blood mononuclear cell (PBMC)-mediated immune responses that were 
characterized by high IL-12p40 and IFNγ secretion, respectively. However, there was no 
tumor rejection in these patients [91]. A similar Phase I clinical trial in 20 advanced PC 
patients was performed with MUC1 peptide-pulsed DCs in combination with MUC1-
specific CTLs. One patient with lung metastases showed complete remission, while five 
other patients demonstrated stable disease for at least six months post-therapy [92]. A 
study was conducted with 6 PC metastatic patient-derived DCs that were co-transfected 
with MUC4 and survivin mRNAs. These mRNA-loaded DCs activated CTLs against the 
MUC4 protein. Anti-MUC4 CTLs effectively targeted a human PC cell line (Capan-2) via 
major-histocompatibility-complex-I (MHC-I)-restricted recognition and released IFNγ. 
MUC4-mRNA-pulsed DCs stimulated more CTLs than survivin-mRNA-pulsed DCs, but 
comparatively elicited fewer CTLs activated by MUC4-survivin-mRNA-loaded DCs [93]. In 
another study, mature DCs were pulsed with a MUC4 epitope peptide (LLGVGTFVV) and 
co-cultured with CD8+ T-cells to generate MUC4-specific CTLs that could effectively kill 
HCT-116 colorectal cancer cells (MUC4+, HLA-A2+). However, the intensity of MUC4 
surface expression on PC cell-line HPAC proportionally increased the apoptosis of MUC4-
specific T-cells, thus rendering the therapy ineffective [94]. Based on these studies, other 
18 
 
mucins like MUC5AC, and MUC16 that are significantly overexpressed in PC may serve 
as potential vaccine candidates to develop novel immunotherapies. 
Telomerase Vaccines 
Due to overexpression of telomerase in PC patients, cancer vaccine containing 
telomerase-derived peptide (GV1001) vaccine is under clinical studies. However, so far 
PC patients treated with a combination of the GV1001 vaccine, GM-CSF, and gemcitabine 
showed transitory and weak Th1-type immune response, reduced infiltration of Treg cells, 
and no significant increase in median overall survival. In a related clinical trial, the GV1001 
vaccine failed to enhance the effects of chemotherapy (gemcitabine and capecitabine) 
[95, 96].  
 CEA Vaccines 
CEA is overexpressed in >90% of PC patients making it a potential 
immunotherapeutic target. A Phase I clinical trial with CAP1-6D, an altered CEA peptide 
ligand/Montanide/GM-CSF vaccine, administered to 66 PC patients elicited robust CD8+ 
T-cell-mediated. In addition, 8 of the patients were found to have high IFNγ production, of 
which four patients showed progressive disease, three patients had stable disease, and 
one patient showed a complete response [97]. 
 KIF20A Vaccines 
 Another cancer vaccine candidate is kinesin-like protein 20A (KIF20A), a member 
of the kinesin super family, which is significantly upregulated in PC.  KIF20A-66, an HLA-
A24-restricted epitope peptide derived from KIF20A peptide vaccine was injected into 29 
PC patients in Phase II clinical trial. The tumor size (as confirmed by CT scan) was 
reduced in 8 patients and 16 patients showed increased CTL responses, which correlated 
with the increased overall survival of vaccinated patients [98]. In a similar Phase I trial, 
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nine advanced PC patients who previously received chemo/radiotherapy were treated with 
KIF20A-10-66 (KVYLRVRPLL) peptide vaccine along with gemcitabine. These patients 
showed increased activation of KIF20A-specific IFNγ-producing T-cells, had stable 
diseases and longer overall survival, indicating that KIF20A-based vaccines are possible 
immunotherapy candidates for PC [99]. 
 K-ras Vaccines 
K-ras is mutated in the majority of PC patients and is currently under investigation 
as an immunotherapy target. Inactivation of the oncogenic mutant K-ras enhances MHC I 
presentation [100]. In an in vivo study, mice were treated with lysates of human PANC-1 
PC cells expressing mutant K-ras, with lysate in combination with K-ras mutant peptide 
(K-ras+peptide), or with lysate and peptide plus cationic nanoparticles (CNP) 
encapsulating K-ras mutant peptide (K-ras+peptide-CNP). The K-ras+peptide-CNP 
activated CTLs induced specific killing of K-ras-positive tumors efficiently and improved 
the survival time of K-ras mutant tumor-bearing nude mice compared to the K-ras mutant 
lysate and K-ras peptide treatment group (132). In addition, a clinical trial testing a mutant 
Ras peptide vaccine (administered in combination with GM-CSF) in 11 patients with 
advanced PC  showed higher antitumor responses (92% exhibiting an immune response) 
with two patients having a complete response and overall survival of 20.8 months [101, 
102].  
 WT1 Vaccines 
 The Wilm’s Tumor protein 1 (WT1) is another suitable vaccine target for PC due 
to its differential overexpression in tumor cells but not in the normal pancreas [103]. In a 
recent study, 32 HLA-A*24:02+ advanced PC patients were treated with an HLA-A*24:02-
restricted, modified 9-mer WT1 peptide (CYTWNQMNL) emulsified with Montanide ISA51 
adjuvant (WT1 vaccine). The MST of patients who responded to the WT1 vaccine was 
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10.9 months. Further, these patients developed strong effector T-cell responses along 
with generation of WT1-specific CD8+ memory T-cells, whereas unresponsive patients 
showed MST of only 3.9 months [104]. In a separate clinical trial, nine patients with 
advanced PC were vaccinated with WT1 peptide vaccine and 8 out of 9 patients 
demonstrated stable disease. However, no WT1-specific T-cells were observed in the 
circulation of these patients [105]. 
 VEGF Vaccines 
VEGF is another protein that is overexpressed in PC. In a trial, nine advanced PC 
patients were vaccinated with four peptides comprised of KIF20A, cell division cycle-
associated 1 (CDCA1), VEGFR1, and VEGFR2. Patients demonstrated increased anti-
CDCA1 and anti-VEGFR2 CD8+ T-cells in circulation. Additionally, 4 out of 9 patients 
presented with stable disease post-vaccination [106]. In a subsequent study, vaccination 
with WT1 and VEGFR2 peptides generated HLA-A24-restricted CTLs, which 
demonstrated strong cytotoxicity towards PC cells that were HLA-A24-positive and 
expressed corresponding TAAs [107]. 
Prophylactic Cancer Vaccines 
Prophylactic vaccines have recently been investigated as immunotherapy tools to 
target endogenous neoantigens by utilizing attenuated bacteria/virus to stimulate 
antitumor adaptive immune responses [108]. Listeria monocytogenes (LM) is a gram-
positive bacterium that induces robust CD4+ and CD8+ T-cell responses by its selective 
infection of APCs (via actA virulence gene) over non-phagocytic cells (inlB gene). An LM 
ΔactA/ΔinlB strain engineered to express human MSLN (CRS-207 vaccine) was 
administered to 10 PC patients, which resulted in induction of expression of Th1 cytokines 
(IL-12, TNF-α). In addition, 6 out of the 10 patients developed MSLN-specific CD8+ T-cells 
[109, 110]. Jaffee et al. conducted a clinical trial on 93 metastatic PC patients, in which 69 
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patients received two doses of cyclophosphamide with GVAX (Cy/GVAX) followed by four 
doses of CRS207 (Arm A) and 21 patients received six doses of Cy/GVAX (Arm B). 
Patients in Arm A  showed increased overall survival of 9.7 months compared to 4.6 
months inArm B, suggesting that the success of this immunotherapy might depend on the 
proper patient selection [111]. The KrasG12D oncogene prophylactic vaccine (LM-K-ras 
vaccine) has been studied in KPC mice, either alone or in combination with Treg depletion 
(anti-CD25 antibody, PC61, and low-dose Cy). KPC mice that received the vaccine at 
early PanIN 1 stages in combination with Treg depletion showed prolonged survival 
compared to mice that received the vaccine alone at either early or late PanINs stage, 
suggesting the potential of Treg depletion therapy as the prophylactic approach for PC 
[112].  
STING activation as an adjuvant to vaccines and other immunotherapies  
 STING is a transmembrane protein that resides on the endoplasmic reticulum, 
which upon activation through cyclic dinucleotides (CDNs), synthetic CDNs, or bacterial 
infection in the host induces interferon beta (IFNβ) and nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB) pro-inflammatory responses via IRF3 and Stat6 
pathways [113].  It has been shown that endogenous STING activation via CDNs in the 
tumor microenvironment enhanced inflammatory responses, thereby inhibiting tumor 
progression and distant metastasis [114].  Recently, intraperitoneal injection of DMXAA, 
an activator of the mouse STING pathway, activated CD8+ T-cells that led to tumor 
rejection [114, 115]. Similarly, synthetic STING activators known as RR-CDGs have 
shown efficacy in the regression of primary pancreatic tumors, and distant metastatic 
lesions through T-cells recruitment in a TNF-α-dependent manner [116]. Furthermore, 
these novel synthetic activators of STING have demonstrated enhanced adjuvant activity 
to accelerate adoptive immune responses in the presence of radiation therapy [116]. The 
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cGAMP-induced activation of endothelial cell-specific STING enhanced the antitumor 
responses of CD8+ T-cells and improved the responses of anti-CTLA-4 and anti-PD-1 
immunotherapies [117]. 
6. Challenges in Pancreatic Cancer (PC) Immunotherapy 
The immune system has the potential to selectively target tumor cells upon 
strategic activation in cancer patients leading to better therapeutic outcomes. However, 
tumors employ extensive measures to escape immune surveillance, suggesting the 
necessity to develop novel counteracting strategies for the improved efficacy. Therefore, 
recent immunotherapeutic approaches alone or in combination with conventional 
treatment modalities need to be re-evaluated for successful therapeutic outcome in terms 
of improved patient survival.  
6.1 Identification of Tumor Associated Antigens for PC Immunotherapy 
Tumor-associated antigens are autologous cellular antigens that are specifically 
expressed by cancer cells and are negligibly expressed by or absent in normal cells. 
Mutation-derived tumor antigens are generated by somatic mutations inherited by tumor 
cells during malignant transformation that may be identified by immune surveillance [118]. 
The Cancer Genome Atlas (TCGA) database analysis showed that notably PC afflicted 
patients carry limited genetic mutations between 4 to 4000 neoantigens [119, 120]. When 
compared to melanoma patients who could likely express 14000 neoantigens that is a 
significantly low number of neoantigen repertoire in PC patients. Further expression 
neoantigens mutation load correlated negatively with T-cell tumor infiltration and 
corresponding overall survival of PC patients [119]. Differentially and spatiotemporally 
overexpressed or post-translationally antigens could potentially serve as tumor antigens 
for immunotherapy purposes [121]. A preferred way utilized to validate the likelihood of 
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these tumor antigens to be immunogenic in patients, is to detect autoantibodies against 
them in cancer patient serums and this strategy has met with moderate success [122, 
123]. Multiple proteins like mucins (MUC1), WT1, VEGF, etc. overexpressed in PC 
patients, have been extensively exploited for PC immunotherapy but have achieved 
limited success as discussed previously in the review. It has been challenging to identify 
eligible TAAs and thus, necessitates coming up with a strategy to discover novel tumor 
antigen that could be targeted efficaciously by immunotherapy in PC patients.  
6.2 Generation of Anti-Tumor Responses Against PC Microenvironment 
Strong immunosuppressive TME, rigid tumor matrix architecture, Tregs infiltration, 
constant antigen exposure mediated T-cell exhaustion, and upregulation of inhibitory 
receptors like PD-1 provide physical obstacles to effector T-cells function and generates 
tolerance towards tumors [124, 125]. Thus, checkpoint inhibitors and depletion of Tregs 
could potentially reverse T-cell exhaustion of effector T-cells. Improper homing and 
inefficient infiltration of CAR T-cells to the tumor bed occur due to tumor blood vessels not 
responding to inflammatory stimuli. Anti-angiogenic therapy matures tumor blood vessels, 
facilitating pericyte recruitment and increasing tumor perfusion, which consequently 
increases the efficacy of CAR T-cell immunotherapy [126]. Apart from improper homing, 
CARs recognize TAAs that are also found at a lower level in normal tissues (which can 
cause toxicities in PC patients), thus if CAR T-cells survive for long periods of time in 
patients they increase the risk of developing autoimmunity in the future [127]. Furthermore, 
activated CAR T-cells containing co-stimulatory domains like CD27, CD28 or 4-1BB 
release a variety of inflammatory cytokines like IL-2, IL-6, and IFNγ after encountering 
tumor cells which induce macrophages to release more inflammatory cytokines thus 
establishing a positive cytokine-based feedback loop to enhance T-cell activity causing 
cytokine release syndrome (CRS), which could be fatal for patients [128, 129]. 
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Development of short-lived CAR T-cells or combination treatment with an IL-6 receptor 
inhibitor like tocilizumab could be effective in reversing the effects of CRS without affecting 
the activity of CAR T-cells [128, 130]. 
 Human PC malignancy is complex because of its TME architecture and cytokine 
milieu that is inefficiently recapitulated in KPC or xenograft mouse models. Secondly, both 
tumor cells as well as normal cells express common antigens (though usually at a lower 
level than normal cells), and therefore cancer vaccines can potentially cause toxicities in 
the patients.  Thirdly, peptide-based cancer vaccines do not capture all unique 
immunogenic epitopes present on original tumor antigens. Pancreas-specific transgene 
expressing spontaneous PC mouse models, and either protein fragments or intact proteins 
as immunogens could address the limitations faced in this field, thereby increasing the 
cancer vaccine efficacy. Additionally, selection of PC patient based on both tumor stage 
and tumor infiltrating lymphocytes (TILs) like CD8+ and PD-1+ T-cells could further 
increase the response to cancer vaccines [131]. 
6.3 Overcoming Immunosuppression in PC Microenvironment 
 Nanoparticles are capable of encapsulating multiple proteins, ligands, nucleic 
acids and other materials, thus increasing the epitope repertoire. Nanoparticles can also 
incorporate immune-stimulatory adjuvants (such as TLR agonists) or chemotherapeutic 
drugs to enhance the overall immunogenicity, stability, delivery and/or direct cytotoxicity 
of the vaccine, therefore overcoming the limitations of current cancer immunotherapies 
[132]. For example, mice immunized with Doxorubicin-CpG-PLGA microparticles showed 
a reduced tumor burden at lower drug concentrations compared to mice that received 
doses of the soluble drug. When combined with an anti-CTLA-4 antibody, the treatment 
successfully reduced aggressive tumor burden at both the injected and distant tumor sites 
in tumor-bearing mice [133]. This co-encapsulation of multiple therapeutics and immune 
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stimulatory molecules may provide dose-sparing capabilities, reducing the cost and 
toxicity of cancer therapeutics [134]. 
 Encapsulation into biodegradable nanoparticles protects the payload until release 
[135, 136]. In addition, tuning the polymer chemistry enables sustained and controlled 
release of encapsulated payloads [137] and immunomodulatory capabilities [138]. 
Particularly, it has been demonstrated that varying chemistries of polyanhydride 
nanoparticles were efficiently internalized by APCs, leading to the upregulation of MHC I, 
major histocompatibility complex II (MHC II) and costimulatory molecules, as well as 
inducing the secretion of cytokines [139-141]. In addition, amphiphilic nanoparticles 
promoted the production of long-lived, high avidity antibody [142] with suboptimal doses 
of antigen [143], suggesting the development of long-lived plasma cells. Polyanhydride 
nanoparticles loaded with OVA-induced memory CD8+ T-cells that were recruited and 
responded to subsequent challenges with OVA-secreting tumor cells [144]. Finally, many 
nanoparticles can be functionalized with ligands or antibodies that may increase selectivity 
and reduce the side effects of chemotherapeutics on healthy tissues [145]. Targeting 
moieties are often attached to the nanoparticle surface via a polyethylene glycol (PEG) 
linker [145]. This method of PEGylation allows for flexibility of the targeting moiety and 
may enhance interactions with cancer cell receptors [145, 146]. For example, PLGA 
nanoparticles covalently modified with folate via PEG demonstrated an increased 
association and uptake with cancer cells in vivo [147]. 
 The limited success of immunotherapeutic studies performed in PC provides a 
generous room for improvement. Tailoring immunotherapy to PC patients by identifying 
unique tumor-specific antigens through genetic screening and expression studies [49, 
148]and combining it with continuous collection and screening of tumor samples in clinical 
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trials to understand immunotherapy resistance, will further improve the response rates 
and survival benefits of PC immunotherapy. 
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Table I: Tumor associated antigens targeted for PC immunotherapy. 
Tumor 
Associated 
Antigen 
(Cancer 
Antigen) 
Expression 
Description 
Normal 
Pancreas 
Pancreatic 
Cancer 
Mucins 
MUC1 
MUC4 
MUC5AC 
MUC4 and 
MUC5AC are 
undetectable, 
while MUC1 is 
expressed at 
low levels. 
Aberrantly 
overexpressed and 
glycosylated in PC 
patients 
Mucins are glycoproteins that 
are differentially overexpressed 
in PC but are not expressed in 
the normal pancreatic 
epithelium (except for MUC1 
which is expressed at low 
level). These mucins (e.g., 
MUC1, MUC4, and MUC5AC) 
are involved in PC 
pathogenesis, provide 
chemoresistance and enhance 
proliferation and survival of PC 
cells. Their overexpression has 
been correlated with poor 
prognosis in patients. 
[Ref. No. 54,64,69-70] 
Telomerase Absent 
Expressed in 80-
90% of PC patients 
Telomerase is a 
ribonucleoprotein enzyme that 
catalyzes the synthesis of 
telomeric DNA. It is involved in 
the formation and protection of 
the telomere, which prevents 
cells from undergoing 
senescence. Telomerase 
activity has been detected in 
pancreatic juice samples of PC 
patients. hTERT expression 
and telomerase activity are 
predictors of poor outcome in 
pancreatic cancer. 
[Ref. no. 55, 71-72] 
Carcinoembr
yonic 
antigen 
(CEA) 
Absent 
Expressed in 77% 
of PC patients and 
detected in patient 
serum. 
Carcinoembryonic antigen 
(CEA), a glycosylated protein of 
MW 180 kDa, is related to 
tumor burden of PC due to its 
close association with cancer 
28 
 
cell adhesion, metabolism, and 
proliferation. In clinical practice, 
CEA is often used to predict the 
outcomes of patients with 
resectable PC. 
[Ref. no. 60,73] 
Mutated K-
ras (G12D) 
Absent 
Expressed in 89.8-
94.9% of PC 
patients 
K-ras is mutated in PC cells 
and inactivation of the 
oncogenic mutant K-ras 
enhances MHC I presentation. 
K-RAS belongs to the 
superfamily of small G proteins 
and plays crucial roles in signal 
transduction in cells. K-
RAS mutations in PC transform 
and alter the biological behavior 
in PC cells including 
metabolism reprogramming, 
thus playing a crucial role in PC 
pathogenesis. 
[Ref. no. 77-80] 
Vascular 
endothelial 
growth 
factor 
(VEGF) 
Absent 
Expressed in 77-
93% of PC 
patients 
VEGF, primarily VEGF-A and 
its receptors (VEGFR1 & 
VEGFR2), are primarily 
involved in the angiogenesis 
process in PC cancer. 
Increased vascularization of 
pancreatic tumors promotes 
their growth and metastasis by 
providing nutritional flow. 
Neovascularization also 
facilitates infiltration of pro-
tumor immune cells (e.g., 
MDSCs). 
[Ref. no. 82-83] 
Mesothelin Absent 
Expressed in 
~86% of PC 
patients 
Mesothelin (MSLN) is a 
glycoprotein overexpressed in 
various epithelial cancers like 
mesothelioma and pancreatic, 
ovarian, and lung cancers. 
MSLN is synthesized as a 71 
kDa precursor protein, which is 
processed to a 30 kDa 
megakaryocyte-potentiating 
factor and a 40 kDa MSLN 
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protein. It is attached to the 
plasma membrane by a 
glycosylphosphatidylinositol 
anchor and is involved in cell 
adhesion. MSLN serves as a 
marker of neoplastic 
transformation of pancreatic 
epithelial cells. 
[Ref. no. 86-87] 
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Table II: Clinical trials testing antibody-based immunotherapies for pancreatic 
cancer. 
Antigen & 
Drug 
Clinica
l 
Trials 
.gov 
Identifi
er 
Phase 
No. of 
Patien
ts 
Status 
Median 
overall 
survival 
(months) 
Median 
progressi
on-free 
survival 
(months) 
Objective 
response 
rate (%) 
CD40 (CP-
870,893) 0.2 
mg/kg 
NCT00
711191 
[Ref. 
No. 35] 
I 22 
Comp-
leted 
7.4  
 (5.5 to 1
2.8) 
5.6  
 (4.0 to 7.
4) 
7.7  
 (0.2 to 36.
0) 
CD40 (CP-
870,893) + 
Gemcitabine 
NCT01
456585
* 
I 10 
Comp-
leted 
NRb NR NR 
PD-1 (CT-
011) alone or 
in 
combination 
with 
Gemcitabine 
NCT013
13416* 
II 29 
Susp-
ended 
NR NR NR 
PD-L1 
(pembrolizum
ab) 
NCT02
362048
* 
II 73 Active NR NR NR 
PD-L1 
(pembrolizum
ab) 
NCT02
009449
* 
I 350 Active NR NR NR 
CTLA-4 
(ipilimumab) 
NCT00
112580 
II 27 
Comp-
leted 
NR NR 
1 patient 
had PRc 
CTLA-4 
(ipilimumab) 
+ Pancreatic 
Cancer 
Vaccine 
NCT00
836407
* 
I 30 
Comp-
leted 
5.7  
(4.3 to 1
4.7) 
NR NR 
* Data obtained from https://clinicaltrials.gov/ 
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HER1 
(Cetuximab) 
+ Irinotecan + 
Docetaxel 
NCT00
042939
* 
II 87 
Compl
eted 
5.3  
 (4.5 to 9.
4) 
4.5  
 (2.7 to 5.
6) 
0.07  
 (0.024 to 
0.198) 
HER1 
(Cetuximab) 
+ 
Gemcitabine 
+ 
Radiotherapy 
NCT00
225784
*8 
II 37 
Compl
eted 
17.3 
 (2 to N/A
) 
9.1 
 (2 to N/A) 
10 out of 
37 had PR 
HER1 
(Cetuximab) 
+  Ixabepilon
e 
NCT00
38314* 
II 54 
Compl
eted 
7.6  
 (5.5 to 1
2.2) 
3.9  
 (2.6 to 4.
4) 
4 patients 
had PR 
HER1 
(Cetuximab) 
+ Irinotecan + 
Oxaliplatin 
NCT00
871169
* 
II 58 
Compl
eted 
NR NR 
6.9  
 (1.91 to 1
6.7) 
HER1 
(Cetuximab) 
+ 
Gemcitabine 
+ VEGF 
(Bevacizuma
b) 
NCT00
326911
* 
II 30 
Termi
nated 
5.41  
 (3.84 to 
6.74) 
3.55  
 (2.00 to 5
.59) 
4 patients 
had either 
PR or CRd 
HER1 
(Cetuximab) 
+ 
Gemcitabine 
+ VEGF 
(Bevacizuma
b) 
NCT00
091026
* 
II 71 
Compl
eted 
7.9  
 (5.5 to 9.
5) 
5.0  
 (3.7 to 5.
5) 
21  
 (12 to 32) 
HER1 
(Cetuximab) 
+ 
Gemcitabine 
+ Oxaliplatin 
NCT00
338039
* 
II 69 
Compl
eted 
19.2  
 (14.2 to 
24.2) 
NR NR 
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HER1 
(Cetuximab) 
+ 
Gemcitabine 
+ 
Capecitabine 
+ Radiation 
NCT00
305877
* 
II 65 
Compl
eted 
0.38  
 (0.26 to 
0.50) 
0.17  
 (0.08 to 0
.26) 
0.30  
 (0.19 to 0.
42) 
HER2 
(Trastuzumab
) + Interleukin 
12 
NCT00
004074
* 
I 15 
Compl
eted 
NR NR NR 
HER2 
(Trastuzumab
) + HER1 
(Cetuximab) 
NCT00
923299 
[Ref. 
No. 51] 
I & II 44 
Compl
eted 
4.6 
(2.7-6.6) 
1.8 
(1.7-2.0) 
NR 
Mesothelin 
(SS1(dsFv)-
PE38 
immunotoxin) 
NCT00
006981
* 
I NR 
Compl
eted 
NR NR NR 
VEGF 
(Bevacizuma
b) + 
Gemcitabine 
+ accelerated 
Radiation 
Therapy 
NCT00
557492
* 
II 43 
Ongoi
ng 
19.7  
 (16.5 to 
28.2) 
12.9  
 (7.0 to 18
.7) 
2.3  
 (0.1 to 12) 
VEGF 
(Bevacizuma
b) + 
Octreotide 
Acetate + 
Everolimus 
NCT01
229943
* 
II 75 
Ongoi
ng 
36.7   
 (31.8 to 
N/A) 
16.7  
 (12.6 to 1
9.7) 
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* Data obtained from https://clinicaltrials.gov/ 
b NR (not reported). 
c PR (partial response). 
d CR (complete response). 
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Table III: Clinical trials testing T cell-mediated immunotherapies for pancreatic 
cancer. 
Antigen & Drug 
ClinicalTrials.g
ov Identifier 
Phase 
No. of 
Patients 
Status 
Anti-CEA CAR-T cells NCT02416466* I 8 Ongoing 
Autologous T cells 
transfected with 
chimeric anti-
mesothelin 
immunoreceptor SS1 
NCT01897415* I 16 Ongoing 
CART-meso-19 T cells 
+ Cyclophosphamide 
NCT02465983* I 12 Ongoing 
GI-4000 Vaccine + 
Activated T Cells 
NCT00837135* I NRb Withdrawn 
MFE23 scFv-
expressing autologous 
anti-CEA MFEz T 
lymphocytes 
NCT01212887* I 14 
Terminated 
due to 
safety 
concerns 
and lack of 
efficacy 
Autologous Natural 
Killer / Natural Killer T 
Cell Immunotherapy 
NCT00909558* I 24 Suspended 
Prostate Stem Cell 
Antigen (PSCA) 
Specific CAR T Cells 
(BPX-601) + 
Rimiducid 
NCT02744287* I 30 Recruiting 
* Data obtained from https://clinicaltrials.gov/  b NR (not reported). 
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Table IV: Clinical trials testing cancer vaccines for pancreatic cancer. 
Antigen & Drug 
ClinicalTrials.
gov Identifier 
Phase 
No. of 
Patients 
Status 
MUC1 Vaccine (Cvac 
vaccine) 
NCT02310971* II 0 Withdrawn 
Falimarev (MUC1 
PANVAC-F vaccine) + 
Inalimarev (MUC1 
PANVAC-V vaccine) + 
Sargramostim (GM-CSF 
vaccine) 
NCT00669734* I 18 Ongoing 
Telomerase vaccine 
(GV1001) + gemcitabine 
+ Sargramostim + 
tadalafil + Radiation 
Therapy 
NCT01342224* I 11 Active 
Telomerase vaccine 
(GV1001) + 
Sargramostim + 
capecitabine + 
gemcitabine 
NCT00425360* III 1110 Completed 
CEA vaccine (ALVAC + 
vaccinia) + aldesleukin 
(IL-2) + Sargramostim 
NCT00003125* II 24 Completed 
CEA vaccine (AVX701) NCT00529984* I & II 28 Completed 
Recombinant fowlpox-
CEA(6D)/TRICOM vacci
ne + GM-CSF vaccine + 
Sargramostim 
NCT00028496* I 48 Completed 
Recombinant fowlpox-
CEA(6D)/TRICOM vacci
NCT00128622* I 24 Completed 
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ne + denileukin diftitox + 
therapeutic autologous 
dendritic cells 
CEA vaccine (TRICOM-
CEA(6D)) 
NCT00027534* I 14 Completed 
CEA RNA-pulsed DC 
cancer vaccine 
NCT00004604* I 24 Completed 
CEA vaccine 
(carcinoembryonic 
antigen peptide 1-6D) + 
incomplete Freund's 
adjuvant + 
sargramostim 
NCT00012246* II 7 Terminated 
K-ras vaccine (TG01) + 
GM-CSF + Gemcitabine 
NCT02261714* I & II 32 Active 
Aldesleukin + ras 
peptide cancer vaccine 
+ sargramostim + 
DetoxPC 
NCT00019331* 
 
II 11 Completed 
HLA-A*02:01-restricted 
VEGFR1-derived 
peptide vaccination 
NCT00683085* I & II 2 Terminated 
VEGFR-2 
DNA vaccine VXM01 
NCT01486329* I 72 Completed 
Mesothelin vaccine 
(CRS-207) + GVAX 
vaccine + gemcitabine + 
capecitabine + 5-FU + 
irinotecan or erlotinib + 
cyclophosphamide 
NCT02004262 
[Ref no. 87, 88] 
II 303 Completed 
GVAX Pancreas 
+ Mesothelin vaccine 
NCT01417000 II 93 Ongoing 
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(CRS-207) + 
Cyclophosphamide 
[Ref. no. 88] 
Mesothelin vaccine 
(CRS-207) 
NCT00585845* I 17 Terminated 
Cancer stem 
cell vaccine 
NCT02074046* I & II 40 Completed 
 
 
  
* Data obtained from https://clinicaltrials.gov/ 
b NR (not reported). 
c PR (partial response). 
d CR (complete response). 
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Figure 1: Pancreatic cancer cells establish an immunosuppressive TME.  
Cancer cells secrete various anti-inflammatory cytokines like IL-10, TGF-β, IL-23, 
along with angiogenic chemokines (e.g., CXCL1-3, CXCL5, CXCL12, CCL2, and VEGF-
A), which generate an immunosuppressive tumor microenvironment (TME) and facilitate 
cancer initiation, progression and metastasis. Upregulation of the expression of these 
cytokines shifts the balance in TME, which facilitates the evasion from immune 
surveillance during PC progression [6, 8, 20, 28]. The PC immunosuppressive 
microenvironment also includes crosstalk between cancer cells and various myeloid and 
lymphoid subsets. Tumor-associated macrophages (TAMs) and myeloid-derived 
suppressor cells (MDSCs) express immuno-inhibitory ligands and reactive oxygen 
species that inhibit infiltration and activation of T and NK cells [3, 11-13]. MDSCs and 
cancer cells also secrete VEGFs that promote angiogenesis, which aids in the metastasis 
of the cancer cells [17]. PC tumor cells and pancreatic stellate cells (desmoplasia) secrete 
inhibitory cytokines and chemokines, and express inhibitory surface ligands such as 
programmed death ligand-1 (PD-L1) and galectin-1 (Gal-1) that lead to inactivation and 
apoptosis of cytotoxic (CD8+) and helper (CD4+) T-cells by programmed death receptor-
1(PD-1) or Gal-1 binding receptor respectively [16, 18, 21, 22]. Treg cells suppress the 
functions of activated T-cells and NK cells in the TME [13, 125]. In addition, the rigid 
architecture of pancreatic tumor bed provides a physical barrier to T-cells infiltration 
thereby excluding them to the edge/boundary of the tumor and thus rendering the 
pancreatic tumor as an immunologically ‘cold’ tumor [28-31]. All these cells are involved 
in the maintenance of the immunosuppressive TME, and cancer progression.  
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Figure 2: Schematic representation of engineering of CAR-T cells. 
CAR T-cells are genetically engineered T-cells expressing tumor antigen-specific 
chimeric TCR [149, 150]. The modified receptor is a chimera of a signaling domain of the 
TCR complex and an antigen-recognizing domain, such as a single chain fragment (scFv) 
of an antibody [151, 152]. CAR T-cells are not dependent on antigen presentation by MHC 
molecules expressed on APCs for antigen-specific activation. Adoptive cell transfer of 
CAR T-cells involves the isolation, stimulation, expansion, transduction, and ultimately re-
infusion of human T lymphocytes [153, 154]. First-generation TCRs included only the 
intracellular domain of the CD3ζ chain but did not show any significant in vivo efficacy in 
transgenic mouse model studies [155]. Second-generation CARs introduced additional 
co-stimulatory domains such as CD28, which significantly augmented CAR signaling, and 
improved cytokine production and T-cell proliferation, as well as differentiation, and 
survival [156, 157]. Third-generation CARs contain multiple co-stimulatory domains such 
as 4-1BB (CD137), and whether they have a clinical benefit over second-generation CAR 
T-cells is still under investigation [152, 158, 159].  
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1. Synopsis 
Mucins are high-molecular-weight, heavily O-glycosylated glycoproteins that are 
differentially overexpressed in pancreatic cancer. Literature surveys has shown the 
instrumental role mucins play in the pathobiology of PC disease. Overexpression, aberrant 
glycosylation and pathological role proposes mucins as lucrative targets for developing 
targeted therapies. Immunotherapy is one of the strategies that specifically target tumor-
associated antigens and simultaneously reprograms the patient’s immune system towards 
the targeted killing of tumor cells. MUC1 has been one of the well-explored mucins for 
developing PC immunotherapies but achieved limited success in PC patients. MUC4 is 
one of the differentially overexpressed mucins in PC and unlike MUC1, MUC4 has unique 
tumor specificity since it is undetectable in normal pancreas. MUC4 plays a crucial role in 
PC disease progression and metastasis. Further MUC4’s expression has been 
demonstrated to be regulated by cytokines such as IFNγ and tumor growth factor beta 
(TGFβ), suggesting a possible interrelationship between immune tumor microenvironment 
and PC disease aggressiveness. Previous studies have provided evidence that makes a 
strong case to evaluate MUC4 as an immunotherapeutic candidate, but to date only limited 
studies have been made. Therefore, in this section we have reviewed existing literature 
and summarized their findings to make a case for investigating MUC4 as a potential 
candidate for PC immunotherapy.  
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2. Mucins: A Target for Pancreatic Cancer Immunotherapy 
 PC cells undergo a cellular and genetic transformation that contributes to the 
expression of proteins that are mostly absent in de novo pancreas cells. One of the 
families of proteins that is aberrantly overexpressed in PC tumor cells and has been 
reported to play a crucial role in the pathogenesis of the disease is mucins. MUCs are high 
molecular weight glycoproteins with O-glycosylated variable number tandem repeat 
(VNTR) region and consists of 21 family members. Fourteen MUC proteins out of 21 mucin 
family members fall under the category of classical mucins, which is characterized by high 
molecular weight O-glycoprotein, secreted in the mucus layer, presence of VNTR 
sequence, predicted peptide domain containing high percentage of serine and threonine 
residues, and lastly a complex mRNA expression of these mucins [1]. MUC glycoproteins 
are classified according to their structure and function into two categories: 
transmembrane/membrane-bound mucins comprising of MUC1, MUC3A, MUC3B, MUC4, 
MUC12 and MUC17; and secretory/gel-forming mucins consisting of MUC6, MUC2, 
MUC5AC and MUC5B [2]. 
 Transmembrane mucins like MUC1, MUC4 and MUC16 are differentially 
overexpressed by PC cancer cells and their expression gradually increases with the 
progression of the disease [3-9]. MUC1 and MUC4 interact with various receptors such as 
receptor tyrosine kinases (RTKs) including epidermal growth factor receptor (EGFR), 
ERBB2 & ERBB3, and fibroblast growth factor receptor (FGFR), that promotes 
proliferation, invasion, metastasis and resistance to therapeutic anti-RTK (Receptor 
Tyrosine Kinase) antibodies [10-14]. MUCs expressed on the PC cancer cell surface due 
to their large structure interact with the TME that induce immune evasion and oncogenic 
signaling-mediated angiogenesis and metastasis [2]. Studies have demonstrated that 
MUCs like MUC1 on PC cells interact with TAMs through sialoadhesin [15]. Interaction 
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between M2 macrophages with PC cells via CA125 (carbohydrate epitope located on 
MUC16) differentiates these macrophages to immunosuppressive phenotype and induces 
secretion of IL10 cytokine [16]. In addition to MUC’s crucial role in pathogenesis and 
immunosuppression of PC, they undergo aberrant glycosylation due to the altered 
expression and localization of glycosyltransferases [17]. Thus, these aspects make MUCs 
an important therapeutic target for PC immunotherapy strategies.  
2.1 Mucin-based Cancer Vaccines for PC 
Due to their contributions in PC pathogenesis, MUCs have been targeted by 
immunotherapy strategies like cancer vaccines to efficaciously treat PC patients. We have 
previously discussed MUC vaccines studied and tested in both pre-clinical and clinical 
trials for PC immunotherapy in our previous chapter [18]. In addition, a recent pre-clinical 
study with MUC1-based DNA vaccine (pVAX1-MUC1-VNTRn DNA vaccine) showed that 
MUC1-VNTR6- and MUC1-VNTR9- transfected DCs were able to activate IFN-γ producing 
CTLs, increase the cytotoxicity of CTLs and suppress Panc02-MUC1 PC tumor cell’s 
growth in tumor-bearing mice [19]. Mice immunized with MUC1-tandem repeat B-cell 
peptide conjugated with Ttox (MUC1-Ttox vaccine) produced high titers of anti MUC1 IgG 
antibodies.  These IgG MUC1 antibodies could specifically differentiate between human 
normal and PC tumor cells [20]. A clinical trial (NCT03114631) with DCs pulsed 
with MUC1/WT-1 peptides is currently under investigation for treating both resectable 
and unresectable PC patients. 
2.2 Limitations of Mucin Vaccines for PC Immunotherapy 
Efficacious MUC cancer vaccines have been a challenge to develop because tumor 
antigens like MUC1 are also expressed by normal cells (self-antigens) causing the 
immune system to develop self-tolerance against them, which leads to 
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hyporesponsiveness of APCs upon exposure to MUC1 cancer vaccines. Efficient 
activation of DCs is instrumental to activate cellular and humoral responses in an antigen-
specific phenotype. In a very detailed study done in MUC1.Tg mice, it was observed that 
MUC1p cancer vaccine couldn’t successfully activate APCs post vaccination in MUC1 
expressing MUC1.Tg mice and was unable to restrict the growth of both transplanted and 
spontaneous PC tumors [21]. Whereas in WT mice, MUC1p cancer vaccination activated 
DCs and induced significant expression of surface markers like MHC-II, CD80, CD86 and 
CD40. Upon further investigation they discovered that MUC1.Tg immunized mice had a 
higher percentage of Fox3+ Tregs cells and these Tregs inhibited the expression of pancreatic 
enzymes such as trypsin and CBP1 transcript in DCs recovered from spleens of MUC1.Tg 
mice. Specific depletion of Tregs by anti-CD25 treatment or blocking of IL-10 by anti-IL10R 
antibody prior to MUC1p cancer vaccination rescued the expression of these enzymes in 
DCs to the similar levels of DCs isolated from WT mice [21]. This study suggests the 
necessity of discovering TAAs that are distinct from their counterparts being expressed on 
normal cells to prevent the formation of self-tolerance against them. A strategy to 
recognize MUCs against which self-tolerance is likely compromised in naïve PC patients 
who haven’t received any treatments or surgery, could enable identifying the immunogenic 
MUC candidate that will probably overcome the hyporesponsiveness of APCs and 
generate corresponding anti-tumor responses.  
Another limitation of MUC vaccines is the number of available epitopes to activate 
APCs. Peptides from VNTR region of MUC proteins have been utilized to develop cancer 
vaccines like peptide-toxin vaccines [20] or DC vaccines [19]. But these vaccines have 
achieved only limited success in clinical trials. Peptide-based vaccines have certain 
limitations such as peptides are mostly designed to have an MHC-I restriction that leads 
to the presentation of individual peptides on only certain HLA types. In addition, if selected 
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peptides have low affinity for MHC, they may be poorly immunogenic and induce weak or 
transient immune responses by APCs upon exposure [22]. As previously discussed in our 
review [18], protein provides an array of epitopes having multiple immunogenicities and 
thus could be presented by different MHC-I HLA types, potentially leading to the 
generation of strong immune responses. Expression, isolation and purification of 
transmembrane MUC glycoproteins come with its challenges. Due to the high molecular 
weight of MUCs, their purification and maintenance of their native antigenicity have not 
been feasible to date. 
3. MUC4 as Tumor-Associated Antigen for PC 
3.1 MUC4 in Pancreatic Cancer 
In contrast to MUC1, MUC4 expression in normal organs is mostly restricted and is 
undetectable in normal pancreas and inflammatory diseases of the pancreas [23, 24] thus 
providing a better tumor specificity for targeting purposes. MUC4 is one of the most 
differentially overexpressed multi-domain transmembrane glycoprotein in PC [2, 7, 23, 25]. 
MUC4 protein carries a high percentage of allelic polymorphism in the VNTR domain that 
is rich in serine, threonine, and proline residues and it extensively undergoes mucin-type 
O-linked glycosylation [2, 23, 26] thus contributing to the high molecular weight of the 
apoprotein. MUC4 has a putative cleavage site comprising of Glycine-Aspartate-Proline-
Histidine (GDPH) that can undergo autocatalysis and generate two subunits: MUC4α 
upstream of GDPH cleavage site and MUC4β downstream of the site [26-28]. MUC4α 
subunit is the large N-terminal domain that is composed of VNTR domain, nidogen-like 
domain (NIDO), and adhesion-associated domain in MUC4 and other proteins (AMOP). 
MUC4β on the other hand is a smaller subunit composed of von Willebrand factor type D 
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domain (vWD), three epidermal growth factor (EGF)-like domains, a transmembrane 
domain and a short cytoplasmic tail [23].  
MUC4 has been demonstrated to play a fundamental role in the pathobiology of PC. 
Over the years studies have shown that MUC4’s interaction with EGFR family members, 
HER2 and HER3 is mediated by the 3 EGF-like domains present in the MUC4β subunit 
[29-31]. These interactions subsequently activate an intracellular cascade of signaling 
events including mitogen-activated protein kinases (MAPK), c-Jun N-terminal 
kinases  (JNK), and signal transducer and activator of transcription 1 (STAT-1) that 
promote cell proliferation, migration and metastasis [12, 29-32]. The NIDO domain on 
MUC4 interacts with fibulin-2 that competitively disrupts its interaction with extracellular 
matrix (ECM) proteins present in the basement membrane, thus abrogating normal ECM 
protein-protein interactions [33]. An overall survey of the literature shows that MUC4 can 
modulate diverse pathways such as drug resistance [34], epithelial to mesenchymal 
transition (EMT) and metastasis [35], tumor cell proliferation and invasion [12], and thus 
PC patients with a MUC4 expression on tumors have a worse prognosis [36]. Given the 
tumor-promoting nature and PC-specific expression of MUC4, various studies have 
focused on utilizing MUC4 as a diagnostic/prognostic marker. MUC4 has emerged as a 
useful diagnostic tool for PC in fine needle aspirates (FNAs) [37, 38]. Also studies with 
patient serum samples for MUC4 serving as biomarkers have been investigated [39, 40]. 
In summary, MUC4 has been undisputedly established as a PC tumor-specific molecule 
that plays an instrumental role in progression and metastasis of PC disease, as well as 
serves as a useful diagnostic marker. 
3.2 Immune Regulation of MUC4 in Pancreatic Cancer 
Multiple signaling pathways regulate MUC4 expression in PC through the binding of 
different transcription factors at the MUC4 promoter site [41, 42]. Previous studies have 
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shown cytokine-mediated expression of MUC4 in PC cells. IFNγ and retinoic acid (RA) 
synergistically upregulates the expression of MUC4 in PC cells through the dual activation 
of STAT-1 and transforming growth factor beta-2 (TGFβ) pathways [43, 44]. TGFβ can 
upregulate MUC4 expression either by cooperative activation of Smad3 and Smad4 
signaling pathways, or by activating MAPK, phosphatidylinositide 3-kinases (PI3K) and 
protein kinase A (PKA) signaling pathways [45]. Further, in other cancers such as gastric 
and colon cancer cell lines, it has been observed that interleukin (IL)-4, IL9, IL6, & IL24 
could upregulate MUC4 expression by activating JAK/STAT pathway [46, 47] or in a 
STAT-3 dependent manner [48, 49]. PC has an elaborate TME composed of multiple 
immune cells such as TAMs, MDSCs, M2 macrophages etc. that secrete Th2 cytokines 
such as IL4, IL9 and IL24 (an IL-10 cytokine family member) to establish and maintain 
immunosuppression [18]. In addition, aberrant glycosylation of MUC4 appears to induce 
MUC4-specific immune responses such as generation of both Th1 and Th2 cytokines in 
MUC4-expressing pancreatic tumors [44]. Cumulatively these studies demonstrate that 
immune cells in TME can regulate the expression of MUC4 on PC cells by secretion of 
cytokines, which reveals an unexplored relationship between MUC4 and PC 
immunosuppression.  
4. Summary and Conclusion 
PC immunotherapy faces some major challenges in the selection of a suitable antigen. 
It has to meet three criteria: tumor-specific expression, antigen availability due to sufficient 
expression, and high immunogenicity to elicit strong immune responses. Due to its 
deregulated overexpression in PC and functional role in pathogenesis, MUC4 has 
emerged as a promising diagnostic and therapeutic candidate. MUC4’s central role in 
eliciting tumor proliferation, invasiveness, drug-resistance and metastasis, has led to 
considerable interest in targeting MUC4 to avail therapeutic benefits. Further, due to 
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aberrant glycosylation [50] and cleavage [26-28], MUC4 expressed on PC tumor cells will 
be distinct from the expression on normal tissues. Circulating autoantibodies to MUC4 has 
been detected in colorectal patients [51] and preliminary study with MUC4 peptide-induced 
DNA vaccine showed that MUC4 DC vaccine could efficiently present the antigen and 
elicit potent MUC4-specific CTL response [52]. 
Further, the structural complexity and various glycoforms of MUC4 adds a challenge 
in designing strategies for immunotherapy. Previous studies have been focused on 
peptides located in the VNTR region. Since MUC4 could putatively get cleaved at the 
GDPH site into alpha and beta subunits, thus there is a possibility of MUC4α (containing 
VNTR domain) to be not attached to the cell surface of tumor cells because MUC4 
fragments have been discovered in secretions [53, 54].  
In conclusion, MUC4 is a cancer-specific tumor-promoting glycoprotein that could 
serve as an effective antigen to develop vaccines against PC. However, investigations 
exploring MUC4 as a candidate for immunotherapy are in infancy. It requires multiple 
optimizations like identifying optimal biodegradable adjuvant delivery systems, 
identification of helper epitopes and developing platforms with good adjuvant properties 
that conserve the antigenicity of the epitopes. Thus, further studies are necessary to 
establish MUC4 as a suitable target for PC immunotherapy.  
66 
 
References 
[1] N. Moniaux, M. Andrianifahanana, R.E. Brand, S.K. Batra, Multiple roles of mucins in 
pancreatic cancer, a lethal and challenging malignancy, Br J Cancer, 91 (2004) 1633-
1638. 
[2] S. Kaur, S. Kumar, N. Momi, A.R. Sasson, S.K. Batra, Mucins in pancreatic cancer and 
its microenvironment, Nat Rev Gastroenterol Hepatol, 10 (2013) 607-620. 
[3] M.J. Swartz, S.K. Batra, G.C. Varshney, M.A. Hollingsworth, C.J. Yeo, J.L. Cameron, 
R.E. Wilentz, R.H. Hruban, P. Argani, MUC4 expression increases progressively in 
pancreatic intraepithelial neoplasia, Am J Clin Pathol, 117 (2002) 791-796. 
[4] M. Saitou, M. Goto, M. Horinouchi, S. Tamada, K. Nagata, T. Hamada, M. Osako, S. 
Takao, S.K. Batra, T. Aikou, K. Imai, S. Yonezawa, MUC4 expression is a novel prognostic 
factor in patients with invasive ductal carcinoma of the pancreas, J Clin Pathol, 58 (2005) 
845-852. 
[5] H. Yamasaki, S. Ikeda, M. Okajima, Y. Miura, T. Asahara, N. Kohno, F. Shimamoto, 
Expression and localization of MUC1, MUC2, MUC5AC and small intestinal mucin antigen 
in pancreatic tumors, Int J Oncol, 24 (2004) 107-113. 
[6] D. Haridas, S. Chakraborty, M.P. Ponnusamy, I. Lakshmanan, S. Rachagani, E. Cruz, 
S. Kumar, S. Das, S.M. Lele, J.M. Anderson, U.A. Wittel, M.A. Hollingsworth, S.K. Batra, 
Pathobiological implications of MUC16 expression in pancreatic cancer, PLoS One, 6 
(2011) e26839. 
[7] M.A. Hollingsworth, J.M. Strawhecker, T.C. Caffrey, D.R. Mack, Expression of MUC1, 
MUC2, MUC3 and MUC4 mucin mRNAs in human pancreatic and intestinal tumor cell 
lines, Int J Cancer, 57 (1994) 198-203. 
[8] Y. Hinoda, Y. Ikematsu, M. Horinochi, S. Sato, K. Yamamoto, T. Nakano, M. Fukui, Y. 
Suehiro, Y. Hamanaka, Y. Nishikawa, H. Kida, S. Waki, M. Oka, K. Imai, S. Yonezawa, 
Increased expression of MUC1 in advanced pancreatic cancer, J Gastroenterol, 38 (2003) 
1162-1166. 
[9] D.C. Chhieng, E. Benson, I. Eltoum, M.A. Eloubeidi, N. Jhala, D. Jhala, G.P. Siegal, 
W.E. Grizzle, U. Manne, MUC1 and MUC2 expression in pancreatic ductal carcinoma 
obtained by fine-needle aspiration, Cancer, 99 (2003) 365-371. 
67 
 
[10] K.G. Kohlgraf, A.J. Gawron, M. Higashi, J.L. Meza, M.D. Burdick, S. Kitajima, D.L. 
Kelly, T.C. Caffrey, M.A. Hollingsworth, Contribution of the MUC1 tandem repeat and 
cytoplasmic tail to invasive and metastatic properties of a pancreatic cancer cell line, 
Cancer Res, 63 (2003) 5011-5020. 
[11] H. Tsutsumida, B.J. Swanson, P.K. Singh, T.C. Caffrey, S. Kitajima, M. Goto, S. 
Yonezawa, M.A. Hollingsworth, RNA interference suppression of MUC1 reduces the 
growth rate and metastatic phenotype of human pancreatic cancer cells, Clin Cancer Res, 
12 (2006) 2976-2987. 
[12] P. Chaturvedi, A.P. Singh, N. Moniaux, S. Senapati, S. Chakraborty, J.L. Meza, S.K. 
Batra, MUC4 mucin potentiates pancreatic tumor cell proliferation, survival, and invasive 
properties and interferes with its interaction to extracellular matrix proteins, Mol Cancer 
Res, 5 (2007) 309-320. 
[13] A.P. Singh, N. Moniaux, S.C. Chauhan, J.L. Meza, S.K. Batra, Inhibition of MUC4 
expression suppresses pancreatic tumor cell growth and metastasis, Cancer Res, 64 
(2004) 622-630. 
[14] P.K. Singh, M.A. Hollingsworth, Cell surface-associated mucins in signal transduction, 
Trends Cell Biol, 16 (2006) 467-476. 
[15] D. Nath, A. Hartnell, L. Happerfield, D.W. Miles, J. Burchell, J. Taylor-Papadimitriou, 
P.R. Crocker, Macrophage-tumour cell interactions: identification of MUC1 on breast 
cancer cells as a potential counter-receptor for the macrophage-restricted receptor, 
sialoadhesin, Immunology, 98 (1999) 213-219. 
[16] P. Allavena, M. Chieppa, G. Bianchi, G. Solinas, M. Fabbri, G. Laskarin, A. Mantovani, 
Engagement of the mannose receptor by tumoral mucins activates an immune 
suppressive phenotype in human tumor-associated macrophages, Clin Dev Immunol, 
2010 (2010) 547179. 
[17] L. Tu, D.K. Banfield, Localization of Golgi-resident glycosyltransferases, Cell Mol Life 
Sci, 67 (2010) 29-41. 
[18] K. Banerjee, S. Kumar, K.A. Ross, S. Gautam, B. Poelaert, M.W. Nasser, A. Aithal, 
R. Bhatia, M.J. Wannemuehler, B. Narasimhan, J.C. Solheim, S.K. Batra, M. Jain, 
Emerging trends in the immunotherapy of pancreatic cancer, Cancer Lett, 417 (2018) 35-
46. 
68 
 
[19] Y.F. Gong, Q.B. Zhou, Y.D. Liao, C. Mai, T.J. Chen, Y.Q. Tang, R.F. Chen, Optimized 
construction of MUC1-VNTRn DNA vaccine and its anti-pancreatic cancer efficacy, Oncol 
Lett, 13 (2017) 2198-2206. 
[20] B. Palitzsch, N. Gaidzik, N. Stergiou, S. Stahn, S. Hartmann, B. Gerlitzki, N. Teusch, 
P. Flemming, E. Schmitt, H. Kunz, A Synthetic Glycopeptide Vaccine for the Induction of 
a Monoclonal Antibody that Differentiates between Normal and Tumor Mammary Cells 
and Enables the Diagnosis of Human Pancreatic Cancer, Angew Chem Int Ed Engl, 55 
(2016) 2894-2898. 
[21] A.M. Farkas, D.M. Marvel, O.J. Finn, Antigen choice determines vaccine-induced 
generation of immunogenic versus tolerogenic dendritic cells that are marked by 
differential expression of pancreatic enzymes, J Immunol, 190 (2013) 3319-3327. 
[22] C.L. Slingluff, Jr., The present and future of peptide vaccines for cancer: single or 
multiple, long or short, alone or in combination?, Cancer J, 17 (2011) 343-350. 
[23] P. Chaturvedi, A.P. Singh, S.K. Batra, Structure, evolution, and biology of the MUC4 
mucin, FASEB J, 22 (2008) 966-981. 
[24] M. Andrianifahanana, N. Moniaux, B.M. Schmied, J. Ringel, H. Friess, M.A. 
Hollingsworth, M.W. Buchler, J.P. Aubert, S.K. Batra, Mucin (MUC) gene expression in 
human pancreatic adenocarcinoma and chronic pancreatitis: a potential role of MUC4 as 
a tumor marker of diagnostic significance, Clin Cancer Res, 7 (2001) 4033-4040. 
[25] S.K. Gautam, S. Kumar, A. Cannon, B. Hall, R. Bhatia, M.W. Nasser, S. Mahapatra, 
S.K. Batra, M. Jain, MUC4 mucin- a therapeutic target for pancreatic ductal 
adenocarcinoma, Expert Opin Ther Targets, 21 (2017) 657-669. 
[26] N. Moniaux, S. Nollet, N. Porchet, P. Degand, A. Laine, J.P. Aubert, Complete 
sequence of the human mucin MUC4: a putative cell membrane-associated mucin, 
Biochem J, 338 ( Pt 2) (1999) 325-333. 
[27] N. Moniaux, F. Escande, S.K. Batra, N. Porchet, A. Laine, J.P. Aubert, Alternative 
splicing generates a family of putative secreted and membrane-associated MUC4 mucins, 
Eur J Biochem, 267 (2000) 4536-4544. 
[28] N. Moniaux, F. Escande, N. Porchet, J.P. Aubert, S.K. Batra, Structural organization 
and classification of the human mucin genes, Front Biosci, 6 (2001) D1192-1206. 
69 
 
[29] K.L. Carraway, 3rd, E.A. Rossi, M. Komatsu, S.A. Price-Schiavi, D. Huang, P.M. Guy, 
M.E. Carvajal, N. Fregien, C.A. Carraway, K.L. Carraway, An intramembrane modulator 
of the ErbB2 receptor tyrosine kinase that potentiates neuregulin signaling, J Biol Chem, 
274 (1999) 5263-5266. 
[30] I. Lakshmanan, P. Seshacharyulu, D. Haridas, S. Rachagani, S. Gupta, S. Joshi, C. 
Guda, Y. Yan, M. Jain, A.K. Ganti, M.P. Ponnusamy, S.K. Batra, Novel HER3/MUC4 
oncogenic signaling aggravates the tumorigenic phenotypes of pancreatic cancer cells, 
Oncotarget, 6 (2015) 21085-21099. 
[31] N. Jonckheere, N. Skrypek, J. Merlin, A.F. Dessein, P. Dumont, E. Leteurtre, A. Harris, 
J.L. Desseyn, C. Susini, F. Frenois, I. Van Seuningen, The mucin MUC4 and its membrane 
partner ErbB2 regulate biological properties of human CAPAN-2 pancreatic cancer cells 
via different signalling pathways, PLoS One, 7 (2012) e32232. 
[32] P. Seshacharyulu, M.P. Ponnusamy, S. Rachagani, I. Lakshmanan, D. Haridas, Y. 
Yan, A.K. Ganti, S.K. Batra, Targeting EGF-receptor(s) - STAT1 axis attenuates tumor 
growth and metastasis through downregulation of MUC4 mucin in human pancreatic 
cancer, Oncotarget, 6 (2015) 5164-5181. 
[33] S. Senapati, V.S. Gnanapragassam, N. Moniaux, N. Momi, S.K. Batra, Role of MUC4-
NIDO domain in the MUC4-mediated metastasis of pancreatic cancer cells, Oncogene, 
31 (2012) 3346-3356. 
[34] S. Bafna, S. Kaur, N. Momi, S.K. Batra, Pancreatic cancer cells resistance to 
gemcitabine: the role of MUC4 mucin, Br J Cancer, 101 (2009) 1155-1161. 
[35] S. Rachagani, M.A. Macha, M.P. Ponnusamy, D. Haridas, S. Kaur, M. Jain, S.K. 
Batra, MUC4 potentiates invasion and metastasis of pancreatic cancer cells through 
stabilization of fibroblast growth factor receptor 1, Carcinogenesis, 33 (2012) 1953-1964. 
[36] X. Huang, X. Wang, S.M. Lu, C. Chen, J. Wang, Y.Y. Zheng, B.H. Ren, L. Xu, 
Clinicopathological and prognostic significance of MUC4 expression in cancers: evidence 
from meta-analysis, Int J Clin Exp Med, 8 (2015) 10274-10283. 
[37] N. Jhala, D. Jhala, S.M. Vickers, I. Eltoum, S.K. Batra, U. Manne, M. Eloubeidi, J.J. 
Jones, W.E. Grizzle, Biomarkers in Diagnosis of pancreatic carcinoma in fine-needle 
aspirates, Am J Clin Pathol, 126 (2006) 572-579. 
70 
 
[38] M. Higashi, S. Yokoyama, T. Yamamoto, Y. Goto, I. Kitazono, T. Hiraki, H. Taguchi, 
S. Hashimoto, Y. Fukukura, C. Koriyama, Y. Mataki, K. Maemura, H. Shinchi, M. Jain, 
S.K. Batra, S. Yonezawa, Mucin expression in endoscopic ultrasound-guided fine-needle 
aspiration specimens is a useful prognostic factor in pancreatic ductal adenocarcinoma, 
Pancreas, 44 (2015) 728-734. 
[39] G. Wang, R.J. Lipert, M. Jain, S. Kaur, S. Chakraboty, M.P. Torres, S.K. Batra, R.E. 
Brand, M.D. Porter, Detection of the potential pancreatic cancer marker MUC4 in serum 
using surface-enhanced Raman scattering, Anal Chem, 83 (2011) 2554-2561. 
[40] A.V. Krasnoslobodtsev, M.P. Torres, S. Kaur, I.V. Vlassiouk, R.J. Lipert, M. Jain, S.K. 
Batra, Y.L. Lyubchenko, Nano-immunoassay with improved performance for detection of 
cancer biomarkers, Nanomedicine, 11 (2015) 167-173. 
[41] M. Perrais, P. Pigny, M.P. Ducourouble, D. Petitprez, N. Porchet, J.P. Aubert, I. Van 
Seuningen, Characterization of human mucin gene MUC4 promoter: importance of growth 
factors and proinflammatory cytokines for its regulation in pancreatic cancer cells, J Biol 
Chem, 276 (2001) 30923-30933. 
[42] A.P. Singh, S.C. Chauhan, M. Andrianifahanana, N. Moniaux, J.L. Meza, M.C. Copin, 
I. van Seuningen, M.A. Hollingsworth, J.P. Aubert, S.K. Batra, MUC4 expression is 
regulated by cystic fibrosis transmembrane conductance regulator in pancreatic 
adenocarcinoma cells via transcriptional and post-translational mechanisms, Oncogene, 
26 (2007) 30-41. 
[43] M. Andrianifahanana, A. Agrawal, A.P. Singh, N. Moniaux, I. van Seuningen, J.P. 
Aubert, J. Meza, S.K. Batra, Synergistic induction of the MUC4 mucin gene by interferon-
gamma and retinoic acid in human pancreatic tumour cells involves a reprogramming of 
signalling pathways, Oncogene, 24 (2005) 6143-6154. 
[44] M. Andrianifahanana, S.C. Chauhan, A. Choudhury, N. Moniaux, R.E. Brand, A.A. 
Sasson, P.M. Pour, S.K. Batra, MUC4-expressing pancreatic adenocarcinomas show 
elevated levels of both T1 and T2 cytokines: potential pathobiologic implications, Am J 
Gastroenterol, 101 (2006) 2319-2329. 
[45] N. Jonckheere, M. Perrais, C. Mariette, S.K. Batra, J.P. Aubert, P. Pigny, I. Van 
Seuningen, A role for human MUC4 mucin gene, the ErbB2 ligand, as a target of TGF-
beta in pancreatic carcinogenesis, Oncogene, 23 (2004) 5729-5738. 
71 
 
[46] G. Damera, B. Xia, H.R. Ancha, G.P. Sachdev, IL-9 modulated MUC4 gene and 
glycoprotein expression in airway epithelial cells, Biosci Rep, 26 (2006) 55-67. 
[47] G. Damera, B. Xia, G.P. Sachdev, IL-4 induced MUC4 enhancement in respiratory 
epithelial cells in vitro is mediated through JAK-3 selective signaling, Respir Res, 7 (2006) 
39. 
[48] R. Mejias-Luque, S. Peiro, A. Vincent, I. Van Seuningen, C. de Bolos, IL-6 induces 
MUC4 expression through gp130/STAT3 pathway in gastric cancer cell lines, Biochim 
Biophys Acta, 1783 (2008) 1728-1736. 
[49] A. Andoh, M. Shioya, A. Nishida, S. Bamba, T. Tsujikawa, S. Kim-Mitsuyama, Y. 
Fujiyama, Expression of IL-24, an activator of the JAK1/STAT3/SOCS3 cascade, is 
enhanced in inflammatory bowel disease, J Immunol, 183 (2009) 687-695. 
[50] S. Chugh, V.S. Gnanapragassam, M. Jain, S. Rachagani, M.P. Ponnusamy, S.K. 
Batra, Pathobiological implications of mucin glycans in cancer: Sweet poison and novel 
targets, Biochim Biophys Acta, 1856 (2015) 211-225. 
[51] J.W. Pedersen, A. Gentry-Maharaj, A. Nostdal, E.O. Fourkala, A. Dawnay, M. Burnell, 
A. Zaikin, J. Burchell, J.T. Papadimitriou, H. Clausen, I. Jacobs, U. Menon, H.H. Wandall, 
Cancer-associated autoantibodies to MUC1 and MUC4--a blinded case-control study of 
colorectal cancer in UK collaborative trial of ovarian cancer screening, Int J Cancer, 134 
(2014) 2180-2188. 
[52] J. Wei, W. Gao, J. Wu, K. Meng, J. Zhang, J. Chen, Y. Miao, Dendritic cells expressing 
a combined PADRE/MUC4-derived polyepitope DNA vaccine induce multiple cytotoxic T-
cell responses, Cancer Biother Radiopharm, 23 (2008) 121-128. 
[53] B. Liu, G.D. Offner, D.P. Nunes, F.G. Oppenheim, R.F. Troxler, MUC4 is a major 
component of salivary mucin MG1 secreted by the human submandibular gland, Biochem 
Biophys Res Commun, 250 (1998) 757-761. 
[54] J. Zhang, A. Perez, M. Yasin, P. Soto, M. Rong, G. Theodoropoulos, C.A. Carothers 
Carraway, K.L. Carraway, Presence of MUC4 in human milk and at the luminal surfaces 
of blood vessels, J Cell Physiol, 204 (2005) 166-177. 
 
 
72 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 1C: DISSERTATION GENERAL 
HYPOTHESIS AND OBJECTIVES 
  
73 
 
1. Background and Rationale 
PC is the third leading cause of cancer-related death in the U.S. claiming 45,000 
lives every year because of its poor prognosis and resistance to conventional therapies 
[1]. Much like other solid tumors, PC evades immune surveillance by manipulating immune 
cells to establish an immunosuppressive TME. Immunotherapy has emerged as an 
alternative approach for PC immunotherapy. It reprograms the patient’s immune system 
to selectively target and kill cancer cells thus reducing the non-specific side-effects. PC 
immunotherapy faces multiple challenges such as: i) identification of tumor-associated 
antigen that could be targeted; ii) preservation of TAA antigenicity and its sustained 
delivery; iii) generation of robust anti-tumor responses; and iv) overcoming 
immunosuppression on effector immune cells in PC tumor microenvironment.  
PC harbor limited genetic alterations which render it as an immunologically ‘cold’ 
tumor. Overexpression and altered glycosylation of mucins in tumor cells can trigger 
humoral and cellular immune responses. Among various mucins, MUC4, heterodimeric 
transmembrane mucin is aberrantly overexpressed in PC but is undetectable in normal 
pancreas and is associated with poor prognosis in PC patients [2]. In PC, MUC4 is 
aberrantly glycosylated, and thus could serve as a potential source of neoantigenic 
epitopes, which could be exploited for cancer immunotherapy. Additionally, due to the 
transmembrane nature of MUC4 only a very limited amount is released into the blood, and 
that makes MUC4 a very strong candidate for vaccine [3-6]. A survey of literature has 
shown that mucins like MUC1 have been targeted by immunotherapy approaches for PC 
treatment but have not fared well in clinical trials. Further detection of circulating serum 
autoantibodies to MUC4 has shown its potential to be immunogenic in colorectal cancer 
patients [7]. However, MUC4 immunogenicity in PC patients has yet not been studied. 
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These summarized findings suggest that MUC4 has potential to be a candidate for PC 
immunotherapy. 
 Polyanhydride nanoparticles represent an ideal vaccine adjuvant/delivery platform. 
Polyanhydride nanoparticles have been demonstrated to provide sustained release and 
enhanced stability of encapsulated antigens (peptides, proteins etc.) [8]. The ratio of 
polyanhydride nanoparticle’s formulation provides an immune modulation property that 
could be utilized to tune the immune responses to either Th1 or Th2 phenotype [9, 10].  In 
addition, their adjuvant properties enhance antigen internalization by antigen-presenting 
cells and stimulate both antibody- and cell-mediated immunity [11-13]. Due to their 
pathogen-mimicking, immune-modulation and biodegradable nature, the polyanhydride 
nanoparticles platform could be utilized to develop vaccines for PC immunotherapy. 
2. Hypothesis 
Based on previous studies demonstrating the tumor-specific overexpression of 
MUC4 in PC and suitable qualities of polyanhydride nanoparticles to serve as a vaccine 
delivery platform, we hypothesized that i) MUC4 is immunogenic in PC patients, and ii) 
delivery of encapsulated MUC4 in unique amphiphilic polyanhydride nanovaccine will elicit 
robust immune responses in an antigen-specific manner. 
3. Objectives 
Aim 1: To determine whether tolerance will be broken against MUC4 in pancreatic cancer 
patients and elucidating it as a suitable target it for immunotherapy studies. 
Aim 2: To evaluate whether MUC4 nanovaccine can elicit robust immune responses. 
Aim 3: To evaluate whether MUC4 nanovaccine can elicit antigen-specific anti-tumor 
responses in PC-subcutaneous tumor-bearing mouse model.  
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MATERIALS AND METHODS 
 
  
78 
 
1. Human Serum Sample Description 
Human sera were obtained after written informed consent was acquired from 
individuals {the protocol was approved by the UPMC Review Board (IRB number 
PRO07030072), and UNMC Review Board (IRB number 209–00)} from the University of 
Pittsburgh Medical Center (UPMC) and shipped to UNMC. Patients with benign 
pathologies or abnormal imaging of pancreas were categorized as Healthy; PC staging 
was determined surgically by pathologists; chronic pancreatitis (CP) was defined based 
on standard clinical practices at UPMC. Sera from PC patients were collected close to the 
time of the first diagnosis of cancer, prior to surgery and before chemotherapy treatment. 
All samples collected at UPMC were shipped by overnight mail to the UNMC. After 
receiving the samples, they were stored following clotting of sera for 30 min, aliquoted and 
immediately frozen at -70°C within 60 min of collection. The sample set was comprised of 
21 CP patients, 27 Healthy, and 31 PC patients, which could be divided among 16 early-
stage patients (Stage I–II) and 15 late-stage patients (Stage III–IV) who were recruited at 
UPMC. To evaluate the presence of autoantibodies against MUC4 peptides, randomized 
patient sera was selected to make a cohort of 10 Healthy, 10 CP patients and 22 PC 
patients. Details on the groups of patients are provided in the supplementary section, and 
patient demographic data are described in Supplementary Table 1 &2. 
2. Prediction of MUC4 Immunogenic Peptides by Bioinformatics 
MUC4 immunogenic peptides were predicted by multiple software: T-cell epitopes 
for human MHC-I (most common: HLA-A*-02:01) were predicted and scored by Immune 
Epitope Database and Analysis Resource (IEDB) [24-31] and TepiTool [32], and combined 
human HLA isoforms scores were predicted by NetCTL-1.0 [33] online prediction tools. 
Human MUC4 peptides that could be loaded on C57BL/6 mouse MHC-I & MHC-II 
complexes were predicted and scored by IEDB online prediction tool; and linear B cell 
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epitopes were predicted and scored by IEDB and BCPred [34] online prediction tools. 
Lowest percentile rank scoring peptides were selected to be synthesized for our study. 
For our study, we selected the amino acid sequence derived from the MUC4 sequence 
isolated and characterized at www.uniprot.org (UniProtKB/Swiss-Prot: Q99102.4) [20, 22, 
35, 36]. 
3. MUC4 Peptide and MUC4β Purification  
Predicted MUC4 9-mer-amino-acid peptides, MUC4 VNTR peptide (TR) and 
pancreatic differentiation 2 (PD2) peptide used in this study were locally synthesized and 
purified at UNMC. Seven peptides from the randomized regions of MUC4α (excluding the 
TR region) and four peptides from the MUC4β region (upstream of the transmembrane 
domain) were used to detect autoantibodies in PC patients, CP patients and Healthy sera.  
Recombinant human MUC4β protein was expressed in E. coli R-2 (DE3) strain 
transformed with MUC4β-6-His-Tag expression plasmid and purified by AKTA Ni-NTA 
affinity chromatography. Eluted protein fractions were assessed by Coomassie Blue 
stained 10% SDS-PAGE gels and by immunoblotting using anti-His tag antibody (Thermo 
Fisher, Pierce # 31430), confirming the presence of MUC4β fractions. MUC4β fractions 
were concentrated by using Amicon Ultra centrifuge filters and further purified by dialysis 
in ultra-purified endotoxin-free water. Purified MUC4β fractions were passed through an 
endotoxin removal spin column (Thermo Fisher, Pierce # 88277) and the final endotoxin 
level measured by Pierce LAL Chromogenic Endotoxin assay kit (Pierce, # 88282) was 
less than <1. The purified recombinant MUC4β protein fraction was quantified by BCA 
protein assay kit (Thermo Fisher, Pierce # 23225) for the study.  
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4. Encapsulation of MUC4β in Polyanhydride Nanoparticles  
 The 20:80 CPTEG:CPH polymer was synthesized via melt polycondensation [23]. 
Next, nanoparticles encapsulating MUC4β were synthesized using a solid-oil-oil double 
emulsion technique previously described in [28].  Briefly, purified MUC4β was dialyzed to 
nanopure water and lyophilized. Next, 20:80 CPTEG: CPH polymer containing three wt.% 
MUC4β was dissolved 20 mg/mL in methylene chloride. The solution was sonicated for 
30 s to ensure even distribution of the protein. The nanoparticles were precipitated into 
chilled pentane (-10°C; 1:250 methylene chloride: pentane) and collected via vacuum 
filtration. Nanoparticle morphology was verified by scanning electron microscopy (FEI 
Quanta 250, FEI, Hillsboro, OR) and their size subsequently analyzed with ImageJ 
(ImageJ 1.48v, NIH). The release kinetics of MUC4β from 20:80 CPTEG: CPH 
nanoparticles were monitored as previously described [22]. Briefly, nanoparticles were 
incubated in PBS at 37°C. Periodically, the samples were centrifuged, supernatant 
collected, and particles were resuspended in fresh buffer. The amount of protein in the 
collected supernatant was quantified using a microBCA assay. At the end of approximately 
one month, the buffer was exchanged with 40 mM sodium hydroxide to quickly degrade 
the nanoparticles and release any remaining protein. The encapsulation efficiency was 
determined by comparing the total amount of protein released to the amount theoretically 
encapsulated. 
5. Primary Dendritic cells (DCs) Isolation  
C57BL/6 mice were kept under SPF conditions at UNMC animal facilities in 
accordance with UNMC Institutional Animal Care and Use Committee (IACUC) standards. 
Femurs and tibiae of female, 6-8 weeks old female C57BL/6 mice were removed and 
purified from the surrounding muscle tissue by rubbing with kleenex tissues. Thereafter 
intact bones were disinfected in phosphate buffered saline pH 7.2 (PBS) containing 
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penicillin (100 U/mL, Sigma) and streptomycin (100 m/mL, Sigma) solution for 2-5 min. 
Then both ends were cut with scissors and the marrow was flushed with PBS using a 1 
mL syringe attached to 25 G needle. Homogenous pipetting disintegrated clusters within 
the marrow suspension. Cells were centrifuged at 2000 rpm for 2.5 min and the cell pellet 
was resuspended in 10 mL of 1X RBC lysis buffer in the dark for 5 min. Ten mL of RPMI 
was added to stop the lysis. Cells were centrifuged at 2000 rpm and washed 3 times in 10 
mL of RPMI. After the last wash, cells were resuspended homogeneously in a 1 bone:1 
mL of media ratio. Resuspended cells were passed through a single cell strainer to remove 
clumps. Single cell suspensions were poured in 10 mL RPMI containing 10% FBS, 
penicillin (100 U/mL, Sigma) and streptomycin (100 mg/mL, Sigma) media in a 10 cm 
tissue culture plate that was kept in an incubator for 3 h. After incubation, we collected all 
floating cells and washed the plate with media twice to collect rest of the suspended cells 
in a 50 mL falcon tube. The cells were pelleted by centrifugation and the media aspirated. 
The cells were resuspended in 10 mL RPMI media and transfered into T75 flasks for our 
in vitro studies.  
6. DC Maturation and Pulsing  
To enhance the DC population, we added 100 ng/µl of rmGM-CSF and 50 ng/µl 
rmIL-4 reconstituted and diluted in serum-free RPMI to freshly isolated DC cultures on 
Day 0. On Day 3, 5, and 7, we collected the nonadherent cells in 50 ml centrifuge tubes, 
pelleted them and resuspended them in a total volume of 10 ml having 75% of fresh media 
containing 10% FBS + antibiotics and 100 ng/µl of GM-CSF and 50 ng/µl IL-4 in a fresh 
T75 flask. At day 9, immature DCs were counted and seeded in 24 well plate for activation 
studies. Polyanhydride nanoparticles were suspended in complete culture medium, 
sonicated briefly (30s on ice), and added to the DC cultures at day 9 at a concentration 
of 100 μg/mL. DCs were pulsed in the following groups: 3 µg/ml free MUC4β protein 
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(MUC4), free MUC4β protein (3 µg/ml) mixed with blank nanoparticles (100 μg/mL) 
(MUC4+NP) and MUC4 nanovaccine (100 μg/mL). Unstimulated DCs (US) and DCs 
stimulated with LPS (200 ng/mL) were used as negative and positive controls, 
respectively. Cultures were incubated for 48 h (37 °C, 5% CO2). Activated dendritic cells 
were harvested from 24-well plate and centrifuged at 1000 x g for 5 minutes to collect the 
culture medium and the pellet was processed further for flow cytometry studies. 
Supernatant was collected for ELISA studies from each treatment groups.  
7. Flow Cytometry of Activated DCs 
Dendritic cells were resuspended and washed 3 times in FACS buffer {1X PBS (pH 
7.2) + 1% Fetal bovine serum (FBS)} to remove any residual culture medium. DCs were 
fixed in 4% paraformaldehyde for 15 min at RT and washed by centrifugation with excess 
FACs Buffer. After that, the 1X105 DCs were resuspended in100 µl volume of conjugated 
antibody cocktail for detection of DC surface markers consisting of CD11c, MHC-I, MHC-
II, CD40, CD80, CD86, and CD205 was prepared at 1:300 dilution in FACs Buffer. 
Corresponding isotype controls were also prepared at 1:300 dilution in FACs buffer. The 
washed DCs were suspended in either DC surface markers antibody cocktail or in 
isotype-antibody cocktail and incubated for 60 min on ice (40C) in the dark. The labelled 
cells were again washed and analyzed using a BD LSR-II Green Flow Cytometer (BD 
Biosciences). FlowJo® and BD FACSDIVA software were used to analyze the data. 
8. Cytokine Analysis by ELISA 
Supernatants were preserved at -800C and thawed on ice for cytokine analysis. IL-6, 
IFN-γ and IL-12/IL-23p40 cytokines in supernatants were measured by enzyme-linked 
immunosorbent assay (ELISA) kits from BioLegend and the manufacturer’s protocol was 
followed for the assay. 96-well ELISA strips were coated with capture antibodies (1:200 
dilution) diluted in carbonate-bicarbonate buffer (0.5M, pH 9.6) and incubated overnight 
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at 40C. The next day coated strips were washed 4 times with 1X PBST (0.05% Tween 20) 
and blocked with 3% bovine serum albumin (BSA) in PBS for 2 hours at 370C. Strips were 
then washed 4 times and 100 µl of supernatants were added to coated strips and 
incubated for 2 hours at 370C. Plates were washed with PBST for 4 times, followed by 
incubation with detection antibody (1:200) for 1 hour at 370C. Secondary antibody was 
washed away with 4 PBST washes. Avidin (1:1000) was added to ELISA strips and 
incubated for 30 min at RT in dark.  Excess Avidin was washed away with 5 PBST 
washes, followed by addition of TMB (3,3',5,5'-Tetramethylbenzidine) substrate in the 
dark and incubated at RT for color to develop. Absorbance was measured after the 
reaction was stopped (~15 mins) with 1N H2SO4 at 450 nm using a SpectraMax® Plus384 
microplate reader (Molecular Devices LLC, Sunnyvale, California). For serum cytokines 
analysis, serum samples were collected post-animal sacrifice and stored at -800C. Serum 
samples were added at 1:10 dilution to capture-antibody coated plates for cytokine 
analysis. IL-6, IFN-γ and IL-12/IL-23p40 were measured by ELISA kits from BioLegend 
using a similar manufacturer’s protocol. 
9. Mice Immunization for Anti-MUC4 Antibodies Generation  
Eight weeks C57BL/6 mice were immunized with various formulations of 
recombinant MUC4β protein, including protein alone (20 µg/mouse/dose), encapsulated 
MUC4β protein (300 µg/mouse/dose), protein plus nanoparticle, and saline control, 
constituted in Freund’s adjuvant. First booster dose was given after 2 weeks of primary 
immunization. The blood was withdrawn form submandibular vein after 1 week of a single 
booster dose. The serum was isolated from the blood after overnight storage at 4°C and 
stored at -20 °C for further use. 
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10.   MUC4 Autoantibody ELISA 
 To detect circulating MUC4 autoantibodies in sera of the sample set, a novel 
modified sandwich ELISA-assay was developed. Briefly each 96-well plate was coated 
with five μg/mL of recombinant MUC4β protein or with one μg/mL of MUC4 peptides or 
control peptides (PD2 & TR) in carbonate-bicarbonate coating buffer (0.5 M, pH 9.6) and 
incubated overnight at 40C. The plate was washed two times with 1X PBST and blocked 
with 3% BSA in PBS for 3 hours at 370C. Further, the plate was washed four times and 
then a serial dilution (1:16000) of the serum samples were added to MUC4β-coated plate 
and a serial dilution of 1:2000 was added to MUC4 peptide-coated plates. ELISA plates 
with primary serum dilutions were incubated overnight at 40C. Plates were washed with 
PBST for four times, followed by incubation with horseradish-peroxidase (HRP) 
conjugated goat anti-human IgM+ IgG+ IgA (H+L) (Jackson ImmunoResearch), or for 
isotyping HRP conjugated IgM, IgG (H+L) and IgA (Jackson ImmunoResearch) 
respectively for 1 hour at 370C. The excess secondary antibody was washed away with 5 
PBST washes and followed by addition of TMB substrate in the dark. Absorbance was 
measured after the reaction was stopped (~15mins) by adding 1N H2SO4 at 450 nm using 
a SpectraMax® Plus384 microplate reader (Molecular Devices LLC, Sunnyvale, 
California). 
11.  Anti-MUC4β Antibodies Detection in Immunized Mice Serum Using 
ELISA 
Serum samples were collected post-animal sacrifice and stored at -800C for detection 
of anti-MUC4β antibodies using ELISA techniques. To detect anti-MUC4β antibodies, we 
used a modified ELISA protocol. A 96-well plate was coated with 5 μg/mL of recombinant 
MUC4β protein in carbonate-bicarbonate coating buffer (0.5 M, pH 9.6) and incubated 
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overnight at 40C. Plate was washed 2 times with 1X PBST and blocked with 3% BSA in 
PBS for 3 hours at 370C. Further, the plate was washed 4 times and then serial dilutions 
of the serum samples were incubated in MUC4β coated plate for 2 hours at 370C. Plates 
were washed with PBST for 4 times, followed by incubation with horseradish-peroxidase 
(HRP) conjugated goat anti-mouse IgG (total H+L) (Thermo Fisher), IgG1 (Abcam) and 
IgG2b (Abcam) for 1 hour at 370C. Excess secondary antibody was washed away with 5 
PBST washes and followed by addition of TMB substrate in the dark. Absorbance was 
measured after the reaction was stopped (~15 min) with 1N H2SO4 at 450 nm using a 
SpectraMax® Plus384 microplate reader (Molecular Devices LLC, Sunnyvale, California). 
12.  Generation of MUC4-Expressing Murine PC Cell Lines 
A MUC4-expressing mouse pancreatic cancer cell line derived from KPC mice 
(KPC960) was developed by transfection of KPC960 cell lines with miniMUC4-pSecTagC 
plasmid using the Lipofectamine method (Invitrogen) and single colonies were obtained 
by zeocin selection as published previously in Moniaux et.al 2007 and confirmed by 
immunoblotting with a MUC4 peptide mouse monoclonal antibody (8G7). The miniMUC4 
expressing KPC960 cells were kindly developed, validated and gifted by Dr. Shailendra 
Gautam for our in vivo and ex vivo studies.  
13.  Tumor Implantation and Mice Immunization  
For in vivo characterization of MUC4 nanovaccine in mice, 8 weeks C57BL/6-FBP 
mixed background mice were immunized with different formulations of recombinant 
MUC4β protein, including protein alone (MUC4- 35 µg/mouse/dose), free MUC4 protein 
mixed with nanoparticles (MUC4+ NP) (35 µg/mouse/dose of MUC4 + 500 µg/mouse/dose 
empty nanoparticles), MUC4 nanovaccine (500 µg/mouse/dose), and unimmunized mice 
(negative control). First booster dose was given after two weeks of primary immunization. 
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Two weeks after first booster, mice were injected with 1x106 cells of mini-Muc4 or Vector 
expressing KPC derived mouse pancreatic cell lines(KPC960) into right and left flanks of 
mixed background mice (n=5), respectively. Tumor growth was monitored till the tumor 
volume reached to 100mm3 volume. Mice were then immunized with second booster dose 
but the MUC4 protein dose was reduced to 20 µg/mouse/dose in all treatment groups 
except for saline control. Tumors were harvested at 23rd-day post second booster 
immunization and preserved in formalin for further use.  
14.  T-cell Isolation and In Vitro Activation 
Naïve T-cells were isolated from 8-10weeks old C57BL/6-FBP mixed background 
mice. Mice were sacrificed, and spleens were isolated in RPMI+10%FBS+Pen-Strp 
(RPMI) medium in 50 ml Falcon tube on ice. Media was removed by suction inside the 
laminar hood and one spleen was added to one of the wells of 6 well plates. Spleens were 
teased with a 25G syringe needle and 1 ml pipette tip. Teased-out splenocytes were 
transferred to 15 ml falcon tube in RPMI media and was centrifuged for 2-3mins at 2000 
rpm. The supernatant was removed and the pellet was resuspended in 10-12ml of 1X 
RBC lysis buffer, then the tube was kept for 5 min in the dark. The tube was centrifuged 
again for 2-3 min at 2000 rpm and the supernatant was aspirated. The pellet was 
resuspended and splenocytes were washed for 3 times with RPMI media. After the last 
wash, the pellet was resuspended in 2 ml of RPMI media and counted total cells/ml. We 
centrifuged the cell suspension at 2000 rpm for 10 min and removed the supernatant 
completely. We resuspended the cell pellet in 40 μL of MACs Buffer (1X PBS pH 7.2, 0.5% 
BSA, 2mM EDTA) per 107 cells. We added 10 μL of Pan T cell Biotin-Antibody Cocktail 
(MACS Miltenyi Biotech, Inc.) per 107 cells and mixed it well. We incubated the mixture for 
5 min in the refrigerator (2-8o C) and then added 30 μL of MACs buffer per 107 cells, and 
followed by addition of 40 μL of Anti-Biotin Microbeads per 107 cells. We mixed all the 
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components well & incubated for additional 10 min in the refrigerator (2-8o C). We took the 
mixture and processed the sample in an autoMACS® Pro Separator (MACS Miltenyi 
Biotech, Inc.). Tubes were placed in the following Chill Rack positions: position A = 
sample, position B = negative fraction position C = positive fraction. We prepared and 
primed the instrument and followed the instructions that were given in the user manual.  T 
cells were isolated by magnetic separation and we used the ‘Depletes’ program to do the 
separation into positive (other splenocytes) and negative (T cells) population.  
Naïve T-cells were then cultured and expanded in RPMI on day 0. On day 1, 
purified T cells were incubated with phorbol 12-myristate 13-acetate (PMA) (25 ng/mL) 
Ionomycin (500 ng/mL, Abcam) for 48 hours at 37°C. On day 3, these T-cells were co-
cultured in 12-well plate with 48hour-pulsed DCs in the following groups: 3 µg/ml free 
MUC4β protein (MUC4), free MUC4β protein (3 µg/ml) mixed with blank nanoparticles 
(100 μg/mL) (MUC4+NP) and MUC4 nanovaccine (100 μg/mL). Unstimulated DCs (US) 
and DCs stimulated with lipopolysaccharides {LPS} (200 ng/mL) were used as negative 
and positive controls, respectively. T-cells were co-cultured for 48 hours with pulsed DCs 
and then collected for further analysis. The experiment was done in triplicates. 
Since the Pan T cell Isolation kit can purify both naïve and activated T cells, a 
similar T-cell isolation protocol was utilized to isolate T-cells from immunized mice and 
expanded in vitro by treatment with PMA/Ionomycin (25 ng/mL/500ng/mL, Abcam) for 48 
hours at 37°C. On day 3, the expanded T-cells were analyzed by flow cytometry for 
phenotyping T-cells and cytokine secretion studies. 
15.  Cytotoxicity Assay of T-cells 
The miniMUC4 KPC960 cells and KPC960 vector control cells (500 cells/well) 
were seeded in 96-U bottom plates and cultured overnight in a 370C incubator. The plate 
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was centrifuged and the media was removed. Activated T-cells were added from each of 
the treatment groups to target cancer cells at 10:1 dilution into their respectively labeled 
wells. T-cell mediated cytotoxicity was measured by the CytoTox 96® Non-Radioactive 
Cytotoxicity Assay Kit (Promega) and the manufacturer’s protocol was followed for the 
assay. The plate was centrifuged at 250 × g for 4 minutes and the plate was incubated at 
37°C for 4 hours. At 45 minutes prior to supernatant harvest, Lysis Solution was added to 
wells of both cancer cell lines that didn’t have T-cells added to them, which served as our 
Target Cell Maximum LDH Release Control. The plate was centrifuged at 250 × g for 4 
minutes and 50 μl of the supernatant from each well of the assay plate was transferred to 
the corresponding well of a flat-bottom 96-well enzymatic assay plate. Substrate Mix was 
reconstituted using Assay Buffer and 50 μl of the reconstituted Substrate Mix was added 
to each well of the plate. The plate was incubated at room temperature in the dark for 30 
min. Absorbance was measured after the reaction was stopped with 50 μl of the Stop 
Solution at 450 nm using a SpectraMax® Plus384 microplate reader (Molecular Devices 
LLC, Sunnyvale, California).  
16.  Flow cytometry of Activated T-cells 
T-cells isolated from immunized mice were expanded by PMA + Ionomycin 
treatment. Brefeldin A (2 ug/mL) was added to the treated flask and untreated flask and 
cells were incubated for 4 hours in a 37oC incubator. T-cells were resuspended and 
washed three times in FACS buffer {1X PBS (pH 7.2) + 1% Fetal bovine serum (FBS)} to 
remove any residual culture medium. After that, the 1X105 T-cells were resuspended in 
100 µl volume of conjugated antibody cocktail for detection of T-cell surface markers 
(consisting of Th1 phenotype CD4, CD8, and Tbet) which was prepared at 1:300 dilution 
in FACs buffer. Corresponding isotype controls were also prepared at 1:300 dilution in 
FACs buffer. The washed T-cells were suspended in either DC surface marker’s antibody 
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cocktail or in isotype-antibody cocktail and incubated for 60 min on ice (40C) in the dark. 
The labelled cells were again washed with FACs buffer. T-cells labelled with surface 
antibodies were fixed in 4% paraformaldehyde for 15 min at RT and washed by 
centrifugation with excess FACs buffer. For intracellular labeling of cytokines, antibodies 
and their corresponding isotype controls were prepared in pre-chilled Phosflow Buffer™ 
(BD Biosciences) at 1:300 dilution and keep it on ice. Fixed T-cells were centrifuged, and 
4% paraformaldehyde was discarded by gentle flicking and washed one time with FACs 
buffer. Fixed T-cells were permeabilized by adding 100 ul of PhosFlow Buffer™ in the dark 
and on ice for 30 min. T-cells were centrifuged and the permeabilization buffer was 
decanted. For intracellular cytokine staining, 100 ul of IL2, IL12, TNFα and IFNγ 
(eBioscience) antibody cocktail or isotype control antibody cocktail added to T-cells and 
incubated for 60 min on ice (40C) in the dark. The labelled cells were again washed with 
FACs buffer and analyzed using a BD LSR-II Green Flow Cytometer (BD Biosciences). 
FlowJo® and BD FACSDIVA software were used to analyze the data. 
17.  Immunohistochemistry and Immunofluorescence staining of tumor 
tissue sections 
The miniMUC4-expressing and vector control murine subcutaneous tumor 
sections were evaluated for PD-L1 expression by immunohistochemistry (IHC) and for 
CD4 and CD8 T-cell’s infiltration by immunofluorescence (IF). Harvested tumors were 
fixed in 10% neutral buffered formalin, embedded in paraffin, and 4 μm thick sections were 
placed on slides. After deparaffinizing with xylene and rehydrating with decreasing alcohol 
gradients with final rehydration in MilliQ water, for IHC staining, tumor sections were 
treated with 5% H2O2 in 100% methanol for 1 hour at room temperature in the dark for 
quenching of endogenous peroxidases. For IF, tumor sections were treated with 100% 
methanol for 1 hour at room temperature in the dark for fixing the tissue. Antigen retrieval 
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was done using Tris-EDTA buffer, pH 9.0 in the microwave (1100W) at high power for 15 
min. For simple hematoxylin and eosin staining of tumor tissue sections, tissue slides were 
counterstained with hematoxylin and eosin, followed by dehydration with increasing 
alcohol gradients, xylene washes, and mounting with a cover slip. All hematoxylin and 
eosin-stained slides were shown to the pathologist for analysis and quantification. 
Tissues were blocked with 2.5% normal horse serum for 3 hours, and then 
incubated with a primary anti-mouse PD-L1 antibody (cc-50298, Santa Cruz 
Biotechnology Inc.) at 1:200 dilution in Tris-buffered saline (TBS) at 4°C overnight. For T-
cell’s IF staining, two separate tissue sections were incubated with anti-mouse CD4 or 
CD8 antibodies (Thermo Fisher Scientific) respectively at 1:400 in PBS at 4°C overnight. 
PD-L1 stained slides were rinsed with TBST and T-cells stained slides were washed with 
PBST. After wash, PD-L1 labeled slides were incubated with an HRP-conjugated goat 
anti-rabbit secondary antibody for 1 hour. T-cell’s labeled sections were incubated with 
Alexa Fluor 488 conjugated goat-anti-mouse secondary antibody for 1 hour in the dark. 
IHC slides were rinsed with 2 washes of TBST and 3 washes of TBS, and subsequently, 
using DAB substrate kit (Vector Laboratories) the color was developed. Sections were 
counterstained with hematoxylin, followed by dehydration with increasing alcohol 
gradients, then xylene washes and mounting with a cover slip. IF slides were again 
washed with 4 washes with PBST and two washes with PBS, followed by covering the 
section with a glass slide and the anti-fade VECTASHIELD mounting media (Vector 
Laboratories Inc., Burlingame, CA, USA). IF staining was observed under the Zeiss 510 
LASER SCAN confocal microscope and quantified by ImageJ software 
(https://imagej.nih.gov/).  
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18.  Statistical Analysis  
For our autoantibodies analysis, the differences among group means were tested 
by one-way analysis of variance (ANOVA) F-test using JMP® Data Analysis Software (SAS 
Institute Inc., NC). If the F-test was significant, paired Wilcoxon sign rank t-tests were 
performed for pairwise comparisons of group means. Significance was defined as p < 
0.001.  
For our nanovaccine in vitro, ex vivo and in vivo studies differences among group 
means were tested by one-way analysis of variance (ANOVA) F-test using GraphPad 
Prism v. 7.0 (GraphPad, La Jolla, CA). If the F-test was significant, Tukey’s t-tests and 
Student’s t-tests were performed for pairwise comparisons of group means. Significance 
was defined as p < 0.05.  
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19. Table I: List of antibodies 
 
S.No. Antibodies Company Catalogue No. 
1 
Alexa Fluor® 700 anti-mouse CD11c 
(clone N418) 
eBioscience (San 
Diego, CA) 
56-0114-80 
2 
FITC conjugated anti-mouse/rat MHC 
Class II (I-Ek, clone 14-4-4S) 
eBioscience (San 
Diego, CA) 
11-5980-81 
3 (APC) anti-mouse CD40 (clone 1C10) 
eBioscience (San 
Diego, CA) 
17-0401-81 
4 
(PE)-Cy7 conjugated anti-mouse F4/80 
(clone BM8) 
eBioscience (San 
Diego, CA) 
25-4801-82 
5 
Anti-Mouse MHC Class I (H-2Kd) 
eFluor® 450 (Clone: SF1-1.1.1) 
eBioscience (San 
Diego, CA) 
48-5957-80 
6 
Alexa Fluor® 700 conjugated Armenian 
hamster IgG (clone eBio299Arm) 
eBioscience (San 
Diego, CA) 
56-4888-80 
7 FITC IgG2a κ (clone eBR2a) 
eBioscience (San 
Diego, CA) 
11-4321-80 
8 
Rat IgG2a K Isotype Control APC 
(clone eBR2a) 
eBioscience (San 
Diego, CA) 
17-4321-41 
17-4321-81 
9 PE-conjugated rat IgG2a (clone eBR2a) 
eBioscience (San 
Diego, CA) 
12-4321-80 
10 
Rat IgG2a K Isotype Control PE-
Cyanine7 (clone eBR2a) 
eBioscience (San 
Diego, CA) 
25-4321-81 
11 PE/Cy7 anti-mouse CD86 (Clone GL1) BD Biosciences 560582 
 
12 
PE conjugated anti-mouse CD80 (clone 
16-10A1) 
eBioscience (San 
Diego, CA) 
12-0801-81 
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13 
PE/Cy 5.5 antimouse CD205 (MMR, 
clone NLDC-145) 
BioLegend 138207 
14 
PerCP/Cy5.5 Rat IgG2a, κ Isotype Ctrl 
Antibody 
BioLegend 400531 
15 
Rat IgG2a K Isotype Control eFluor® 
450 (clone eBR2a) 
eBioscience (San 
Diego, CA) 
48-4321-80 
16 
T-bet (Anti-Human/Mouse T-bet PerCP-
Cyanine5.5 
eBioscience (San 
Diego, CA) 
45-5825-80 
17 
GATA-3 (Anti-Human/Mouse Gata-3 
eFluor® 660) 
eBioscience (San 
Diego, CA) 
50-9966-41 
18 CD4 (Anti-Mouse CD4 eFluor® 450) 
eBioscience (San 
Diego, CA) 
48-0042-80 
19 CD8 (Anti-Mouse CD8a PE) 
eBioscience (San 
Diego, CA) 
12-0081-81 
20 IL-2 (Anti-Mouse IL-2 PE-Cyanine7) 
eBioscience (San 
Diego, CA) 
25-7021-80 
21 IL-10 (Anti-Mouse IL-10 FITC) 
eBioscience (San 
Diego, CA) 
11-7101-41 
22 
IL-12 (Anti-Mouse IL-12/IL-23 p40 Alexa 
Fluor® 488) 
eBioscience (San 
Diego, CA) 
53-7123-80 
23 IL-13 (Anti-Mouse IL-13 PE-Cyanine7) 
eBioscience (San 
Diego, CA) 
25-7133-80 
24 IFNγ (Anti-Mouse IFN gamma APC) 
eBioscience (San 
Diego, CA) 
17-7311-81 
25 Rat IgG2b Isotype Control eFluor® 660 
eBioscience (San 
Diego, CA) 
50-4031-80 
26 
Rat IgG2a K Isotype Control Alexa 
Fluor® 488 
eBioscience (San 
Diego, CA) 
53-4321-80 
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27 Rat IgG2b K Isotype Control FITC 
eBioscience (San 
Diego, CA) 
11-4031-81 
28 Rat IgG1 K Isotype Control eFluor® 450 
eBioscience (San 
Diego, CA) 
48-4301-80 
29 CD4 Monoclonal Antibody (RIV6) 
ThermoFisher 
Scientific 
MA1-7631 
30 CD8 Monoclonal Antibody (RIV11) 
ThermoFisher 
Scientific 
MA1-7632 
31 
Pdcd-1L1 (H-130) {Discontinued 
Antibody} 
SantaCruz 
Biotechnology INC. 
Sc-50298 
32 Goat Anti-mouse IgG2b-HRP 
ThermoFisher 
Scientific 
M32407 
33 Goat Anti-mouse IgG1-HRP 
ThermoFisher 
Scientific 
A10551 
34 
Peroxidase AffiniPure Goat Anti-
Human IgM, Fc5μfragment specific 
Jackson 
ImmunoResearch 
Laboratories, INC. 
109-035-129 
35 
Peroxidase AffiniPure Goat Anti-
Human IgG (H+L) 
Jackson 
ImmunoResearch 
Laboratories, INC. 
109-035-003 
36 
Peroxidase AffiniPure Goat Anti-
Human IgA + IgG + IgM (H+L) 
Jackson 
ImmunoResearch 
Laboratories, INC. 
109-035-064 
37 
Peroxidase AffiniPure Goat Anti-
Human Serum IgA, α Chain Specific 
Jackson 
ImmunoResearch 
Laboratories, INC. 
109-035-011 
38 
Goat anti-Mouse IgG (H+L) Cross-
Adsorbed Secondary Antibody, Alexa 
Fluor 488 
ThermoFisher 
Scientific 
A-11001 
39 
Goat anti-Mouse IgG (H+L) Secondary 
Antibody, HRP 
ThermoFisher 
Scientific 
31430 
40 
Goat anti-Rabbit IgG (H+L) Secondary 
Antibody, HRP 
ThermoFisher 
Scientific 
31460 
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Supplemental Table 1. Patient characteristics, all subjects 
Supplemental Table 2. Patient characteristics, limited subjects 
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1. Synopsis 
A major challenge in pancreatic cancer (PC) immunotherapy is identifying tumor-
associated-antigens (TAAs) that can be targeted. In PC, Mucin-4 (MUC4) is differentially 
overexpressed and aberrantly glycosylated, thus potentially serving as a source of neo-
antigenic epitopes, which could be exploited for cancer immunotherapy. Literature review 
has shown that an immune response developed in the form of autoantibodies to various 
tumor antigens could serve as a surrogate for immunogenicity (and compromised self-
tolerance) in cancer patients. The presence of MUC4 autoantibodies was analyzed in 
serum samples taken from patients at the time of pancreatic cancer diagnosis prior to any 
treatments, from patients with chronic pancreatitis, and healthy controls. By using indirect-
ELISA techniques we were able to detect autoantibodies against recombinant human 
MUC4-beta (MUC4β) protein in 77.41% of PC patient’s sera, whereas only 33.33% of age-
matched healthy controls and 23.81% of chronic pancreatitis (CP) patients had positive 
sera. In addition, we used a panel of 7 MUC4-alpha region peptides and 4 MUC4β 
peptides to identify highly immunogenic MUC4 epitopes. Furthermore, isotyping these 
autoantibodies in PC patient sera indicates that IgM antibodies to peptides A2, D4 and B1 
correlate with better prognosis. Our novel study suggests that MUC4 expressed by 
pancreatic tumors is immunogenic in PC patients and could be used as a target for cancer 
immunotherapy. Further these studies suggest that segregation of PC patients based on 
the presence of MUC4 autoantibodies against multiple MUC4 peptide, could be helpful in 
identifying patients for personalized MUC4-based immunotherapy treatment of pancreatic 
cancer. 
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2. Background and Rationale 
Pancreatic cancer (PC) is a fatal disease with a poor 5-year overall survival of 
merely 8% [1]. Conventional therapies for PC such as chemotherapy, radiation therapy 
and surgery have fared with limited success, thus necessitating the need to develop 
alternative treatment strategies [2, 3]. Immunotherapy has emerged as a viable option but 
had stunted success in the efficacious treatment of pancreatic cancer patients [4, 5]. PC 
has limited genetic mutations, notably at the KRAS codon position with 12 mutations, and 
bear at the maximum 4000 potential immunogenic neoantigens, whereas melanoma has 
a predicted neoantigen count of 14000 that corroborates with success seen in melanoma 
immunotherapy [6-8]. Thus, one of the major challenges in PC immunotherapy is the 
identification of tumor-associated antigens (TAAs) that could be specifically targeted to 
cancer with negligible side-effects on healthy cells/organs.  
 TAAs expressed by cancer cells are mostly recognized as self-antigen due to the 
overriding of the immune system by immunoediting, therefore establishing a potent 
cancer-mediated tolerance against its TAAs [3, 9, 10]. Abnormal expression of antigens 
by cancer cells being recognized by immune surveillance that leads to the generation of 
autoantibodies is reflective of the immune response generated in cancer patients [10]. 
Expression of the antigen at the aberrant location where it is neither expressed in normal 
organ nor during other malignancy affecting that organ makes it a lucrative target for 
immune cells. In addition, post-translational modifications of such antigens affect their 
processing and loading on major histocompatibility complex (MHC molecules). The 
modified antigen-loaded MHC interacts with T cell receptors (TCRs), hence activating 
CD4+ T helper cells to mount a humoral autoantibody response, overriding immunological 
tolerance against the TAA [10, 11].  
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Mucin 4 (MUC4), a high molecular weight glycoprotein, is aberrantly 
overexpressed by and glycosylated in PC cancer cells, whereas it is negligibly present in 
normal pancreas and chronic pancreatitis (CP) patients [12-14]. Presence of 
autoantibodies against the VNTR region of another aberrantly overexpressed mucin in 
PC, Mucin 1 (MUC1), has been detected in platinum based drug resistant lung and ovarian 
cancers [15, 16], but there were no significant increase in MUC1 autoantibodies detected 
in PC patients when compared to age-matched controls [17]. Unlike MUC1, the MUC4 
expression is restricted in most of the normal organs except for low levels being expressed 
in urogenital tracts and trachea in lungs [18]. In addition, autoantibodies against MUC4-
TR region glycopeptides have been detected in colorectal cancer patients [19]. Thus, we 
hypothesized that MUC4 could be potentially immunogenic because of its spatial 
expression and post-translational modifications leading to tolerance against MUC4 being 
compromised in PC patients. 
MUC4 has a potential autocatalytic Gly-AspPro-His (GDPH) cleavage site that 
generates the N-terminal MUC4α subunit (containing the TR region) and a membrane-
tethered MUC4β subunit [20-22]. In contrast to the published studies on MUC4 
autoantibodies [19], our study encompassed the entire length of MUC4 to demonstrate 
that MUC4 is immunogenic in PC patients. This design provided us a unique opportunity 
to assess the development of the humoral response to the entire protein backbone of 
MUC4 in PC patient serum. Due to the large molecular weight of MUC4α we were unable 
to express and purify the recombinant protein in a bacterial system. We successfully 
purified the MUC4β recombinant protein, which was used in our autoantibody study. Our 
lab is interested in utilizing MUC4 to develop an immunotherapy strategy to treat PC. 
Therefore, we also predicted potential major histocompatibility complex-I (MHC-I) HLA-
binding immunogenic peptides using a reverse immunology approach [23] across the 
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entire protein sequence of MUC4. Most of the available studies on cancer vaccine 
immunotherapies primarily focus on HLA-binding peptides to induce T-cell mediated 
responses. Humoral response analysis against such peptides have not been investigated 
and thus excludes an equivalently crucial arm from factoring in the overall clinical outcome 
status of vaccine-immunized patients. We predicted the B-cell probability score for the 
same peptides and were keen to observe if an autoantibody signature was present against 
these T-cell peptides. Our study reported the presence of circulating autoantibodies 
against both MUC4β protein and MUC4 peptides present in PC patient serum when 
compared to CP patient’s and healthy individual’s serum. This interesting observation 
suggests that MUC4 protein could potentially stimulate both T-cells and B-cells that may 
affect the overall clinical outcome.  Further, we elucidated the various isotypes of 
autoantibodies present produced against MUC4 in PC patients. In addition, since the 
humoral response against MUC4 serves as a surrogate of compromised tolerance, we 
stratified and predicted patients who could have a higher probability of response to 
personalized MUC4-based immunotherapy. 
3. Results 
3.1 Analysis of Circulating MUC4 Autoantibody in PC patients 
 The primary aim of this study was to develop a novel platform for selective 
detection of circulating autoantibodies against the human MUC4β recombinant protein. To 
our knowledge we are the first group to purify a recombinant human MUC4β protein, which 
we have been utilized to develop the assay. Circulating autoantibodies against 
recombinant human MUC4β protein was observed to be upregulated in PC patients as 
compared to healthy individuals and chronic pancreatitis patients. The low level of 
antibody positive sera and high level of antibody positive sera was defined at its cut-off 
values of <1.283 and ≥1.283 respectively (Figure 1A). Based on the cut-off values we 
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were able to determine that 76.7% of PC patients had high levels of MUC4 autoantibodies, 
whereas only 37% of healthy and 28.6% of CP patients showed high levels of MUC4β 
autoantibodies (Figure 1A). We didn’t observe a significant advantage in survival between 
PC patients with high levels of MUC4 autoantibodies and low levels of MUC4 
autoantibodies (Figure 1B). Further we performed stage-wise analysis and observed that 
86.7% of early-stage PC patients and 66.7% of late-stage patients had circulating MUC4 
autoantibodies in their sera (Figure 1C). PC patient survival days analysis demonstrated 
that patients with higher serum reactivity had mean survival days (MSD) of 179 days for 
Stage 1-II and 309 days for Stage II-IV, compared to the patients with lower serum 
reactivity had MSD of 131 days for Stage 1-II and 244 days for Stage II-IV (Figure 1C). 
3.2 Bioinformatics Analysis Predicts Potential MUC4 Peptides 
 Due to the difficulty in purification of the MUC4α domain, we predicted potential 
adequate HLA-binding immunogenic MHC-I peptides inside both MUC4α and MUC4β 
domains to capture the entire MUC4 protein. A prerequisite for an immune response to 
arm, immunogenic peptides of MUC4 must be loaded on major histocompatibility 
complexes that would be cross-represented to effector immune cells (i.e. T-cells and B-
cells). HLA-A2 is one of the widely used HLA-subtype for peptide predictions that have 
been used in designing vaccinations for melanoma and lung cancer [29, 37-39]. We used 
3 prediction tools NetCTL1.0 and IEDB (Tepi Tool and Peptide processing) for determining 
HLA A2-binding T cell epitopes. NetCTL1.0 (based on a combined prediction of peptide 
MHC binding, proteasomal C terminal cleavage and TAP transport efficiency) software 
analyzed MUC4 sequence and predicted potential HLA-binding 9-mer amino acid 
sequences scored across 10 major human HLA-A2 isoforms. Peptides with combined high 
scores have higher specificity, sensitivity and higher affinity binding to HLA-A2 MHC-I 
complex. We further analyzed these peptides using IEDB (http://tools.iedb.org/tepitool/) 
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prediction TepiTool which is based on consensus method employing artificial neural 
network, combinatorial library networks and SMM-align. TepiTool scored the NetCTL1.0 
predicted peptides based on their likelihood to bind to human HLA-A2*02.1 (mostly used 
in vaccine studies [39]), as well as, C57BL/6 mouse HLA-Db and HLA-Kb MHC-I isotypes. 
In addition IEDB Processing (http://tools.iedb.org/processing/) analysis, which scores 
based on proteasomal C terminal cleavage, TAP transport efficiency and MHC-I complex 
loading, ranked these predicted peptides for both mouse and human HLA MHC-I loading. 
Lower predicted rank score suggests a higher probability of these peptides to be loaded 
on MHC-I complex and cross-presented to T-cells for activating them in an antigen-
specific manner (Figure 2).  
 Our autoantibody analysis demonstrated MUC4β specific antibodies being 
generated specifically in PC patients. Bioinformatics analysis predicted MHC-I peptides in 
MUC4β region that made us curious to analyze the potential of these peptides to serve as 
B-cell immunogenic epitopes. For the same, we ran and scored these peptides on the 
IEDB B-cell prediction tool (http://tools.iedb.org/bcell/) and performed BCPred analysis 
(http://ailab.ist.psu.edu/bcpred/predict.html). Our B-cell epitope analysis showed that 
there was a difference in predicted scores between each peptide. Only 13 out of 24 
predicted peptides were picked up by both prediction software and scored for the potential 
of them getting recognized by B-cells. We ranked these peptides based on their BCPred 
scores (Figure 3), and randomly selected peptides that represent all differentially scored 
B-cell epitope regions of both MUC4α and MUC4β to elucidate the plausibility of 
autoantibodies generated against these predicted peptides. 
3.3 Screening of Autoantibody Signature against MUC4 Peptides 
 Our initial experiment elucidated the presence of autoantibodies against a MUC4β 
recombinant protein which provides a large repertoire of epitopes that could be recognized 
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by B cells. In addition, our bioinformatics analysis predicted peptides that have the 
potential to serve as both T-cell and B-cell epitopes. To validate our observations, we 
developed a modified indirect ELISA to detect autoantibodies if any, generated against 
these epitopes. Our ELISA studies revealed differential serum reactivity to each of the 7 
MUC4α peptides whereas significantly low/ reactivity was seen against TR and PD2 
peptides and 5 µg/ml of BSA protein (Figure 4A). Further, we were curious to understand 
whether any peptide specifically fared better when compared to the survival status of PC 
patients. Our study showed that patients with high serum reactivity to peptides D3 and F3 
survived longer than their low serum reactivity counterparts, but the rest of the 5 MUC4α 
peptides didn’t show similar relationship (Figure 4B).  
Similarly, PC patient serum significantly reacted with all 4 peptides from MUC4β 
region and low reactivity was observed with control peptides and protein (Figure 5A). In 
addition, high serum reactivity to MUC4β peptides didn’t provide a survival advantage 
(Figure 5B). Thus, our study shows for the first time that MUC4 MHC-I HLA-binding T-cell 
peptides could potentially be recognized by B-cells and might have a dual (activate both 
cellular and humoral immune pathway) epitope property. Further, we stratified PC patients 
with high autoantibody levels detected in their sera and observed that we could potentially 
design a selection strategy to elucidate patients who likely might have compromised 
peripheral tolerance (Table I). To ensure the specificity of the detected antibodies, we 
compared the serum reactivity of randomly selected 10 healthy and 10 chronic pancreatitis 
individuals and we observed that PC patient specific reactivity was seen to all 11 MUC4 
peptides and negative in healthy or CP individuals (Supplemental Figure 1 & 2). 
3.4 Isotype Analysis of MUC4 Autoantibodies in PC Patients 
 Autoantibody isotypes such as IgM autoantibodies in cancer patient serum have 
been shown to correlate with poor prognosis and overall survival of those patients [15]. 
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Activation of B-cells to its mature form after receiving secondary stimulation from CD4+ T-
cells induces isotype switching to generate various classes of antibodies with the same 
variable antigen binding region as the original antibody generated to the antigen by the 
VD (J) recombination pathway [40, 41]. Our observations demonstrated that 
autoantibodies are present against both recombinant MUC4 protein and its peptides, but 
higher levels of these autoantibodies didn’t significantly correlate with patient survival data. 
Isotyping of mucin autoantibodies could provide some insight into understanding whether 
activation of B-cells confers any survival advantage to PC patients. We measured different 
isotypes (IgA, IgM and IgG) of MUC4 autoantibodies present in PC patient sera and 
correlated with overall patient survival and prognosis. All three MUC4β protein 
autoantibody isotypes were detected, however presence of IgG isotype autoantibodies in 
serum segregated PC patients in two groups. Despite the segregation, we didn’t observe 
any significant correlation between autoantibody isotypes and patient survival 
(Supplemental Figure 3). 
 Isotype analysis of autoantibodies against MUC4α peptides demonstrated 
differential levels of isotypes present in PC patient serum (Figure 6A). Our data further 
elucidated that high levels of IgM autoantibody against A2 and D4 MUC4α peptides 
correlate strongly with overall patient survival (P<0.001) (Figure 6B). Analysis of MUC4β 
peptides also demonstrated that all isotypes were detected (Figure 7A). Similarly, Kaplan-
Meier graph shows that high levels of IgM autoantibody to B1 peptide correlated strongly 
with PC survival (Figure 7B). Our data showed that MUC4 is not only immunogenic in PC 
patients but also induces maturation of B-cells. Interestingly, for all MUC4 peptides, 
patients with IgM isotype autoantibodies had better median survival than patients with 
either IgG or IgA autoantibodies (Supplemental Figure 4). 
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4. Discussion 
 The present study investigated the possibility of MUC4 being immunogenic in PC 
patients. We developed a modified ELISA strategy and tested both MUC4 recombinant 
protein and peptides to determine the presence of autoantibodies in patient sera. MUC4 
is aberrantly overexpressed in PC patients and its expression increases with gradual 
progression of the malignancy [42]. MUC4 overexpression and aberrant glycosylation in 
PC and its absence in the normal pancreas [14] makes it a potential antigen that might 
get recognized by the immune system (specifically by B-cells). The modified indirect 
ELISA discovery platform for detecting human serum autoantibodies was developed for 
efficient antigen-antibody binding and provide a remarkably low background. Cancer-
associated autoantibodies to recombinant MUC4β protein were identified in PC patient 
sera, whereas healthy individuals and CP patients were negligible for MUC4 
autoantibodies, although survival analysis didn’t reveal any robust correlation with levels 
of autoantibodies present in PC patient sera. Presence of circulating MUC4 autoantibodies 
in PC patients therefore supports the hypothesis that immunological tolerance is 
compromised against MUC4 and gets recognized by B-cells. 
 In our study, we utilized both recombinant protein and peptides to investigate 
whether different domains/regions of MUC4 is immunogenic other than just the TR region 
sequence that is well studied. Bioinformatics analysis predicted HLA-binding peptides that 
have potential to serve as a dual epitopes for both cellular and humoral immune pathways 
in human as well as in mouse. To capture MUC4α region we randomly selected peptides 
corresponding to that region due to unavailability of purified recombinant MUC4α protein. 
The rationale behind using peptides of MUC4β region was to recognize immunodominant 
region present in MUC4β protein and it was investigated on a peptide-based ELISA 
platform. Our study revealed that only PC patient serum contained autoantibodies against 
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MUC4 peptides, whereas there was negligible reactivity detected in control individuals. 
Our patient stratification strategy based on their serum reactivity with respective MUC4 
peptides elucidate that the tolerance against each peptide is compromised in patient-to-
patient basis. Such case basis-compromised tolerance might correlate with the differential 
response of PC patients to MUC4-based immunotherapy that needs to be investigated in 
the future.  
 Detection of specific autoantibody isotypes suggests activation and maturation of 
B-cells leading to the systemic availability of neutralizing antibodies protecting against 
cancer, which could be translated to the observed negative correlation of immature IgM 
antibodies with the survival of patients [15, 19]. Our data in contrast showed that high 
levels of IgM autoantibodies against A2, D4 and B1 have a statistically strong correlation 
with longer survival of PC patients. Further, PC patients with high levels of IgM 
autoantibodies have better survival than those who have IgG/IgA circulating 
autoantibodies, thus making a case for a better understanding of the role of humoral 
responses in the survival of patients.  
 Overall our studies provide enough evidence to suggest that entire MUC4 is 
immunogenic and peripheral tolerance to MUC4 is compromised in PC patients. In a 
recent study, it has been shown that CD8+ T cell-specific MUC16 neoantigen epitopes 
provide a survival advantage to PC patients [43]. Interestingly our data for the first time 
reveals that T-cell epitopes located on various regions of the MUC4 protein sequence 
(excluding VNTR region), could simultaneously be recognized by B-cells and activate the 
humoral arm of the immune system. Further, circulating IgM MUC4 autoantibodies against 
particular peptides, showed to provide protection to the PC patients and correlates with 
increased overall survival status. Cancer vaccines have emerged as an alternative 
treatment modality for cancer patients who respond poorly to traditional therapies. An 
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efficient vaccine-mediated immunity requires strong activation of both humoral (antibody 
and memory B-cell generation) and cellular responses (activation of both CD4+ helper T-
cells, CD8+ cytotoxic T cells and memory T-cells), which provides optimal protection from 
the disease [44]. We propose that the dual antigenic (activate both B & T cells) epitope 
quality and aberrant expression of MUC4 in all the stages of PC tumor development 
qualifies it to be a strong candidate for immunotherapy strategies like cancer vaccines. 
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Table I: Autoantibodies reactivity against MUC4 peptides can predict 
patients with compromised tolerance  
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 Figure 1: Autoantibodies against MUC4β were detected in PC patient serum. 
Indirect ELISA study revealed that PC patients had high expression of 
circulating autoantibodies to recombinant human MUC4β protein (A). The high 
levels of MUC4 autoantibodies didn’t correlate with PC survival as seen in Kaplan-
Meier graph (B). Further analysis showed that patients with high levels of MUC4 
autoantibodies, both at early (Stage I-II) and late (Stage IV) stages of PC, had 
longer survival than patients with low levels of autoantibodies (C). 
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 Figure 1 
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Figure 2: Bioinformatics analysis predicted T-cell immunodominant epitopes 
of MUC4. 
NetCTL1.0 and IEDB software analysis based on combined prediction of 
peptide MHC binding, proteasomal C terminal cleavage and TAP transport 
efficiency, predicted and ranked T-cell immunodominant epitopes. Lower predicted 
rank score suggests a higher probability of these peptides to be loaded on MHC-I 
complex and cross-represented to T-cells for activating them in an antigen-specific 
manner. 
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 Figure 2 
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Figure 3: Bioinformatics analysis predicted B-cell immunodominant 
epitopes of MUC4.  
IEDB B-cell prediction software analysis based on sequence characteristics 
of the antigen using amino acid scales and HMMs, predicted and ranked B-cell 
immunodominant epitopes. High predicted rank score suggests higher probability 
of these peptides to be recognized by B-cells.   
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 Figure 3 
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Figure 4: Reactivity against predicted MUC4α epitopes was found in PC 
patients.  
Indirect ELISA study demonstrated that PC patient serum contains 
circulating autoantibodies against MUC4α immunodominant predicted epitopes, 
whereas low reactivity to PD2 internal protein control was observed. The serum 
reactivity to MUC4 α was observed to be significantly higher than PD2 and TR 
control peptides (A). Presence of autoantibodies against these peptides didn’t 
confer any survival advantage (B). ANOVA analysis of group means was 
significant (P<0.001), ** and ** denotes paired T-test between PD2 vs. MUC4 
peptides and TR vs peptides respectively (P<0.001) 
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Figure 4 
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Figure 5: Reactivity against predicted MUC4β epitopes was found in PC 
patients.  
Indirect ELISA study demonstrated that PC patient serum contains 
circulating autoantibodies against MUC4β immunodominant predicted epitopes, 
whereas low reactivity to PD2 internal protein control was observed. The serum 
reactivity to MUC4 α was observed to be significantly higher than PD2 and TR 
control peptides (A). Presence of autoantibodies against these peptides didn’t 
confer any survival advantage (B). ANOVA analysis of group means was 
significant (P<0.001), ** and ** denotes paired T-test between PD2 vs. MUC4 
peptides and TR vs peptides respectively (P<0.001)   
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Figure 6: IgM autoantibodies to MUC4α peptides show a better prognosis in 
PC patients.  
Isotyping analysis revealed that differential levels of all three IgM, IgG and 
IgA isotypes have been detected against all MUC4α peptides (A). Kaplan-Meier 
graph shows that high levels of IgM autoantibodies to A2 and D4 (blue arrows) 
significantly correlated with PC patient survival (MSD: 344 days & 535 days 
respectively).  
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Figure 7: IgM autoantibodies to MUC4β peptides show a better prognosis in 
PC patients.  
Isotype analysis revealed that differential levels of all three IgM, IgG and 
IgA isotypes have been detected against all MUC4β peptides (A). Kaplan-Meier 
graph shows that high levels of IgM autoantibodies to B1 (blue arrow) significantly 
correlated with PC patient survival (MSD: 344 days).  
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Supplemental Figure 1: Reactivity against predicted MUC4α epitopes was 
found only in PC patients.  
PC specific reactivity was found against MUC4α peptides with significantly 
low reactivity in both healthy and CP controls, suggesting that these peptides could 
serve as unique immunodominant epitopes being immunologically recognized 
specifically by PC patient’s immune system. 
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Supplemental Figure 1 
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Supplemental Figure 2: Reactivity against predicted MUC4β epitopes was 
found only in PC patients.  
PC specific reactivity was found against MUC4β peptides with significantly 
low reactivity in both healthy and CP controls, suggesting that these peptides could 
serve as unique immunodominant epitopes being immunologically recognized 
specifically by PC patient’s immune system. 
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Supplemental Figure 2 
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Supplemental Figure 3: Isotyping of MUC4 circulating antibodies didn’t show 
any correlation with survival status of PC patients.  
Isotype analysis of autoantibodies to recombinant human MUC4β protein 
showed that PC patients could be segregated on the levels of IgG autoantibodies 
present in PC patient serum. However, none of these isotypes correlated with PC 
patient survival.  
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Supplemental Figure 4: Autoantibodies isotype to MUC4α and MUC4β 
peptides reveals a differential correlation with patient survival.  
Correlation of PC patient survival with isotypes of autoantibodies to MUC4 
peptides present in patient sera demonstrates that high levels of IgM 
autoantibodies seem to positively correlate with patient survival compared to IgG 
or IgA autoantibodies for all peptides.  
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CHAPTER 4: DEVELOPMENT OF 
MUC4 NANOVACCINE 
The material covered in this chapter is the subject of a research article 
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1. Synopsis 
Mucin 4 (MUC4) is high molecular weight glycoprotein that is differentially 
overexpressed in pancreatic cancer (PC) and functionally contributes to disease 
progression while its expression correlates with poor survival. Further, due to its aberrant 
glycosylation and extensive splicing in cancer, MUC4 is a potential target for cancer 
immunotherapy. Our previous studies have demonstrated the utility of amphiphilic 
polyanhydride nanoparticles as a useful platform for the development of protein-based 
prophylactic and therapeutic vaccines. In present study, we encapsulated purified 
recombinant human MUC4 (MUC4β) protein in 20:80 ratio of amphiphilic polyanhydride 
(CPTEG & CPH) adjuvants (MUC4-nanovaccine) and evaluated its ability to activate 
dendritic cells and induce anti-tumor immunity. Immature dendritic cells when pulsed with 
MUC4-nanovaccine exhibited more than 2-fold increase in surface expression of 
activation markers (MHC-II and MHC-I) and 1.5-fold increase in pro-inflammatory 
cytokines (IFN-γ, IL-6, and IL-2) levels as compared to cells exposed to  MUC4β alone or 
MUC4β mixed with blank nanoparticles (MUC4 +NP). Further, the antibody analysis in the 
sera collected from immunized mice showed two-fold higher levels of IgG2b antibodies 
than IgG1 antibodies, suggesting a predominantly Th1-type of immune response in 
MUC4-nanovaccine group. Thus, our findings demonstrate MUC4-nanoformulation as a 
novel platform for PC vaccine development.  
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2. Background and Rationale 
 Pancreatic cancer (PC) has a dismal prognosis with an overall survival rate of 8%, 
due to the limited efficacy of existing treatment modalities like surgery, chemotherapy, and 
radiation [1, 2]. Furthermore, PC has an elaborate immunosuppressive tumor 
microenvironment comprising of high desmoplasia, immune-suppressive cells and an anti-
inflammatory cytokine milieu [3]. Due to high level of chemotherapy-induced toxicity, PC 
patients seldom benefit from chemotherapy. Recent studies have shown that 
immunotherapy-based strategies like cancer vaccines can provide therapeutic benefit by 
breaking the tolerance, overcoming immunosuppression and thereby, improving the 
overall survival and quality of life [4, 5]. However, the development of anti-cancer vaccines 
are rather more arduous due to the challenges in finding optimal tumor-associated 
antigens (TAAs), because the majority of these antigens behave as “self”, and therefore, 
are immunologically ignored by the host immune system leading to development of 
tolerance against TAAs [4].  
 Mucins are high molecular-weight glycoproteins that are overexpressed on 
pancreatic tumor cells and have oncogenic functions in PC pathogenesis. MUC family 
members have emerged as TAAs for PC and are currently being exploited for cancer 
immunotherapy. Mucin1 (MUC1) is one of the well-studied targets for PC vaccine studies 
[6]. MUC1 peptide and glycopeptide vaccine studies have shown the potential of 
reprogramming the immune system against mucins and generating anti-tumor responses 
in various malignancies [7-12]. However, limited immunogenic epitopes provided by 
peptide-based MUC1 vaccines have achieved suboptimal clinical success in PC patients 
[9, 13, 14]. Unlike MUC1, Mucin4 (MUC4) is undetectable in normal pancreatic tissue and 
its expression progressively increases with disease progression and [15]. MUC4 is 
putatively cleaved at a Gly-AspPro-His (GDPH) site in an autocatalytic manner into two 
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subunits: a large N-terminal MUC4α containing the tandem repeat region and a smaller 
membrane-tethered MUC4β [16-18]. The membrane-tethered MUC4β region is considered 
functionally important as it has 3 EGF-like domains that interact with HER-2 and promote 
cell proliferation. Further, targeting MUC4β is simplified since the subunit will still be 
present on the cell surface of PC tumor cells post-cleavage due to its transmembrane 
region. In a study, mice immunized with MUC4 glycopeptides mixed with tetanus toxin 
induced strong immune responses and predominantly produced IgG1 antibodies [19]. 
Such “cherry-picked” immunodominant peptides limit the epitopes that can be employed 
to elicit immune response in an unbiased manner, are of limited translation values. While 
large size of MUC4 can potentially provide a large epitope repertoire for eliciting potent 
immune response, it also makes the production and purification of intact protein equally 
challenging. We thus investigated the utility of recombinant MUC4β-domain for cancer 
vaccine development. To circumvent these, we investigated the utility of recombinant 
MUC4β subunit for tumor vaccine development.  
 One of the major challenges of vaccine delivery vehicles is to ensure protein 
stability and release over a sustained period in circulation [20, 21]. Amphiphilic 
polyanhydride nanoparticles, composed of 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane 
(CPTEG) and 1,6-bis(p-carboxyphenoxy)hexane (CPH), have been shown to stabilize the 
structure and activity of encapsulated proteins while providing sustained release via a 
surface erosion mechanism [22, 23]. Furthermore, these nanoparticles have been shown 
to be readily internalized by antigen presenting cells (APCs), such as dendritic cells and 
macrophages, leading to the upregulation of surface activation markers including major 
histocompatibility complexes class I and II (MHC-I & MHC-II), co-activating ligands (CD86, 
CD40), secretion of inflammatory cytokines and generation of humoral responses [24-27]. 
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In the present study, we encapsulated endotoxin free recombinant human MUC4β 
in 20:80 CPTEG:CPH nanoparticles (MUC4-nanovaccine). We investigated the 
relationships between antigen release kinetics, immunological activity in terms of APC 
activation, and induction of humoral responses by the MUC4-nanovaccine. Our study 
demonstrates that the MUC4-nanovaccione activated mature DCs, eliciting a Th1 type of 
immune response. We further observe that MUC4 nanovaccine-immunized mice generate 
more IgG2b anti-MUC4β serum antibodies than IgG1 antibodies, suggesting that MUC4-
nanovaccine elicits a predominantly Th1-type response. Therefore, recombinant human 
MUC4β-based polyanhydride nanovaccine has the potential to be an effective 
immunotherapy against pancreatic cancer and other MUC4 overexpressing malignancies.  
3. Results 
3.1 Encapsulation of MUC4β into Polyanhydride Nanoparticles Provides 
Sustained Antigen Release Kinetics 
The 20:80 CPTEG:CPH nanoparticles loaded with 3 wt. % MUC4β were synthesized  via 
solid-oil-oil double emulsion. Scanning electron microscopy showed the nanoparticles to 
be relatively spherical with a geometric mean diameter of 147 nm (with a geometric 
standard deviation of 1.3) (Figure 1A). The release kinetics of MUC4β from 20:80 showed 
a burst of ca. 20% at early time points followed by slow, sustained release with smaller 
amount of protein released over 30 days. The data showed that after one month, the 
hydrophobic 20:80 CPTEG:CPH particles released ca. 25% of the encapsulated protein in 
a near-zero order release profile, which was consistent with previous work on protein 
release kinetics from CPTEG:CPH polyanhydrides formulations [22, 23, 27-29]. Finally, the 
encapsulation efficiency of the MUC4β was determined to be 32 ± 1% (Figure 1B).  
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3.2 MUC4 Nanovaccine Enhances Surface Expression of MHC and Co-
Stimulatory Molecules on DCs 
While the functional role of MUC4 in pancreatic cancer pathobiology has been 
studied extensively, the immunogenicity of MUC4 protein has not been assessed until now. 
To examine the antigenicity of MUC4β protein (MUC4) and characterize the potential of 
MUC4 nanovaccine in activating CD86+ CD11c+ DCs (Supplementary Figure 1), flow 
cytometry was used to measure expression of cell surface markers such as major 
histocompatibility complex molecule class II (MHC II) and class I (MHC I), co-stimulatory 
molecule CD80, and C-type lectin CD205 (DEC-205: DC maturation marker). Recombinant 
MUC4β protein alone or delivered with empty nanoparticles did not upregulate surface 
expression of MHC I and II on DCs over controls. However, a significant 4-fold increase in 
mean fluorescence intensity (MFI) of MHC I and II was observed on DCs cultured with 
MUC4 nanovaccine in contrast to unstimulated DCs. Moreover, DCs cultured with MUC4 
nanovaccine expressed high levels of MHC II (2-fold higher) than LPS-stimulated DCs 
(Figure 2 A & B). Furthermore, MUC4 nanovaccine enhanced the DC surface expression 
of the co-stimulatory molecule CD80 by 75% when compared to MUC4 only treated DCs, 
but no significant difference was observed in CD40 expression (Figure 2 C & D). In 
addition, DC surface expression of CD205 was 60%, 20% and 25% higher on MUC4-
nanovaccine stimulated DCs when compared to unstimulated, LPS- and MUC4β protein-
treated DCs (Figure 2E) suggesting a higher proliferation and maturation of DCs which is 
shown in Figure 2F. Altogether, these results demonstrate that the MUC4 nanovaccine 
significantly enhanced the expression of surface markers and co-stimulatory molecules 
involved in DC maturation and antigen presentation. 
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3.3 MUC4 Nanovaccine Induces Pro-Inflammatory DC Cytokine Secretion 
Dendritic cells direct immune responses by not only cross-presenting antigens to 
effector T and B cells, but also by secreting an array of cytokines to modulate these 
responses. After culturing DCs with various treatment groups for 48 h, we observed that 
the MUC4 nanovaccine significantly enhanced DC secretion of the cytokines IL-12p40, IL-
6, and IFNγ in comparison to untreated DCs and free MUC4 simulated DCs (Figure 3). 
The amounts of IL-12p40 and IL-6 in culture supernatants of DCs treated with MUC4 
nanovaccine were 40% and 30% higher than that of DCs stimulated with LPS respectively 
(Fig 3A & B), and the levels of IFNγ were comparable between these two stimulants (Fig 
3C). DCs treated with MUC4β alone (MUC4) or MUC4β mixed with empty nanoparticles 
(MUC4+NP) expressed low or undetectable levels of cytokines, which were no different 
from unstimulated DCs. Similar to the data obtained for surface expression of MHC II and 
DC co-stimulatory molecules, encapsulation of MUC4β protein in 20:80 CPTEG:CPH 
nanoparticles significantly enhanced DC cytokine production. 
3.4 Single Immunization with MUC4 Nanovaccine Elicit Robust Anti-MUC4 
Humoral Responses 
Polyanhydride nanovaccines have been shown to generate germinal centers and B 
cells thus leading to sustained serum antibody responses in a single dose [30]. Apart from 
measuring antigen-specific antibody levels (which indicates the degree of humoral 
stimulation), isotyping of antibodies (IgG1 and IgG2b levels) demonstrate the type of 
immune responses (Th1 or Th2) generated through the determination of IgG2b:IgG1 ratios. 
The presence of high levels of antigen-specific IgG2b antibodies over IgG1 antibodies 
indicates preferred isotype-switching to Th1 type responses, whereas low IgG2b:IgG1 ratio 
is indicative of a Th2 type response [31]. To investigate if a single immunization with MUC4 
nanovaccine induced robust humoral immune responses, animals were immunized 
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subcutaneously with MUC4β-loaded 20:80 CPTEG:CPH nanoparticles. Serum antibodies 
were detected at 1:1000 serum dilution in mice that were immunized with MUC4β alone, 
MUC4β mixed with empty nanoparticles and MUC4 nanovaccine. Antibodies against 
MUC4β were detected at higher dilutions in mice administered MUC4β only and MUC4 
nanovaccine, but not when free protein was mixed with empty particles (Figure 4A).  
Since it has been shown that MUC4 peptides induce primarily IgG1 Th2 antibodies and not 
IgG2b [19], we evaluated the isotypes of the antibodies in MUC4β-immunized mice. Mice 
immunized with the MUC4 nanovaccine demonstrated a high IgG2b:IgG1 ratio, whereas 
mice immunized with MUC4β alone had a low IgG2b:IgG1 antibody ratio (Figure 4B). 
These results indicate that encapsulation of MUC4β protein into 20:80 CPTEG:CPH 
nanoparticles modulates the immune response towards a Th1 phenotype , which could 
likely provide anti-tumor protection. 
3.5 Immunization with MUC4 Nanovaccine Enhances the Presence of 
Inflammatory Cytokines in Sera 
Since the analysis of antibody isotypes demonstrated an induction of a Th1 immune 
response, we also investigated the presence of Th1 cytokines (IL-12p40, IL-6, IL1β, and 
IFNγ) in sera of immunized mice. Sera from MUC4 nanovaccine immunized mice had a 
slightly higher increased mean amount of IL-6 compared to MUC4 and MUC4+NP 
immunized mice (Figure 5A). In addition, sera from MUC4 nanovaccine immunized mice 
had significant amounts (~50 fold increase) of IL1β Th1 cytokine when compared to other 
treatment groups and PBS-treated mice (negative control) (Figure 5B) that correlates with 
Th1 isotype switching of antibodies in these mice. The amounts of IL-12p40 and IFNγ were 
below detection levels in all treatment groups (data not shown). 
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4. Discussion 
To date vaccine studies involving mucins have been based on selected peptides 
which have limited repertoire of immunogenic epitopes. In pre-clinical studies, these 
vaccines have not shown promising results which could be attributed to studies done only 
with the tandem repeat regions of mucins including MUC4. Recombinant proteins could 
address these limitations by presenting the entire spectrum of possible epitopes present 
on the original antigens in an unbiased manner [3]. In this study, the β-subunit of MUC4 
was expressed in a bacterial system and its immunogenicity was investigated. The data 
presented showed that MUC4β (MUC4) induces a Th2 type immune responses such as 
low expression of MHC-I and II complexes and co-stimulatory molecule CD80 (Fig 2 A-C), 
and low levels of inflammatory cytokine generation by pulsed DCs (Fig 3 A-C). In addition, 
mice immunized with only MUC4 produced significantly high levels of Th2 IgG1 antibodies 
to MUC4 (Fig 4B). This indicated that utilizing the free protein by itself will likely not provide 
an effective immunotherapeutic response. Th2 immune responses have been well 
established to promote tumor pathogenesis and aggressiveness, whereas shifting the 
immune response to Th1 phenotype provides anti-tumor protection [32-34]. Thus, we 
encapsulated MUC4β into 20:80 CPTEG:CPH nanoparticles (MUC4 nanovaccine) and 
investigated whether the MUC4 nanovaccine could enhance activation of dendritic cells 
and modulate Th1 type humoral responses in vivo. 
The MUC4 nanovaccine enhanced surface expression of MHC I and MHC II  in 
CD86+ CD11c+ DCs (Figure 3 A-B), which are implicated in presentation of antigen to T 
cells and B cells, along with CD80 (Figure 3C), a co-stimulatory molecule required for 
activation of naïve CD4 helper T cells. Proper antigen presentation followed by secondary 
activation signal provided by CD80 is crucial in programming effector immune cells to 
specifically target the cancer cells. Upregulation of these markers by MUC4-nanovaccine, 
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when compared to the free MUC4 pulsed DCs, suggests that the encapsulated 
formulation was able to reprogram the DCs from Th2 to a Th1 response phenotype. 
Further, we observed that only stimulation with MUC4-nanovaccine enhanced DC 
secretion of the cytokines IL-12p40, IL-6 and IFNγ in vitro when compared to free MUC4 
or free protein mixed with empty nanoparticle (MUC4+NP) that corroborated with the DC 
activation marker expression data. These results indicate that the encapsulation of 
MUC4β protein in CPTEG:CPH nanoparticles is crucial to enhancing the immunogenicity 
of recombinant MUC4β. Thus, the result suggests that the encapsulation of MUC4β 
protein in CPTEG:CPH polymers is important for modulating the immunogenic response 
of Th2-inducing recombinant MUC4β. 
Previously, it has been shown that a single immunization of polyanhydride 
nanovaccines can induce high antibody titers and provide protective immunity against 
multiple pathogens in mice [28, 35]. Additionally, it is important to consider the quality of 
antibody response generated by the nanovaccine, which may be characterized by the 
specificity, avidity and isotype profile of the antibody response [36]. It is therefore 
noteworthy that MUC4-nanovaccine immunized mice had the highest IgG2b:IgG1 ratio 
which indicates Th1 type antibodies, whereas MUC4β alone or in combination with blank 
nanoparticles preferentially induced Th2 type IgG1 anti-MUC4β antibodies in alignment 
with its immunogenic nature (Figure 4B). This observation supports our in vitro 
observation that encapsulation of MUC4β into polyanhydride nanoparticles likely plays a 
crucial role in activating dendritic cells in favor of Th1 type immune responses, which was 
further validated with the detection of higher levels of IL-6 and IL-1β cytokines (Figure 5). 
The data herein shows encapsulating MUC4β in 20:80 CPTEG:CPH nanoparticles is an 
effective strategy to activate dendritic cells in MUC4-specific manner and modulate the 
response towards an anti-tumor Th1 phenotype. The presence of IgG2b antibodies could 
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possibly further provide immunity against MUC4-expressing tumors by inducing antibody-
dependent cellular cytotoxicity (ADCC) or antigen-mediated tumor killing by NK cells that 
can recognize the FcR region of antibodies bound to tumor cells [37, 38]. The current 
studies provide a basis for investigating the use of the MUC4 nanovaccine as an 
immunotherapeutic strategy in cancer models that overexpress MUC4 as a tumor-
associated antigen.  
5. Conclusion 
Our data have clearly demonstrated that the MUC4-nanovaccine enhances DC 
surface expression of both MHC molecules and co-stimulatory ligands, and Th1 cytokine 
secretion. Further, in in vivo studies, the MUC4 nanovaccine effectively induced 
production of anti-MUC4β antibodies and isotype-switching of these antibodies to primarily 
IgG2b (Th1 type) isotypes, which typically correlates to anti-tumor immune responses [39]. 
Thus, this work demonstrates that polyanhydride MUC4 nanovaccines are a promising 
platform for immunotherapies against pancreatic cancer.  
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Figure 1: Synthesis, encapsulation and release kinetics of MUC4 
nanovaccine.  
Endotoxin-free recombinant MUC4β protein was isolated from Rosetta bacteria 
and purified by affinity chromatography. 20:80 CPTEG:CPH nanoparticles encapsulating 
3% MUC4 were synthesized via a solid/oil/oil double emulsion flash nanoprecipitation 
process. SEM images of 20:80 CPTEG :CPH nanoparticle encapsulated recombinant 
mucin fragment: MUC4-β (A). Antigen release kinetics were characterized by incubating 
the nanoparticles in PBS and measuring MUC4 released at regular intervals with a 
microBCA assay. 3% MUC4-loaded 20:80 CPTEG:CPH nanoparticles exhibited an initial 
burst (20%) release of protein followed by sustained release. The encapsulation efficiency 
of protein was determined to be 32%, suggesting low affinity between the polymer and 
MUC4 protein.  
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Figure 1  
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Figure 2: MUC4 nanovaccine activates DCs and induces expression of MHC 
II and co-stimulatory molecules.  
Flow cytometry analysis demonstrated that MUC4 nanovaccine have activated 
DCs robustly like the LPS positive control. MUC4β (MUC4) protein has Th2 immunogenic 
activity that abrogates DC activation and expression of MHC and co-stimulatory 
molecules. Free MUC4 mixed with empty nanoparticles (MUC4+NP) slightly increases the 
immunogenicity of MUC4β, but only MUC4 nanovaccine could significantly activate DCs, 
suggesting encapsulation of MUC4β is crucial for inducing a Th1 immune responses (A-
E). Increased DC proliferation was observed in MUC4 nanovaccine group compared to 
unstimulated DCs and other MUC4 treatment groups (F). Statistical significance was set 
at p<0.05. ANOVA analysis of the data was p<0.05. Statistical comparison between 
MUC4, MUC4+NP & US with MUC4 nanovaccine is denoted by #, * & + respectively. 
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Figure 2 
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Figure 3: MUC4 nanovaccine induced robust Th1 DC cytokine secretion.  
Cytokine analysis demonstrated that MUC4 nanovaccine activated DCs secrete 
Th1 cytokines. Free MUC4 mixed with empty nanoparticles (MUC4+NP) and MUC4 
pulsed DCs have low expression of Th1 cytokines, suggesting that mixing of a strong 
adjuvant was not able to modulate the immune response induced by MUC4. Only 
encapsulation of MUC4 could modulate and reprogram DCs to secrete IL12, IL6 and IFNγ 
Th1 cytokines (A-C). Statistical significance was set at p<0.05. ANOVA analysis of the 
data was p<0.05. Statistical comparison between MUC4, MUC4+NP & US with MUC4 
nanovaccine is denoted by #, * & + respectively. 
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Figure 3 
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Figure 4: Mice immunized with MUC4β nanovaccine generated anti-MUC4β 
Th1 humoral response.  
Eight week-old C57BL/6 mice were immunized with a single dose and serum was 
collected for detecting antibodies. ELISA studies showed that MUC4, MUC4+NP and 
MUC4 nanovaccine immunized mice serum carried MUC4β antibodies (A). Further, 
isotyping of MUC4β antibodies demonstrated that isotype switching was predominantly to 
Th1 IgG2b in MUC4 nanovaccine immunized mice, whereas in MUC4 immunized mice it 
was predominantly in IgG1 Th2 isotype (B). Statistical significance was set at p<0.05. 
ANOVA analysis of the data was p<0.05. Statistical comparison between MUC4, 
MUC4+NP and US with MUC4 nanovaccine is denoted by #, * & + respectively. 
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Figure 4 
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Figure 5: Presence of Th1 cytokines in mice immunized with MUC4β 
nanovaccine.  
MUC4 nanovaccine immunized mice serum had significantly higher levels of IL6 (A) and 
IL1β (B) Th1 cytokines that correlated with the predominant Th1 IgG2b MUC4β antibodies 
present in these mice. Statistical significance was set at p<0.05. ANOVA analysis of the 
data was p<0.05. Statistical comparison between MUC4, and MUC4+NP with MUC4 
nanovaccine is denoted by # & * respectively. 
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Figure 5 
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Supplementary Figure 1: MUC4 nanovaccine elicits robust proliferation of 
dendritic cells (DCs).  
Total of 1X105 DCs were pulsed with free MUC4β protein (MUC4), free MUC4β 
protein mixed with empty nanoparticles (MUC4+NP) and MUC4-nanovaccine. 
Unstimulated DCs (US) and LPS-treated DCs serve as negative and positive controls. 
Antigen-matured DCs were characterized as CD86hi CD11c positive (CD86+CD11c+) cells. 
MUC4 nanovaccine strongly stimulates DCs and robust 3-fold proliferation is observed 
when compared to MUC4-pulsed DCs.   
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CHAPTER 5: COMBINING IMMUNE 
CHECKPOINT BLOCKADE WITH 
MUC4 NANOVACCINE FOR PC 
TREATMENT 
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1. Synopsis 
Pancreatic cancer (PC) is a highly metastatic and therapy-resistant malignancy 
characterized by immunosuppressive tumor microenvironment (TME) mucin 
overexpression. Immunotherapy strategies for PC treatment are constantly being 
developed and tested in clinical trials but have achieved underwhelming outcomes. MUC4 
is the most differentially overexpressed mucin and functionally contributes to PC disease 
aggressiveness. Our previous studies have demonstrated that MUC4 is immunogenic in 
PC patients and is thus an ideal candidate for targeted therapies. We developed a novel 
vaccine using recombinant MUC4 fragments and exploiting adjuvant-like properties of an 
amphiphilic polyanhydride-based nanoparticle delivery system. In addition, we showed 
that recombinant human MUC4β protein encapsulated in amphiphilic polyanhydride 
nanoparticles (MUC4 nanovaccine) successfully activates dendritic cells and induces Th1 
anti-MUC4β antibodies in immunized C57BL/6 mice.  Tumor cells are also known to 
express programmed death ligand 1 (PD-L1) to suppress effector immune cells activity 
via the PD-L1-PD-1 axis. Our preliminary study elucidated that MUC4 nanovaccine-
immunized mice exhibited slower tumor growth kinetics than unimmunized control mice. 
However, we did not observe complete tumor regression and detected PD-L1 expression 
on MUC4-expressing tumors only. Based on this, we rationalized that PD-L1 expression 
by MUC4-expressing tumor cells suppressed and inhibited the therapeutic benefits of the 
nanovaccine in-vivo. The strong involvement of MUC4 in disease aggressiveness and PD-
L1 in immunosuppression thus makes a compelling case for their combined targeting.  
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2. Background and Rationale 
The PC tumor microenvironment is a complex relationship between cellular 
components, desmoplasia and cytokine milieu. PC’s dense stroma/desmoplasia harbor 
immune cells such as TAMs, MDSCs, and Treg cells that directly inhibit the activity of 
effector CD4+ and CD8+ T-cells. These pro-tumor immune cells further secrete anti-
inflammatory Th2 cytokines like IL-4, IL-10 and IL-13, which negatively regulate the 
infiltration and functionality of effector immune cells by precluding immunological 
recognition [1-3]. To overcome the immune suppression elicited by the TME of pancreatic 
cancer, reprogramming of patient’s immune system and generation of strong anti-tumor 
Th1 responses are necessary. Therapeutic cancer vaccines have emerged as a tool to 
reprogram and activate the patient’s immune system in a tumor antigen-specific manner 
to effectively target tumor cells [4, 5]. Cancer vaccines have seen limited clinical success 
in some solid tumors such as lung cancer, breast cancer and renal cancer. A major factor 
that could improve the efficacy of these vaccines is firstly identifying TAAs that could be 
targeted [5]. Our previous study has identified MUC4 to be immunogenic in PC patients, 
suggesting that these patients have compromised peripheral tolerance.  
A second major factor is a generation of robust anti-tumor responses to cancer 
vaccines to overcome peripheral immune tolerance and escape immune suppression of 
TME. To break tolerance and constrain immune suppression, selection of a strong 
immunological adjuvant to be combined with the antigen is required [5-7]. Adjuvants are 
an instrumental component of a potent vaccine that enhances the immunogenicity of the 
antigen and increases the antigen-specific immune response. However, developing a 
cancer vaccine with a successful adjuvant is not easy because the adjuvant must preserve 
the antigen and needs to be safe, potent and economically viable [6, 7]. We developed a 
novel MUC4 nanovaccine by encapsulating human MUC4β recombinant protein in 
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pathogen-mimicking amphiphilic polyanhydride nanoparticles. We observed that the 
MUC4 nanovaccine elicited robust activation of DCs by upregulating surface expression 
of DC activation markers, as well as secretion of Th1 cytokines like IL12, IL6 and IFNγ. 
Further, we elucidated that mice immunized with MUC4 nanovaccine carried high levels 
of Th1 IgG2b anti-MUC4β antibodies circulating in their serum. These data provide initial 
evidence that MUC4 nanovaccine could potentially serve as a potent immunotherapy 
strategy to treat PC. 
The PD-L1 co-inhibitory molecule expressed on tumor cells binds to its receptor 
programmed cell death protein 1 (PD-1) present on T cells and negatively regulates T-cell 
signaling and effector functions [8]. PD-1 is expressed only on antigen-experienced CD4+ 
and CD8+ T cells, as well as B cells, and is absent on resting T and B cells [9]. Its ligand 
PD-L1, also known as cluster of differentiation 274 (CD274) or B7 homolog 1 (B7-H1), is 
expressed on activated DCs and macrophages[10], as well as non-lymphoid tissues like 
cancer cells upon IFNγ stimulation [11]. PD-L1 is also expressed in peripheral tissues, 
thus suggesting its role in peripheral tolerance against self-reactive T and B cells, and may 
serve in regulating inflammatory responses at these sites [12]. PD-L1, upon binding to its 
receptor PD-1, inhibits T cell proliferation and its effector functions by inducing apoptosis. 
In addition, this axis promotes differentiation of CD4+ T cells into Foxp3+ regulatory T cells 
[13-15].  
One of the major challenges that have emerged from recent preclinical studies is 
the counter PD-L1 mediated-suppression elicited on infiltrating effector lymphocytes by 
tumor cells, therefore inhibiting the efficacy of these vaccines [16-18]. Expression of PD-
L1 by tumor cells is an indicator of an active immune interaction occurring between 
cytotoxic CD8+ T-cells and tumor cells. Blockade of PD-1 receptor on effector T-cells to its 
ligand PD-L1 by PD-1 inhibitors have shown some promise in rescuing anti-tumor effects 
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as been discussed in the following review [1]. However, PC patients show differential 
expression of PD-L1 in tumors due to the various degree of effector T-cells infiltration 
found in the TME [19]. Combined high percentage of infiltrating CD8+ T-cells and high PD-
L1 expression is correlated with lymph node metastasis and poor survival of PC patients 
[20-22].  
Based on the data, our working goal was to investigate whether MUC4 
nanovaccine could provide immunity against MUC4 tumor-bearing mice. Our preliminary 
data suggest that MUC4 nanovaccine has the potential to induce anti-tumor responses. 
We observed a positive correlation between TILs and tumor regression. Accumulation of 
infiltrating CD8+ and CD4+ T cells was greater in mice receiving the MUC4 nanovaccine 
compared to soluble MUC4 delivered with blank nanoparticles (MUC4+NP), indicating the 
benefit of sustained availability of antigen via encapsulation. However, we didn’t achieve 
complete clearing of the MUC4-expressing tumor and thus investigated the PD-L1 
expression in them. We did observe that MUC4 tumors had high expression of PD-L1 on 
tumor cells whereas only low expression of PD-L1 was seen in vector control tumors. 
These results suggest that MUC4 nanovaccine combined with checkpoint blockade could 
have enhanced therapeutic potential. 
3. Results 
3.1 The Cytotoxic Killing of MUC4-Expressing Cell Lines by CTLs 
miniMUC4 construct captures the entire structure of original human MUC4 protein 
but has approximately 90% of the VNTR region missing due to which it runs at a lower 
molecular weight of 250-300 kDa in 2% agarose SDS gel [23]. Our cytotoxicity assay 
demonstrated that T-cells activated ex vivo by MUC4 nanovaccine-pulsed DCs mediated 
25% higher antigenic-specific killing of miniMUC4 expressing-KPC960 cells when 
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compared to T-cells activated by MUC4+NP-pulsed DCs (Figure 1). Based on this, we 
proposed to elucidate the therapeutic potential of MUC4 nanovaccine in in vivo model. 
3.2 MUC4 Nanovaccine Immunized Mice have Slower Tumor Growth Kinetics 
  To fully understand the preventive and therapeutic role of MUC4 nanovaccine, we 
pre-immunized the mice with primary dose and first booster. After tumor cells implantation, 
once the tumor volume reached 100 mm3, we immunized the mice with a lower second 
booster dose (Figure 2A). We observed that miniMUC4 tumors had slower growth kinetics 
with respect to its contralateral vector control KPC960 tumors. In addition, miniMUC4 
tumors in MUC4 nanovaccine-immunized mice had overall lower tumor volume when 
compared to the unimmunized control mice (Figure 2B & C). 
3.3 MUC4 Nanovaccine Enhanced Immune Cell Infiltration in miniMUC4 
Tumors 
Our observation of slower tumor growth kinetics and overall smaller tumor volume 
of miniMUC4 tumors, when compared to vector control tumors, in MUC4 nanovaccine-
immunized mice, made us curious to investigate the immune cell infiltration in miniMUC4 
tumors. Hematoxylin and eosin staining of tumor tissue sections showed a MUC4-specific 
immune cell infiltration in miniMUC4 tumor cells in the MUC4 nanovaccine immunized 
mice (Figure 3A). We did observe some antigen-specific immune cell infiltration in 
miniMUC4 tumors of free soluble MUC4-immunized mice, but the percentage of infiltration 
was significantly lower than MUC4 nanovaccine-immunized mice. The pathologist noticed 
an area of necrosis proximal to the immune infiltrate region, which were quantified. We 
found a positive correlation between tumor necrosis and the degree of immune cell 
infiltration in miniMUC4 tumors. MUC4 nanovaccine-immunized mice had 5% higher 
tumor necrosis than other groups where the MUC4 antigen was provided (Figure 3B). 
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Further, we investigated the percentage of CD8+ and CD4+ T-cells infiltrated in miniMUC4 
tumor cells by immunofluorescence and confocal microscopy (Figure 4 A-B). We 
observed that in MUC4 nanovaccine-immunized mice, 65% CD8+ and 25% CD4+ of 
infiltrating T-cells were present in miniMUC4 tumors, whereas only 33% CD8+ and 9% 
CD4+ of infiltrating T-cells were detected in miniMUC4 tumors of MUC4+NP-immunized 
mice (Figure 4 C-D). These data provide a rationale for the slower miniMUC4 tumor 
growth kinetics observed in MUC4 nanovaccine-immunized mice.  
3.4 MUC4 Nanovaccine Induces IFNγ Mediated PD-L1 Expression on 
miniMUC4 Tumor Cells 
Our data suggest that MUC4 nanovaccine is inducing immunological targeting of 
miniMUC4 tumors; however we did not achieve complete tumor regression. To overcome 
immunosuppression of PC tumor cells, it is well understood that cancer vaccines need to 
generate robust cellular responses as well as high levels of Th1 cytokines. To evaluate 
whether MUC4 nanovaccine was able to induce strong cytokine secretion, we analyzed 
through flow cytometry the levels of Th1 cytokines produced by effector T cells. Our 
analysis demonstrated that significantly high levels (P<0.01) of Th1 CD4+ (Tbet-positive) 
T-cells were present in MUC4 nanovaccine-immunized mice. In addition, both CD8+ and 
CD4+ T-cells produced robust levels of IFNγ cytokine in contrast to unimmunized mice 
(Figure 5 A-B). 
Survey of literature has elucidated that IFNγ secreted by effector T-cells could 
potentially induce PD-L1 expression by tumor cell as a counterattack mechanism and 
inactivate the functionality of cytotoxic T-cells [11]. Since our data showed that significantly 
higher levels of IFNγ are produced by effector T-cells, we were curious to understand 
whether IFNγ was inducing PD-L1 expression on miniMUC4 tumor cells that lead to the 
limited success of MUC4 nanovaccine in our in vivo mouse model. IHC staining of PD-L1 
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revealed that PD-L1 was expressed on the surface of miniMUC4 tumor cells and stroma 
from MUC4 nanovaccine-immunized mice (Figure 5C). There was some low-intensity 
stromal staining and no tumor cell staining was observed in vector control tumors, whereas 
cellular surface staining of PD-L1 was observed on miniMUC4 tumor cells, suggesting an 
active cross-talk between effector T-cells and tumor cells, which corroborates with the high 
degree of immune infiltration detected in miniMUC4 tumors removed from MUC4 
nanovaccine-immunized mice. 
4. Discussion 
The present study investigated whether MUC4 nanovaccine could elicit anti-tumor 
responses and abrogate from tumor growth. Studies from our lab have shown that MUC4 
nanovaccine could potentially activate dendritic cells and humoral responses. But whether 
the cancer vaccine could provide cellular immunity against MUC4 expressing tumor cells 
needed to be investigated. Thus, we did a preliminary study to investigate the preventive 
and therapeutic potential of MUC4 nanovaccine in a subcutaneous PC tumor mice model. 
Our ex vivo experiments provided evidence that MUC4 nanovaccine could activate 
effector T-cells in MUC4-specific manner and induce robust cytotoxic killing of MUC4 
expressing KPC960 cells. Based on this data, we investigated whether MUC4 
nanovaccine could inhibit the growth of MUC4 expressing tumors and lead to complete 
tumor regression. Our results suggest that even though MUC4 nanovaccine could 
significantly reduce the tumor growth kinetics and tumor volume along with increased 
immune cells infiltration and Th1 cytokine production, complete tumor regression was not 
attained in these immunized mice. 
One of the reasons for not being able to attain a complete regression was that this 
study was done in C57BL/6-FBP mixed background mice, due to which different HLA 
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haplotypes could lead to limited activation of cytotoxic T cells and recognition of tumor 
cells by CTLs. Another reason for the limited success was due to the immune suppression 
exhibited by the PD-L1 expressed by tumor cells on CTLs. We propose that IFNγ secreted 
by effector T-cells induced PD-L1 immunoinhibitory ligand expression on miniMUC4 tumor 
cell surface as an immunosuppressive response and thus induced inactivation of CTLs 
that resulted in reduced tumor volume but no complete regression. 
To evaluate and elucidate the full potential of MUC4 nanovaccine as a potent 
immunotherapy strategy for PC, we need to study MUC4 nanovaccine in a syngeneic PC 
mice model. Further to fully replicate clinical settings, we are required to study the 
nanovaccine in human MUC4 transgenic genetically engineered PC mice model. Our data 
suggest that combining checkpoint blockade therapy with MUC4 nanovaccine could 
potentially levitate the immunosuppression exhibited by PC tumor, which needs to be 
investigated in the future.   
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Figure 1: MUC4 nanovaccine pulsed DCs activated CTLs in an antigen-specific 
manner and induced cytotoxic killing of miniMUC4-expressing murine pancreatic 
cancer cell lines. 
Spontaneous pancreatic cancer mouse model (KPC)-derived pancreatic cell line 
(KCT-960) was transfected with the Mini-MUC4 construct and was used for LDH 
cytotoxicity assay. The assay showed the specific killing of Mini-MUC4 expressing cells 
compared to vector control (A).   
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Figure 2: Schematic representation of tumor implantation and treatment by MUC4 
nanovaccine. MUC4 nanovaccine-immunized mice showed a decrease in tumor 
growth.   
Immunization of mice was done as indicated. Mice were injected with 1x106 cells 
of miniMUC4 or Vector expressing into right and left flanks of mixed background mice 
(n=5), respectively. Immunization of tumor-bearing mice to analyze the efficacy of the 
MUC4 nanovaccine (A). Tumors were harvested at day 23. MUC4 nanovaccine-treated 
mice (inverted green triangle) showed tumor size reduction (below the red median line) in 
mini-MUC4 tumors with respect to contralateral vector control tumor, in comparison to 
unimmunized control mice (orange sphere) (B). Representative photograph of tumors 
isolated from Control and MUC4 nanovaccine immunized mice group (C). 
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Figure 3:  MUC4 nanovaccine enhanced immune infiltration and corresponding 
necrosis in the miniMUC4 tumor.    
The miniMUC4- or vector-expressing KCT-960 cells were implanted into 
contralateral right and left flank of the same mouse, respectively. These mice were pre-
immunized and received second booster post-tumor implantation, with MUC4 free protein 
mixed with empty CPTEG: CPH 20:80 nanoparticles (MUC4+NP) in PBS, MUC4 free 
protein in PBS and MUC4 nanovaccine in PBS as indicated in Figure 2A. Mice immunized 
with the MUC4 nanovaccine formulation demonstrated increased infiltration of immune 
cells (A). Pathological analysis of tumor tissues showed that encapsulated MUC4 induced 
greater necrosis in MUC4-expressing tumors compared to all other treatment groups (B). 
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Figure 4:  CD4+ and CD8+ T cell populations in miniMUC4 or Vector expressing 
mouse pancreatic ductal (PDAC) tumors.  
Mice were pre-immunized and received second booster post-tumor implantation, 
with MUC4 free protein mixed with empty CPTEG: CPH 20:80 nanoparticles (MUC4+NP) 
in PBS, MUC4 free protein in PBS and MUC4 nanovaccine in PBS as indicated in Figure 
2A.Tumor tissues were stained with CD8 (A and B) CD4 (C and D) T cells surface marker 
antibodies and were subjected to Immunofluorescence (IF) analysis by EVOS microscope. 
Quantification of infiltrating CD8+ and CD4+T cells in miniMUC4 or Vector expressing 
PDAC tumors in MUC4 nanovaccine- or miniMUC4+NP-immunized mice (p<0.01 by 
Tukey’s t-Test) (B and D).  
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Figure 5: MUC4 nanovaccine immunized mice activates T-cells in Th1 phenotype 
that induces the corresponding expression of PD-L1 by miniMUC4 tumor cells. 
Mice pre-immunized with MUC4 nanovaccine showed that MUC4-delivered 
through nanoparticles induced Th1 immune responses of both CD4+ and CD8+ T-cells in 
immunized mice compared to unimmunized control (** signifies p<0.01 by Tumey’s t-Test) 
(A & B). IHC analysis for PD-L1 on MiniMUC4 tumors and vector control tumors treated 
with MUC4 nanovaccine showed an upregulation in PD-L1 expression only in MiniMUC4 
tumors, indicating an immunosuppressive response by MiniMUC4 tumors (C).  
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1. Summary and Conclusion 
PC has an elaborate immunosuppressive microenvironment and immunotherapy 
has emerged as a tool to effectively target PC and its microenvironment [1]. Developing 
immunotherapy strategies for PC treatment comes with its own challenges that are: i) 
identifying a tumor-associated antigen that could be targeted, ii) identifying biodegradable 
adjuvants that could efficiently deliver antigens while preserving their antigenicity, iii) 
eliciting robust anti-tumor responses on the face of immunosuppression and iv) 
overcoming peripheral tolerance and immunosuppression elicited by the tumor.  
Mucins are overexpressed in PC tumor cells and, due to their overexpression and 
aberrant glycosylation, they have emerged as potential candidates for targeted 
immunotherapeutic strategies for PC treatment [2]. MUC1 is one of the well-studied 
candidates for PC immunotherapy strategies but have attained only limited success in 
clinical trials. Most of these immunotherapies are MUC1 peptide-based vaccines that 
capture limited epitopes and excludes possible antigen epitopes present on the entirety of 
the protein. In addition, MUC1 is expressed at low levels in all normal tissues thus it 
doesn’t provide tumor specificity [1-3]. Over the past several years, various aspects of 
MUC4 function and regulation in PC has been investigated [4-6]. In contrast to MUC1, 
MUC4 has restricted expression on normal tissues and is undetectable in normal pancreas 
[7, 8], whereas it is differentially overexpressed in PC tumor and its expression gradually 
increases with the disease progression [4, 8], thus MUC4 overexpression provides a 
spatiotemporal specificity to PC tumors that could be immunogenic. Further, MUC4 has 
been extensively studied and reported to be instrumental in PC pathogenesis [4], therefore 
we proposed that MUC4 could serve as a potential target for PC immunotherapy. 
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1.1 Pancreatic cancer patients have compromised peripheral tolerance 
against MUC4. 
Here we focused on understanding whether the tolerance against MUC4 in PC 
patients is compromised. Peripheral tolerance is comprised of CD4 T helper cells and B-
cells and identification of tumor-associated antigens activate B-cells to generate 
autoantibodies against those antigens. Thus detection of autoantibodies against MUC4 in 
PC patients will be an indicator of compromised peripheral tolerance in those patients. 
Our data demonstrated that autoantibodies are present against the recombinant MUC4β 
protein as well as to randomly selected MUC4 peptides derived from the entirety of MUC4 
protein. Further our analysis showed that the autoantibodies to MUC4 peptides are 
generated in a PC-specific manner and negligible in healthy or chronic pancreatitis 
individuals. Additionally, IgM autoantibodies to MUC4 peptides (A2, D3 and B1) 
significantly correlated with PC patient overall survival. Thus suggesting that 
immunologically targeting MUC4 through a unique immunotherapy platform could exploit 
this compromised tolerance and generate efficacious anti-tumor responses potentially 
contributing to clinical success. 
1.2 Encapsulation of MUC4β protein in novel amphiphilic polyanhydrides 
nanoparticles shifts its immunogenicity from Th2 to Th1 phenotype, and 
induces robust DC activation and humoral responses. 
Most of the cancer vaccines developed are peptide-based due to the difficulty of 
encapsulating proteins while preserving their antigenicity and allowing sustained release 
in the circulation for activation of immune cells [9, 10]. Prior to our study, isolation and 
purification of MUC4 recombinant proteins and its characterization have not been 
achieved. Here we successfully purified the MUC4β protein from bacterial expression 
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system, and encapsulated the protein in novel amphiphilic polyanhydrides nanoparticles 
to develop MUC4 nanovaccine. Polyanhydride nanoparticles is a suitable platform due to 
its pH-neutral core that stabilizes protein, pathogen-mimicking properties and tunable 
release kinetics that enable immune-modulation [11-16]. In addition, MUC4 recombinant 
protein provides a wide repertoire of potential epitopes when compared to single epitope 
peptide-based immunotherapy strategies thus potentially eliciting a robust and sustained 
anti-tumor Th1 immune responses.  
We demonstrated that soluble MUC4βprotein alone activates DCs in the Th2 
pathway. It is well understood that Th1 immune responses have anti-tumor outcomes, 
therefore the protein by itself is not suitable for PC treatment. However, encapsulation of 
MUC4β protein shifted the overall response to Th1 phenotype. MUC4 nanovaccine 
robustly activated DCs and induced both surface expression of activation markers and 
secretion of Th1 cytokines. Further, in the immunized mice MUC4 nanovaccine induced 
generation of Th1 IgG2b humoral responses, which was not observed in mice immunized 
with soluble MUC4 or MUC4+NP groups. Thus indicating that the encapsulation of MUC4β 
in the nanoparticles is crucial for reprogramming the immune responses from Th2 
phenotype to Th1 phenotype. 
1.3 MUC4 nanovaccine induces immune infiltration in miniMUC4 tumors in 
an antigen-specific pathway. 
Cancer vaccines have been shown to induce effector immune cell infiltration in 
tumors in an antigen-specific pathway that affects the overall tumor growth [17]. Here we 
tried to elucidate the therapeutic potential of a MUC4 nanovaccine in eliciting robust anti-
tumor responses in a PC subcutaneous tumor mouse model. Our study showed that 
miniMUC4 tumors in mice immunized with MUC4 nanovaccine had slower tumor growth 
and lower tumor volume with respect to vector control tumors on the contralateral flank of 
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the same mice. These data suggested a MUC4-specific immune response in these 
vaccinated mice. Upon further evaluation, we observed that only in MUC4 nanovaccine 
immunized mice there is enhanced total immune cell infiltration and also effector T cell 
infiltration which correlated with high levels of necrosis seen in miniMUC4 tumors. Despite 
high T-cell infiltration, we were unable to attain complete regression in miniMUC4 tumors. 
Due to the high levels of IFNγ generated by T-cells isolated from MUC4 nanovaccine-
immunized mice, we hypothesized that tumor cells are expressing PD-L1 upon IFNγ 
induction on the cell surface and inhibiting effector T-cells, cytotoxic activity. Our IHC 
analysis validated our hypothesis and we observed PD-L1 surface expression on 
miniMUC4 tumor cells. Thus, in conclusion, MUC4 nanovaccine could potentially be 
exploited as a PC treatment strategy. 
2. Future Directions 
While our studies elucidated the potential of MUC4 nanovaccine as a potent 
strategy for treating pancreatic cancer, the fact that our in vivo tumor model study was 
done in mixed background mice limits the clinical translation of our work. To fully 
understand the anti-tumor potential of MUC4 nanovaccine we are required to perform our 
studies in a syngeneic mice model. Our lab has recently developed murine PC cell lines 
derived from the C57BL/6 pure background KPC mice model. We will be transfecting 
these cells with miniMUC4 plasmid construct and test the cytotoxic killing of this human 
MUC4-expressing syngeneic mouse PC cell lines by MUC4 nanovaccine-activated T-
cells. This study will give us a better understanding of the potential of MUC4 nanovaccine 
activating T-cells in a MUC4 antigen-specific manner. 
Even though our in vitro and subcutaneous study with human MUC4 expressing 
syngeneic mice model will elucidate the therapeutic potential of MUC4 nanovaccine, the 
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model does not recapitulate PC patient’s immune system where immune cells might 
recognize MUC4 on tumor cells as self-antigen and are tolerant towards MUC4. Our 
autoantibodies study suggests that MUC4 is immunogenic in PC patients and based on 
serum reactivity some PC patients might respond well to MUC4 based immunotherapies. 
To recapitulate this clinical setting and validate our hypothesis, our lab (with the help of 
Dr. Satyanarayana Rachagani) has recently developed a human MUC4 transgenic mice 
model. We will utilize this model to primarily address two questions: i) whether MUC4 
nanovaccine could break the immunological tolerance in MUC4 transgenic PC mice model 
and effectively kill MUC4-expressing PC tumor cells, and ii) whether MUC4 nanovaccine 
will lead to severe side-effects due to the non-specific recognition of MUC4 on other 
normal tissues. Further we have also developed a human MUC4 transgenic KrasG12D Pdx-
1 Cre spontaneous PC mice model that expresses MUC4 only on pancreatic tumor cells. 
This mice model will be used to study whether MUC4 nanovaccine could either stabilize 
or regress human MUC4 expressing spontaneous PC tumor. A culmination of all these 
studies will provide us with a clearer understanding of the efficacy of MUC4 nanovaccine 
as a therapy strategy. 
 There is very limited knowledge about MUC4’s contribution to the PC 
immunosuppressive TME. We are curious to investigate the correlation of MUC4 
expression with the immune-phenotype of resected tumors, and cross-refer the 
observation in our MUC4 transgenic KrasG12D Pdx-1 Cre spontaneous PC mice model 
system. Further, PC tumors are fairly desmoplastic that restricts the infiltration of effector 
T-cells. Our in vivo work provided evidence that PD-L1 is expressed on miniMUC4 tumor 
cells as a counterattack to escape cytotoxic killing by cytotoxic CD8+ T cells. Thus, based 
on the data that we will collect from MUC4 transgenic mice models, combining immune-
checkpoint blockade agents such as anti PD-1 antibody and stroma cell depletion agents 
196 
 
with MUC4 nanovaccine to enhance the therapeutic efficacy of the vaccine needs to be 
tested. 
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